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ABSTRACT

THE UTILIZATION OF FLAVONOIDS AS INHIBITORS OF UREASE AND
AS ANTIMALARIAL AGENTS AND THE DISCOVERY OF BACTERIAL
METHIONINE AMINOPEPTIDASE INHIBITORS

Travis R. Helgren, Ph.D.
Department of Chemistry and Biochemistry
Northern Illinois University, 2016
Timothy J. Hagen, Director

This dissertation explores the inhibition of prominent enzymatic pathways important for
both medicinal and agricultural applications. The research involved three distinct projects: First,
an enzymatic urease inhibitory assay was optimized for plate-based screening of tree bark
extracts to compare with ex vivo results from simulated-barn floor manure slurry assays
performed by Dr. Wayne Zeller (USDA, Madison, WI). It was discovered that the ammonia
abatement activities of each extract exhibited a correlation in both the enzymatic and ex vivo
assays. Second, aminoalkylated quercetin analogs were synthesized and screened for antimalarial
activity. The most potent species were found to exhibit sub-micromolar inhibitory values against
multidrug-resistant strains of Plasmodium falciparum, the malarial parasite. Finally, a library of
potential inhibitors of methionine aminopeptidase, an enzyme necessary for bacterial
proliferation, were synthesized or purchased and screened for enzymatic inhibitory activity. A
number of sub-micromolar inhibitors were discovered, and the most potent compounds were
screened in a host-cell viability assay by Dr. Jonathon Audia (USA, Mobile, AL).
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CHAPTER 1
INTRODUCTORY TOPICS

Overview of Cellular Regulation

One of the most visible applications of the chemical sciences is lifesaving therapeutics
for the treatment of infectious and invasive ailments. Because diseases are not stagnant and
continually evolve, discovery efforts must coevolve. Currently, therapeutics are designed to
interact with various biochemical target molecules to elicit a favorable physiological response.
These targets can be perturbed with specifically designed small molecules to afford regulation of
some cellular process that, in turn, can work to reduce the effects of a defined ailment;
alternatively, some drugs are discovered through the screening of natural product isolates. This
forms the basis of drug discovery for essentially any disease treatable with chemotherapy. For
example, penicillin, the seminal antibiotic, acts by inhibiting the function of penicillin-binding
proteins (PBPs) that are responsible for the cellular production of peptidoglycan, a crucial
component of cell walls.1 Bacterial reproduction involves binary fission, the splitting of the
bacterial cell into identical copies. To achieve this, a bacterium must first grow in size to
accommodate the incorporation of cellular components in both cells; thus, the activity of PBPs is
essential to cellular proliferation, where the inhibition of such activity results in cellular death.
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Additionally, the practice of small molecule-mediated macromolecular regulation can be applied
to fields outside of medicine, such as agriculture, where herbicides and pesticides work by
inhibiting one or more cellular processes necessary for the livelihood of the organism. The use of
herbicides therefore results in increased crop yield affording more efficient and economical food
production.2
Macromolecules are responsible for a wide-range of processes necessary for cellular life.
Mutation or misfolding of one specific protein involved in a biochemical pathway can result in
metabolic or otherwise degenerative diseases. With the completion of the human genome map, it
has been suggested that 10% of the encoded proteins, nearly 3,000 individual species, are
potentially druggable; that is, these proteins are suggested to bind small molecules.3 Of these, the
majority are enzymes, specialized proteins responsible for the catalytic production of cellular
metabolites. It has been suggested that the majority (50 – 75%) of current drug discovery efforts
are focused on the regulation of enzymes.3 Drug side-effects are generally the result of
promiscuous inhibition of numerous druggable targets. Small molecules must therefore be
tailored to achieve maximum uptake, while simultaneously minimizing the effects of rapid
metabolic processes and clearance.
Infectious diseases account for a large number of health complications and deaths, with
children and residents of poor nations affected the most. Fortunately, the same ideology of using
small molecules to target human macromolecules can be applied to the treatment of infection, as
pathogens survive using cellular processes regulated by macromolecules. However, many
complicating considerations must be overcome. For example, bacterial species are unicellular
organisms of relatively simple composition capable of rapidly adjusting to environmental
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changes. As such, resistance to antibacterial therapeutics can evolve in large colonies. Finally,
therapeutics can undergo metabolism following uptake and prior to incorporation into infectious
disease species, which can destroy efficacy. Drugs must therefore be carefully and specifically
designed to account for these factors.

Processes Involved in Early-Stage Drug Discovery

Once a biomolecule is identified as a suitable target for therapeutic treatment, effective
chemical entities capable of binding the target must be discovered. A number of methodologies
have been developed and utilized to accomplish this task. Significant advances include: highthroughput screening and hit-to-lead modification, where promising hit molecules are optimized.
High-throughput screening involves the assay of libraries of compounds against a
biochemical target to assess target binding or, in the case of enzyme targets, inhibition of
catalytic activity. The specific assay varies based upon considerations regarding the receptor, as
macromolecules are found in the correct confirmation only under highly specific conditions.
Changes in buffer identity, concentration, pH, or temperature can alter or degrade target activity.
Enzymatic targets are typically screened by monitoring substrate consumption or product
formation, while binding to other types of receptors is generally accomplished by monitoring
ligand-receptor binding or conformational changes of the receptor.3
Utilizing modern advances in robotics, tens of thousands of individual chemical probes
can be screened in a matter of hours. This generates a large amount of data that must be carefully
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cataloged and organized for meaningful interpretation. The effectiveness of the individual
compounds can be determined by monitoring a number of metrics, including the equilibrium
dissociation constant (Ki) or more frequently the minimum inhibitor concentration able to
diminish enzyme activity by 50% (IC50). The latter value relates to the binding affinity against
the specified target, and can therefore be used to draw conclusions regarding which species are
effective; these compounds are called hits and are optimized to maximize binding affinity to the
target.
Chemists must be cautious when deciding which compounds to include in a highthroughput screening library. The majority of marketed drugs fit within a set of criteria termed
Lipinski’s rule-of-five (Ro5), which describe four key physical and chemical properties of the
molecules.4 The Ro5 sets limits on the molecular weight, number of hydrogen bond donors and
acceptors, and partition coefficient (logP) of compounds to be considered druglike. However,
these criteria describe optimized drug molecules, those that have already been granted FDA
approval. Because screening libraries are generally composed of hit molecules, an analogous set
of criteria has been developed to describe these, called the rule-of-three (Ro3).5 The four criteria
types are the same as those for the Ro5, however the Ro3 constraints limit hit molecules to small
fragments (see Table 1).

Table 1: Comparison of the Rule-of-3 and Rule-of-5
Criteria
Rule-of-3 Rule-of-5
Molecular Weight
≤ 300 Da ≤ 500 Da
LogP
≤ 3.0
≤ 5.0
# of H-Bond Donors
≤3
≤5
# of H-Bond Acceptors
≤3
≤ 10
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High-throughput screening can be utilized to discover small molecules exhibiting
favorable activity against a biochemical target. These hit molecules must then be optimized to
maximize target binding, as more potent inhibition results in lower necessary dosage and a larger
therapeutic window. Once the ligand binding site of the receptor is determined (usually by
crystallographic methods), the hit molecule can be modified by the addition of specific
functional groups to increase the strength of intermolecular interactions with the receptor. A
number of methods have been applied to modify fragment hit molecules to afford more potent
leads. These modification strategies include: fragment linking, where two or more fragments
found to bind in close proximity within the active site of the target are conjoined to afford
maximum target affinity;6 fragment merging, where fragments binding in overlapping pockets
are conjoined to optimize interactions with both pockets;7 and fragment growing, where
systematic changes are applied to fragment hit molecules to exploit potential interactions with
residues near the site of inhibition8 (see Figure 1). Following modification, the compounds are
rescreened against the target to determine the effect of modification on target binding strength.
The resulting structure-activity relationship (SAR), the quantification of how changes to the hit
molecule affect target affinity, is used to guide subsequent synthetic design efforts to produce
even more potent compounds. This process is repeated until a suitably potent compound is
discovered.

6

Figure 1: Flow chart demonstrating the early stages of target-based drug discovery. A biological
target is first identified. Inhibitor libraries are then subject to high-throughput screening where
hits are identified. Hits are modified according to various methodologies and the resulting
species are screened for activity against the target via a biological activity assay. This process is
repeated until an optimized lead exhibiting potent activity is discovered. The compound is then
subjected to further scrutiny in preclinical and clinical trials.
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The Use of Computational Modeling in Drug Discovery

As a ligand binds to a target protein, the receptor often undergoes a conformational
change to reach an equilibrated state of diminished energy. The specific conformation of the
ligand-receptor complex cannot be predicted and therefore must be discovered from
experimental observation. This is accomplished by first crystallizing the complex, then solving
the molecular structure with X-ray diffraction. The resulting structure demonstrates a ligandbound protein conformation and, more importantly, reveals the binding mode of the ligand and
receptor, which can be used as a template for designing new ligands.
To aid hit-to-lead modification efforts, computational docking programs can be employed
to virtually screen modified fragments to determine the predicted binding affinity.9,10 The
experimentally-determined structure of the ligand-receptor complex is imported into the docking
software and crystallographic fragments (buffer, water or additional protein molecules) are
removed. The binding site is identified and the bound ligand molecule is deleted, revealing the
empty binding site. Derivatives of the fragment molecule can then be designed and “docked”
into the receptor. Output docking poses are then generated by sampling the conformational space
accessible to both the ligand and receptor until an estimate of the minimul free energy of binding
is determined.10 The docking program then scores each pose and provides a ranked output file.
Many docking programs also employ algorithms to convert predicted free energy to predicted
binding affinities. However, these predictions are currently minimally reliable and compounds
should therefore be ranked on a combination of predicted docking poses and interactions, as well
as predicted binding affinity.11 The promising species can then be synthesized and screened
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against the target in vitro to discern the relationship between predicted and experimental
activities.

Ligand-Receptor Interactions and Bioisosterism

While the previous sections describe the process involved in fragment modification, the
specific changes to fragments that could afford increased affinity can be difficult to predict.
Because small changes in the fragment structure can result in the obstruction of specific binding
contacts, changes must be made methodically. As such, fragment hit molecules are usually
increased in size to exploit predicted binding interactions with adjacent pockets or residues.
Although some drugs form covalent complexes with their target, most bind noncovalently to the target receptor. It is therefore imperative that medicinal chemists have a
fundamental understanding of the forces responsible for protein-ligand interactions. The basic
principles that govern intermolecular attractive forces in solutions, as discussed in general
chemistry courses, are also responsible for non-covalent ligand binding to proteins. As such,
polar (H-bonding, dipole-dipole, salt bridges) and nonpolar (lipophilic interactions) attractive
forces are commonly manipulated to increase ligand binding to target receptors. For example,
some side chains are polar and can act as H-bond acceptors (Asp, Glu), or donors (Arg, Lys,
Trp), while some still can act as either (Asn, His, Gln, Ser, Thr, Tyr). Aromatic side chains (His,
Phe, Trp, Tyr) can coordinate with aryl rings incorporated within ligands via π–π stacking
interactions. Finally, main chain functional groups, such as amide N-H bonds or carbonyls, can
also interact with ligands via polar interactions.
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Additionally, fragment hits can be modified according to bioisosterism, where
structurally and electrostatically similar functional groups within potent ligands are exchanged
(see Table 2). For example, an alcohol involved in H-bonding can be replaced with an amine to
achieve the same effect.12 The conversion of bioisosteres can also affect potency in both
favorable and unfavorable ways. Some changes increase solubility, such as conversion of a
terminal alkyl chain to a terminal quaternary ammonium salt, which can afford increased potency
for highly lipophilic ligands. However, some bioisosteric replacements afford unpredictable
decreases in potency. As such, many different modifications should be applied and the resulting
species screened for potency to determine the optimum chemical identity for target binding.

Table 2: Examples of Typical Biosteric Groups Useful for Hit Modificationa

Monovalent Bioisosteres
H, D, F
NH, OH
RSH, ROH
F, OH, NH2, CH3
Cl, Br, SH, OH
C, Si

Classical Bioisosteres
Bivalent Bioisosteres
C=C, C=O, C=S
-CH2-, -NH-, -O-, -SRCOR′, RCONHR′, RCOOR′, RCOSR′

Trivalent Bioisosteres
R3CH, R3N
R4C, R4Si, R4N+
alkene, imine
-CH=CH-, -S-, -N=CH-

Nonclassical Bioisoseres

a. Reprinted (adapted) with permission from (Meanwell, N.A., J. Mec. Chem, 2011, 54 (8), 2529-2591).12 Copyright
(2011) American Chemical Society.

In practice, bioisosteric replacements are generally utilized to fine-tune pharmacokinetic
properties. Once the potency of a hit molecule has been maximized against a specific target, the
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hit must be converted to an efficacious species following host administration. This stage of hitto-lead modification is crucial, as any changes to the ligand could result in less potent species,
diminishing the therapeutic window. Various bioisosteric replacements attempt to convert
lipophilic groups to hydrophilic species; aryl H atoms can be replaced with OH, NH2, or F to
increase lipophilicity, thereby increasing bioavailability. Changes such as these could negatively
impact potency; hit molecules are therefore modified to first maximize potency, followed by
efforts to optimize pharmacokinetics with minimal effect on the established activity. This is
known as multiparameter optimization and should be employed in drug discovery efforts13 (see
Figure 2).

Dissertation Overview

This dissertation explores three distinct projects which are related by their application of
small molecule inhibition of enzyme activity. The first project involved the inhibition of jack
bean urease (JBU) by tree bark extracts rich in tannins, a class of polyphenolic phytochemicals.
The bark extracts were screened for urease inhibition and the resulting activities were compared
to the ammonia abatement activity of the extracts when mixed with dairy cattle excrement. The
second project involved the use of quercetin, a tannin, as a potential antimalarial agent. Mannich
reactions were used to synthesize a variety of aminoalkylated quercetin derivatives to increase
the solubility of the quercetin parent compound. The resulting species were screened against
three strains of drug-resistant malaria. The third project involved the inhibition of methionine
aminopeptidase (MetAP), an enzyme necessary for cellular proliferation, for antibacterial
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applications. A wide variety of compounds based upon published inhibitory scaffolds were
purchased or synthesized and screened for MetAP inhibition. Compounds active against the
enzyme in vitro were screened in a host-cell viability assay to determine antibacterial activity in
the presence of mammalian cells.

Figure 2: Trend regarding potency and pharmacokinetic considerations in multiparameter
optimization. The dotted line demonstrates incremental changes to both parameters, with potency
maximization being the primary focus during early discovery stages; the solid gray line
demonstrates the “average” for optimization of both parameters; and the solid black line
demonstrates a discovery effort where both parameters are perfectly optimized simultaneously.
Reprint with permission from John Wiley & Sons, Inc. (Brown, 2012).13

CHAPTER 2
INHIBITION OF JACK BEAN UREASE BY TREE BARK EXTRACTS

Introduction

The application of soil fertilizers to promote increased crop yield has long been utilized
to grow food for sustaining populations. Agricultural practices are documented to have begun
some 12,000 years ago, with a recent report suggesting cultivation efforts were being undertaken
as many as 23,000 years ago on the shores of the Sea of Galilee.14 Early reports of fertilizer use
in the ancient world are found in the works of Plato and Aristotle, demonstrating that the growth
cycle of food crops was well understood and exploited by ancient societies.15,16
Modern agricultural efforts concerning fertilizer use began in the early to mid 19th
century, with advances made in both the understanding of crop growth and soil depletion cycles,
and soil fertility screening.17 Researchers began to discover the relationship between soil
composition and growth outcomes and actively worked to identify nutrients necessary for crop
proliferation. Since then, nutrients have been divided into four primary categories describing
those essential for optimal growth: structural elements, primary nutrients, secondary nutrients,
and micronutrients18 (see Table 3). Carbon, hydrogen and oxygen are structural neutrients that
are incorporated into the cell walls, proteins, and organelles of plant cells, and are readily
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absorbed from atmospheric sources (CO2, O2) and as ground water. Primary and secondary
nutrients are required for cellular processes and the generation of macromolecules necessary for
cellular function; these nutrients are required in differing volumes, with cells utilizing primary
nutrients to a larger degree than secondary nutrients. Finally, micronutrients are required by cells
for similar applications as primary and secondary nutrients, although in much lower
concentrations.

Table 3: Required Cellular Nutrients for Optimum Plant Growth18
Primary Nutrients Secondary Nutrients Micronutrients Structural Nutrients
Nitrogen
Calcium
Boron
Carbon
Potassium
Magnesium
Chlorine
Hydrogen
Phosphorus
Sulfur
Copper
Oxygen
Iron
Manganese
Molybdenum
Nickel
Zinc

Of these key nutrients, nitrogen was the first determined as necessary for plant growth
and incorporation of nitrogen into growth soils was found to substantially increase crop yields.19
This is not surprising; soil conditions are not suitable for the containment of nitrogen salts or
ammonia for extended periods and nitrogen is therefore the most depleted nutrient in growth
soils. Early efforts regarding the regeneration of depleted soil began with the use of livestock
excrement as an organic fertilizer, as fecal matter and urine are high in nitrogen content in the
form of urea. While advances in modern agriculture have involved the formulation of fertilizers
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utilizing nitrogenous species for incorporation, the greatest advancement of fertilizer use and
application came in the early 20th century with the development of the Haber-Bosch process for
the generation of ammonia from atmospheric nitrogen; Fritz Haber and Carl Bosch won the
Nobel prize in chemistry in 1918 and 1931, respectively, for their contributions to the industrial
production of ammonia.
Although it had been established that the inclusion of inorganic nitrogenous salts in
fertilizer compositions increases crop yield, natural sources of these salts were not abundant.20
Ammonium nitrate was an early example of nitrogen based fertilizers, and was imported from
reserves in Norway and Chile for use in American agriculture. However, in 1913, producers in
Germany began the industrial scale production of anhydrous ammonia with the utilization of the
Haber-Bosch process. Early efforts involving the use of liquid ammonia fertilizers were limited
due to the lack of application technology, but anhydrous ammonia is now one of the most widely
utilized nitrogenous fertilizers.19
The Haber-Bosch process involves the use of an iron or ruthenium transition metal
catalyst for the production of gaseous ammonia from elemental hydrogen and nitrogen. Although
the standard enthalpy of formation for ammonia is exothermic (

NH3 = -46.1 kJ/mol, see

Scheme 1), the process is extremely slow under ambient conditions.21 Utilizing present-day
catalysts and combining nitrogen and hydrogen gasses in a 1 to 3 ratio, the conversion can occur
at high temperature (>300 oC) and high pressure (150 – 350 atm).22 The resulting gaseous
mixture is cooled and condensed to afford liquid ammonia which is collected; the remaining
gaseous mixture is reintroduced into the reaction chamber to achieve additional conversion. The
process is hampered by the reaction of other gases to produce undesired species, namely CO2 and
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CO in the production of methanol.22 As such, the initial gases are purified to minimize undesired
reactions (see Scheme 1).

Scheme 1: Haber-Bosch process and potential side reacions

Urea as a Nitrogenous Fertilizer

Anhydrous ammonia revolutionized the agricultural industry; however, the high costs
regarding its application, transportation, and storage have paved the way for solid-state fertilizing
mixtures. Popular nitrogenous fertilizers include: urea, ammonium nitrate, calcium ammonium
nitrate, and ammonium sulfate. Additionally, fertilizing mixtures containing other essential
nutrients are often employed for agricultural purposes, such as ammonium phosphate. However,
in 2000 it was noted that urea (1) was the most widely utilized fertilizer, with 41,042 metric tons
applied to soil;19 for comparison, the next most utilized nitrogenous fertilizer was ammonium
nitrate, with 5,319 metric tons applied in the same year.
Although widely used for fertilization, urea can be detrimental for plant growth. The
phytotoxicity associated with urea based fertilizers is two-fold: first, a major byproduct of the
industrial urea production process is biuret (2), which cannot be metabolized by crops. For
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example, it was found that biuret can accumulate in plants; one study found biuret within the
leaves of orange trees eight months after the original application.23 The second source of toxicity
commonly associated with urea based fertilizers involves urea metabolites and decomposition
products, including cyanate, carbamate, ammonia, and nitrate,18 substances which are toxic for
seed germination. Regardless of the documented drawbacks to urea based fertilizers, they still
remain highly popular among farmers.

Upon application, urea dissolves in ground water and some of the dissolved urea is
inevitably lost to ground water leaching (see Figure 3). However, most urea is subject to the
enzymatic activity of bacterial species residing within the growth soil and is converted to
ammonia and carbon dioxide through the activity of urease enzymes. The resulting ammonia is
then either converted to ammonium salts and trapped within the soil or is lost to volatilization.
Some ammonium is then oxidized by Nitrosomonas to the nitrogen dioxide anion. This anion can
then undergo chemo-denitrification to afford nitrogen loss as N2 or NO, or oxidation by
Nitrobacter to afford the nitrate anion. The nitrate anion can be utilized by plants via uptake and
reduction to ammonium, or can leach into ground water. Additionally, nitrate can be utilized by
soil bacterial species as an oxygen source for anerobic applications, resulting in nitrogen loss as
N2, NO or N2O.18
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Figure 3: Representation of processes dictating urea use and decomposition following
application. Fertilizing nitrogen can be lost when applied as urea via a number of differing
pathways. Initial urea is converted to ammonium via urease activity. The resulting ammonia can
be stored within soil or lost to volatilization and additional microbial metabolism to the nitrogen
dioxide anion. The anion is then denitrified to N2 or NO, or is further metabolized to the nitrate
anion, which can be absorbed and reduced to ammonium, leached into ground water, or serve as
an oxygen source for anerobic oxidation, resulting in nitrogen loss as N2, NO, or N2O. Reprint
with permission from John Wiley & Sons, Inc. (Timilsena, 2014).18
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Urease Activity on Urea Fertilizers

As shown in Figure 3, urea is readily converted to ammonia following soil application.
This is achieved through the enzymatic activity of soil microbes, which begin urea
decomposition immediately upon application depending upon conditions (temperature, pH, soil
composition, moisture content, etc.).24 Urea hydrolysis is achieved via the activity of urease
enzymes in soil ecosystems. Many bacterial25 and archaeal26 genera have been discovered as
responsible for the metabolism of urea. A noteworthy recent discovery was the presence of genes
coding for ureases in Nitrospira, which demonstrated species possess the ability to convert
ammonia to nitrates independently of the synergistic relationship indentified for the two-step
nitrification process.25 Additionally, the soil application of urea or other ammonia based
fertilizers has led to a stark increase in the atmospheric accumulation of nitrous oxide (N2O), a
greenhouse gas.27 As such, efforts to control the hydrolysis of urea upon soil application are ongoing and have large implications for both the agricultural industry, and perhaps, on the
sustained global well-being.
If urea applied to soil is allowed to hydrolyze at unhindered rates, the loss of applied
nitrogen as ammonia can be substantial; up to 50% of the nitrogen content of dry urea applied to
soil can be lost due to volatilization.28 However, this drastic loss of nitrogen can be avoided by
the incorporation of urease inhibitors in urea-based fertilizing mixtures. Many inhibitory species
and mixtures are commercially available and generally act via coordination to the two catalytic
nickel cofactors found universally within all urease structures.29 For agricultural applications,
thiophosphoric triamide based inhibitors are widely applied, and of these, N-(n-
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butyl)thiophosphoric triamide (NBPT) (3) has seen the most widespread use under the trade
name Agrotain®. The application of NBPT with urea as a fertilizing mixture was found to
decrease nitrogen loss as compared to a urea control (8% and 25% loss, respectively), although
the same study found a deleterious effect associated with urea application regarding the nitrogen
uptake of rapeseed.30 An additional study explored the effect of a urea/NBPT fertilizing mixture
on the growth of a cotton field over the course of two years; this study found reductions in
ammonia volatilization by 53% and 63% over consecutive years as compared to a control field
fertilized with urea alone, when NBPT is applied according to the manufacturer’s
specifications.31 The large difference in nitrogen loss between these two studies demonstrates the
variability of the environmental factors governing urease activity. As such, the quantification of
the beneficial effect of NBPT fertilizing mixtures is difficult to discern, although the inhibitor
clearly has benefits regarding nitrogen loss by ammonia volatilization.

Tannin-Based Urease Inhibitors

In addition to those found for crop growth soils, the inhibition of urease activity has
agricultural implications in relation to improved nitrogen incorporation of applied manure
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fertilizers. Waste generation from dairy and beef cattle has been determined to account for 50%
of agricultural nitrogen volatilization;32 the source of ammonia volatilization in raw manure and
slurries is bacterial, where fecal bacteria hydrolyze urea to ammonia via urease activity.33 As
such, NBPT has been applied to manure slurries to determine both the effect of urease inhibition
on organic fertilizers and any resulting increase in nitrogen incorporation. For example,
approximately 60 – 80% of nitrogen output from cattle is found in urine, where 97% of urinary
nitrogen content exists as urea.34 It was determined that the treatment of fertilizer slurries with
NBPT at a concentration of 80 mg/kg manure resulted in the inhibition of noticeable urea
hydrolysis for up to 14 days; interestingly, doubling the concentration of NBPT did not exhibit a
noticeable effect on the abatement of ammonia volatilization.35
Although NBPT can be utilized for reduced ammonia emissions from manure via
application post-excretion, control over the in vivo production of ammonia is desirable. A
reduction in the nitrogen volatilization potential of manure prior to excretion could afford better
nitrogen incorporation, where this cannot be achieved with NBPT additives to feedstock due to
associated toxicity of the solvent commonly found in Agrotain® solutions (N-methyl-2pyrrolidone, NMP). NMP (4) has been shown to have various side-effects in many animal
models;36 notably, increases in arterial pressure indicating potential cardiovascular complications
were discovered upon intravenous application to a screening population of four male sheep.37
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To address the potential adverse side effects of including Agrotain® with feedstock,
researchers began searching for natural alternative additives. Recent reports found that the
inclusion of quebracho (Q) and chestnut (CN) tree bark extracts to dairy cattle diets afforded a
shift in nitrogen content from excreted urine to secreted milk, resulting in an overall increase in
absorption of nitrogen supplied from feed.38 An additional study explored the effect of applying
Q and CN extract to excreted feces and simulated dairy barn floors and found significant
reductions in ammonia production for both experiments.33b Finally, manure slurries of cattle fed
diets containing Q and CN extract were applied to simulated growth fields and were found to
restrict ammonia loss compared to a control, with up to 50% less ammonia production after 48
hours.33a Based upon these studies, it is clear that ammonia production is decreasing both in vivo
and in cattle manure following excretion, suggesting the inhibition of urease activity by the two
bark extracts.
The exact chemical species responsible for this observed reduction in ammonia
volatilization is unknown; however, the broad class of compounds generally associated with
these observations is tannins.33, 38 Tannins are a class of polyphenolic compounds widely
dispersed within nature and are characterized by their use in leather production and their ability
to precipitate various proteins.39 They are generally secondary metabolites and serve as defense
against bacterial and fungal attack; additionally, tannins are involved in photoprotection against
harmful over exposure to ultraviolet radiation not absorbed for photosynthetic use, and are
utilized to mitigate the effects of various environmental stresses (temperature, heavy metal overabsorption, and oxidative stresses).40
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To date, two distinct classes of tannins have been identified: condensed tannins, and
hydrolyzable tannins.41 Condensed tannins obtained from plant sources are generally found as
oligomers of two to six units in length, or as larger polymers which are insoluble in water.39 The
monomeric subunits are composed of flavanoid rings, specifically flavan-3-ols such as (±)catechin (5) or (±)-epicatechin (6). The compounds are generally found to polymerize at the 4
and 8 positions of the flavanol monomer, where species have also been isolated with branched
polymerization at the 6 position.40 Condensed tannins are found widely dispersed within
quebracho bark matter, suggesting that species such as these could be responsible for the
predicted urease inhibitory activity (see Figure 4).
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Figure 4: General numbering scheme and ring naming for condensed tannins. Left: Flavonoids
are numbered starting with the oxygen of the central pyran ring and numbered sequentially going
clockwise. Conventional labeling of the ring system is shown. Right: Condensed tannins are
synthesized by polymerization of the monomeric subunits at the 4 and 8 positions of the
flavonoid ring. Some species have been isolated as branched polymers, where branching is
achieved at the 6 position of the flavonoid ring.
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Hydrolyzable tannins are composed of a carbohydrate core in which some or all of the
alcohols are esterified as either gallate or hexahydroxydiphenate (HHDP) esters.40 The naming
convention for these tannins is such because gallic acid (7) or ellagic acid (8) is recovered upon
subjecting hydrolyzable tannins to acidic (hydrolytic) conditions. The monosaccharide core is
usually glucose, although other species have been isolated.41 Many diverse structures have been
discovered, including some dimerized species linked via the esterification of terminal alcohols
on the carbohydrate core of two adjacent molecules, where HHDP acts as a linker.40 The degree
of esterification also varies, with some species exhibiting esterification of gallate and HHDP
esters by additional gallate moieties. Among gallate based hydrolyzable tannins, 1,2,3,4,6pentagalloyl glucose (PGG) (9) and tannic acid (decagalloyl glucose) (10) have been determined
as widespread within plant extract, especially within tree bark sources.42 It is noteworthy that
commercial tannic acid is labeled as decagalloyl glucose, but actual contains varying species
with differing degrees of galloylation.
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Examination of the extract content of various plant sources has determined relative
hydrolyzable and condensed tannins for a number of species. For example, it was determined
that quebracho (Q) tree bark extract was rich in condensed tannin content, while chestnut (CN)
tree bark extract was rich in hydrolyzable tannin content.43 As such, these two abundant tannin
sources were utilized in the studies by Powell regarding ammonia abatement of bovine manure
slurries before and after simulated growth soil application and in simulated barn floor emission
experiments.33, 38 To discover natural urease inhibitors for decreased nitrogen volatility at all
stages of dairy cattle operations and for use with manure based fertilizers, it is imperative to
discern the exact chemical makeup of the extracts.

26
Experimental Design

To determine the source of the beneficial effects of supplying tannin-rich natural product
extract to bovine feedstock,33, 38 the Q and CN bark extracts must be incrementally fractionalized
and screened for any alterations in the activity as compared to the raw bark extract. The
separation of tannin extract affording individual compounds is difficult, as many species,
especially flavan-3-ol monomers and oligomers, differ only by hydroxyl substitution patterns of
the A and B rings. Initial separation efforts begin with extraction from plant matter. The choice
of extraction solvent can have a large effect on the specific identities of the solvated compounds
(e.g. hexane  lipids, methylene chloride  flavonoid aglycones, alcohol flavonide
glycosides).40 Once a specific collection of tannin mixtures is collected, the concentrated extract
can be subject to preparative chromatography for further purification.
The raw bark extracts, as well as the various solvent extracts, could then be subject to an
ex vivo simulated barn floor assay33b (Wayne Zeller, USDA, Madison, WI) to screen for
abatement of ammonia volatilization from dairy cattle manure slurries. However, this assay
requires exquisite control of many parameters (manure composition, temperature, emission
chamber sterilization, etc.) and takes a significant amount of time (3 days). Because the observed
ammonia emission from cattle manure is suggested to be the result of bacterial urease activity, an
in vitro urease assay was optimized to rapidly screen various samples for inhibitory activity.
After calibration with the ex vivo assay, the in vitro assay can be used to determine the relative
inhibitory activity of solvent extracts, and the most potent fractions can be submitted to
collaborators for manure ammonia abatement determination.
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For our study, it was first necessary to partition the raw extract from each source in
solvents of increasing polarity, separating the soluble and insoluble fractions (see Figure 5).
Beginning with the raw bark extracts, each species was introduced to methanol, stirred overnight
at room temperature, and filtered. The methanol soluble fraction was concentrated to dryness to
yield a powder. This extract was then subject to fractionalization in solvents of increasing
polarity (hexane  chloroform  ethyl acetate  n-butanol), where the insoluble portion of
each fraction was introduced to the next solvent. Each extract can then be screened against
urease to determine the inhibitory activity. The activity could then be monitored throughout the
course of solvent partitioning. Separation efforts can then be focused on the fractions exhibiting
the most potent activity.
Because the exact urease species presumably responsible for the observed ammonia
volatilization is unknown, a model system must be developed to screen for urease inhibitory
activity in vitro. One of the most widely studied urease species was first isolated from jack bean
meal by James B. Sumner in 1926;44 he was also the first to crystallize an enzyme and
demonstrated that enzymes are in fact specialized proteins,44 earning him the Nobel Prize in
Chemistry in 1946. The enzyme isolated by Sumner is referred to as jack bean urease and has
been found to be stable as a lyophilized powder for extended periods of time. Because jack bean
urease (JBU) is commercially available, it was selected as the urease species for utilization in the
in vitro enzymatic assay.
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Figure 5: Flow chart representing planned extraction efforts for the separation of raw tree bark
extract. The raw bark is first partitioned in methanol and separated via filtration. The methanol
insoluble portion was then subject to further fractionalization by solvents of increasing polarity.
Each soluble fraction can be screened for in vitro urease inhibitory activity to direct further
separation efforts.
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X –ray crystal structures of jack bean urease suggest the enzyme exists as a hexamer,
where two homotrimers, each forming a triangular assembly, interact along the relatively planar
external surface constituting the trimer-trimer interface45 (see Figure 6). Recently, gel-filtration
chromatography and analysis by native gel electrophoresis have confirmed that JBU exists as a
hexamer in solution.45 Each monomer is composed of four discrete regions, one of which
contains a catalytic domain utilizing two divalent nickel atoms as cofactors. Although the exact
mechanism of urea hydrolysis is unclear, it is hypothesized that urea first binds through the
carbonyl to one of the cofactors, increasing the electrophilicity of the carbonyl carbon, which is
then attacked by a hydroxide ion generated by the other cofactor.45-46
The initial in vitro assay we employed for the screening of JBU inhibitory activity was
based upon the protocol established by Sigma-Aldrich for determining urease activity of isolated
protein batches (Sigma-Aldrich Product Information Documents U0376 and U7878). Because
the product of urea hydrolysis by JBU is ammonia, there is a marked increase in pH as the
reaction progresses; the assay is run in buffer and ammonia production (enzyme activity) can
therefore be measured as a function of pH. A titration-based assay was therefore employed,
where the enzymatic reaction was allowed to progress for a specific amount of time before back
titrating with dilute hydrochloric acid (0.1M) to quantify ammonia production. The endpoint is
visualized by the addition of a pH indicator, phenol red, which changes color from pale yellow to
purple over the pH range 4.8 – 6.7 (see Figure 7). To determine inhibitory activity of the Q and
CN bark extracts, the raw extracts were added to the assay mixture at varying concentrations to
determine effects upon urease activity. Inhibitory activities were determined by constructing a
dose-response curve from percent inhibition of enzymatic activity for various extract
concentrations.
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Figure 6: Crystalline structure of JBU and urea hydrolysis reaction scheme. Top Left:
Hexameric structure of JBU viewed face on; colored according to monomer domain. Top Right:
Hexameric structure of JBU viewed along the axis of tetrameric coordination; colored by trimer.
Middle Left: Monomeric structure of JBU; colored according to domain, where red spheres
indicate nickel cofactors. Middle Right: JBU active site demonstrating cofactor binding. Bottom:
General reaction scheme for urease catalyzed urea hydrolysis (PDB: 3LA4).45
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Figure 7: Titration assay indicator chlorophenol red pH range. Top: Urease solutions subject to
titration from basic (right) to acidic (left) pH levels. Middle: Structures of chlorophenol red
under both acidic (yellow) and basic (purple) conditions. Bottom: Representation of the
applicable pH range for chlorophenol red (4.8 – 6.7).
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Additionally, a set of seven tannin-based test compounds was selected for screening in
both the in vitro and ex vivo ammonia abatement assays to normalize the two; compounds
included: NBPT (3), (+)-catechin (5), (-)-epicatechin (6), PGG (9), tannic acid (10), quercetin
(11) and (-)-epigallocatechin gallate (EGCG) (12).

Our efforts to utilize this assay to determine the inhibitory activity of the compound test
set and raw bark extracts were largely unsuccessful (see Results and Discussion, page 34). It was
therefore necessary to develop and optimize an alternative assay to determine urease inhibitory
activity. Thus, we decided to pursue a plate-based absorbance assay of similar design as that of
the titration assay, where color changes relating to pH increases could be quantified by
monitoring solution absorbance. A slight adjustment was made concerning the identity of the pH
indicator. The initial buffer pH was fixed at 7.0 (near the optimal pH for JBU at 7.4) which poses
a problem when using the original pH indicator chlorophenol red, as no visible transition will
take place at higher pH levels. Therefore, the pH indicator phenol red, which exhibits a transition
from yellow to red in the pH range of 6.8 – 8.2, was used. The basic form of phenol red exhibits
an absorbance maximum at 570 nm (see Figure 8).
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Figure 8: Plate-based assay indicator phenol red pH range. Top: Structures of phenol red under
both acidic (yellow) and basic (red) conditions. Bottom: Representation of the applicable pH
range for phenol red (6.8 – 8.2). Absmax values are from previously reported sources.47
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Results and Discussion

To determine the relative urease inhibitory activities of the compound test set, an in vitro
acid-base titration assay was utilized, as described in the previous section (see Experimental
Design, page 26). However, initial efforts to determine urease inhibitory activities resulted in a
large degree of experimental error and calculated values could not be easily reproduced for any
test compound screened. Because the assay relied upon visual identification of the indicator
color-change, it was difficult to determine the exact titration end-point. This resulted in
erroneous calculation of the amount of ammonia produced by urea hydrolysis.
We therefore switched to a plate-based assay to facilitate rapid data collection and to
alleviate error associated with absorbance measurements.48 The assay employed a 96-well plate,
which allowed for the determination of inhibitory activities across 12-point dose response-curves
of two compounds in triplicate. This resulted in half the time commitment as the titration assay.
Additionally, the plate reader is able to measure the absorbance of each individual well at a
specific wavelength in real-time, significantly reducing experimental error associated with data
collection and allowing for continuous solution absorbance measurement.
Concerning the assay conditions, each well was incubated with urease and inhibitors at
various concentrations for one hr at 37 oC. Relative enzyme rates were measured as the slope of
an absorbance vs. time plot over the 20 – 30 min interval (see Figure 9). This time interval was
determined to allow for sufficient pre-incubation to minimize error and was found to be early
enough in the reaction profile to suggest calculated enzymatic rates were maximized. Inhibitory
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activity was determined according to 1 – vi/vo, where vi and vo refer to reaction rates for inhibited
and uninhibited urease solutions, respectively.
The in vitro and ex vivo inhibitory activities for the seven compounds are presented in
Table 4. The in vitro results revealed that the commercial inhibitor, NBPT (3), exhibited the most
potent inhibitory activity (IC50 = 0.06µM), followed by tannic acid (10) (IC50 = 0.46 µM) and (-)EGCG (12) (IC50 = 0.54 µM). We had predicted that (-)-EGCG (12) would exhibit potent
activity, as the compound has been reported to potently inhibit urease isolated from H. pylori, the
bacterial species responsible for chronic gastritis and gastric ulcers.49 Stereochemistry of the
flavan-3-ols appears to play a minimal role in observed urease inhibitory activity, as (+)-catechin
(5) and (-)-epicatechin (6) were found to exhibit comparable ammonia production inhibition
(IC50 = 9.9, and 9.2 µM, respectively). Galloylation of the alcohol at the 3-position of the flavan3-ols results in a drastic increase in activity, as demonstrated by the relative inhibitory activities
of (-)-epicatechin (6) (9.2 µM) and (-)-EGCG (12) (0.54 µM). Finally, quercetin (11) was found
to be insoluble in the assay buffer and precipitated at nearly every concentration screened (see
Table 4).
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Figure 9: Experimental data for urease inhibition by NBPT and transformation to determine
inhibitory activity. Top: Absorbance vs. time plot of urease solutions containing NBPT at
increasing concentrations of inhibitor. As concentration is increased, activity is inhibited to a
greater extent, resulting in a decrease in ammonia production and solution absorbance. Each
concentration was measured in triplicate. Bottom: Activity is measured as the slope of the Abs.
vs. time plot over 20-30 min. Dark shading of the curves shows the region used to calculate
reaction rate.
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Table 4: Inhibitory Activities of Compound Test Set
In vitro
Inhibitory
Activity (IC50)a

Ex vivo Ammonia
Abatement
(% Inhibition)b,c,d

NBPT (3)

0.06 ± 0.01

>90

(+)-Catechin (5)

9.9 ± 1.1

50 ‡,Δ

(-)-Epicatechin (6)

9.2 ± 3.0

27 ɺ

6.4 ± 2.2

43 Δ

0.46 ± 0.07

62 †,‡

Quercetin (11)

NAe

NAe

(-)-EGCG (12)

0.54 ± 0.08

76 †

Compound

Structure

PGG (9)

Structure on Page 25

Tannic Acid (10)

Structure on Page 25

a.
b.
c.
d.
e.

IC50 values expressed in units of µM; see Appendix A (page 240) for dose-response curves.
% Inhibition at 90mg/8g of manure; measurements recorded as ammonia collected over 48 hrs
Values were calculated by collecting ammonia with acid traps connected to chamber gas outlet and
quantified with flow injection analysis; data collected by Wayne Zeller, USDA (Madison, WI)
Symbols indicate measurements differing by statistical significance (P <0.05) in a Tukey test
comparing least square means; e.x. Δ means PGG and (+)-catechin were not differentiable, statistically
Activity not calculated due to inhibitor insolubility in the assay buffer
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Ammonia volatilization from manure slurries containing inhibitors is also detailed in
Table 4. However, we should note the measurements used to determine inhibitory activities in
the ex vivo assay relied upon the determination of the mass of ammonia produced, and all values
were below 15 mg. This could potentially result in a large amount of error associated with each
measurement, especially for trials where the inhibition of urease activity was essentially
complete, as a loss of even 1 mg of ammonia could change the calculated inhibitory value by
7%. As such, activities of compounds not differing statistically according to a comparison of
least square means (Tukey test)50 are marked with a similar symbol in Table 4 (e.x. the Δ next to
measurements for (+)-catechin (5) and PGG (9) indicates the observed activities are not
significantly different). Concerning the relation between the activities calculated for both assays,
the relative observed activities for the inhibitors at 90 mg/8 g manure roughly mirrored the
results from the plate-based assay, with the activity series being NBPT > (-)-EGCG > tannic acid
> (+)-catechin = PGG > (-)-epicatechin. The data in Table 4 therefore demonstrates the two
assays can differentiate between inhibitory species, especially when observed activities differ
greatly. As such, the plate-based assay can be used to rapidly screen compounds for urease
inhibitory activity and can identify active compounds. Compounds active in the in vitro assay
should exhibit similar ammonia volatilization abatement when subject to the manure slurry
assay. This suggests we can use the in vitro assay to pre-screen for urease inhibition and use the
results to guide separation efforts to identify the individual active compounds.
Once the in vitro and ex vivo assays were correlated, we screened the raw bark extracts
from quebracho (Q) and chestnut (CN) sources, which are rich in condensed and hydrolyzable
tannins, respectively, in each assay to determine relative inhibitory activities (see Table 5).
Additionally, a mixture of the two bark extracts was also screened to determine any additive
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effects of the two different tannin types on urease inhibition. The plate-based assay determined
the CN extract was more active than both the Q and Q/CN mixture extracts. This is noteworthy,
as CN extracts are rich in hydrolyzable tannins and Q extracts are rich in condensed tannins.
Also, tannic acid (10) was found to exhibit potent activity in both the in vitro and ex vivo assays.
This could suggest that hydrolyzable tannins are more effective urease inhibitors than condensed
tannins, although the raw manure slurry certainly contains a plethora of potential receptors other
than urease.
Differences in the activity of the bark extracts were not as pronounced in the manure
slurry assay; the extracts all exhibited similar ammonia abatement at each for the four dosing
levels. However, the extracts did exhibit dose-dependent behavior, as ammonia abatement
increased with dosage. Interestingly, ammonia volatilization was barely observable with dosages
of 360 mg/8 g manure slurry. This observation is important, establishing that tannin-rich extracts
in high concentration are capable of inhibiting ammonia volatilization at levels comparable to
Agrotain®. Encouraged by the correlation between the two assays and the determination of the
greater inhibitory activity for CN extract in the plate-based assay, we set out to separate the CN
extract according to the extraction flow-chart (see Figure 5, page 28).
To begin our separation efforts, the CN bark extract was partitioned in methanol and
stirred at room temperature for 24 hrs. The mixture was then filtered and the filtrate concentrated
to dryness. The two resulting fractions (soluble and insoluble) were dried in a vacuum oven at 25
o

C for 24 hrs. We found that approximately 75% of extract was soluble in methanol. Finally, the

soluble and insoluble CN fractions were screened using the in vitro assay to determine urease
inhibitory activity. We were therefore shocked to discover that both fractions exhibited no urease
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inhibitory activity up to 1,000,000 ng/mL. Similarly, extraction of the Q tannin source and
subsequent screening for urease inhibitory activity suggested that neither Q fraction exhibited
ammonia volatilization abatement. The exact source of the universal loss of urease inhibitory
activity is not immediately apparent, although introducing the fractions into a vacuum oven at 25
o

C could have facilitated the decomposition of condensed tannin oligomers and polymers.

Additionally, tannins are known antioxidants and could have decomposed in the presence of
methanol, as the extraction was not performed under inert atmosphere.

Table 5: Inhibitory Activities of Raw Bark Extracts

a.
b.

c.
d.

Extract Identity

In vitro
Inhibitory Activity (IC50)a

Quebracho (Q)

450 ± 100

Chestnut (CN)

20 ± 10

Q/CN Mixture

250 ± 120

Ex vivo Ammonia
Abatement
(% Inhibition)b,c,d
45 †mg : 25%
90 Δmg : 40%
180 ɺ, mg : 80%
360 mg : 95%
45 †,‡mg : 20%
90 Δmg : 35%
180 ɺ, mg : 85%
360 mg : 95%
45 ‡mg : 7%
90 Δmg : 40%
180 ɺmg : 75%
360 mg : 95%

IC50 values expressed in units of ng/mL; exact concentration is unknown as samples are mixtures; see
Appendix A (page 240) for dose-response curves.
Symbols indicate measurements differing by statistical significance (P <0.05) in a Tukey test comparing
least square means; e.x. ∆ means Q 45 mg and CN 45 mg measurements were not differentiable,
statistically
% Inhibition at indicated mass of extract/8g of manure; measurements recorded as ammonia collected over
48 hrs
Values were calculated by collecting ammonia with acid traps connected to chamber gas outlet and
quantified with flow injection analysis; data collected by Wayne Zeller, USDA (Madison, WI)
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Conclusions

To streamline the separation efforts of tree bark tannins with demonstrated ammonia
abatement activity against manure slurries both immediately following excretion33b and after
application to growth soils,33a we sought to develop an in vitro urease inhibitory assay to predict
activity in a related ex vivo simulated barn floor assay. The plate-based assay was found to afford
the rapid assessment of urease inhibitory activity as IC50 values calculated from 12-point doseresponse curves. After determining inhibitory activities of the initial seven-compound test set,
the relative activities from the in vitro assay were found to correlate to results of the ex vivo
ammonia abatement assay. This was encouraging, as it was thus confirmed that the in vitro assay
can be used to determine inhibitory activities for bark fractions prior to screening within the ex
vivo assay, decreasing the total resource commitment required for the isolation of the component
responsible for the documented manure slurry ammonia abatement.
However, the screening results from both assays demonstrated that, while the in vitro
assay was able to detect differences in the urease inhibitory activity of the Q and CN bark
extracts, the two sources exhibited essentially identical inhibitory activities in the manure-slurry
assay. This is not surprising; the in vitro assay conditions include only one possible receptor
(JBU), while the manure slurry likely contains a large number of potential targets. The extracts
did exhibit dose-dependent behavior, as ammonia abatement was more pronounced at higher
extract concentrations. In fact, at a dosing of 360 mg extract/8 g manure, the tannin mixtures
exhibited inhibitory activities comparable to that of NBPT at the manufacturer’s recommended
dosage. This observation is encouraging and suggests that determination of the responsible
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component or components could afford a natural tannin mixture capable of potent ammonia
abatement with at applicable concentration.
The bark mixtures were subjected to extraction in methanol and were separated as soluble
and insoluble fractions. When screening these fractions in the JBU in vitro assay, we found that
the inhibitory activities of both fractions were essentially non-existent. This was surprising, as
we had already established that the whole bark extract did inhibit urea hydrolysis by JBU. One
possible explanation is the thermal decomposition of the active tannin component resulting from
drying the fractions in a vacuum oven overnight at 25 oC. Regardless of the source, the extraction
procedure must be amended to achieve separation of the tannin extracts while maintaining urease
inhibitory activity.
The results of this study establish the correlation between the two assays for the test
compounds. The in vitro assay can therefore be used to screen tannin fractions for activity to
suggest potent fractions capable of ammonia abatement within the ex vivo assay. Future efforts
involving the determination of the urease inhibitory component of the Q and CN tannin extract
should focus on screening a wide number of extraction conditions, such as initial extraction with
short alcohols (methanol, ethanol, isopropanol) under cold conditions (20 oC), followed by
filtration and filtrate concentration via rotavap and lyophilization. The resulting fractions could
then be screened using both assays, with at least one of the two fractions exhibiting ammonia
abatement. Tannin mixtures have also been separated by chromatographic methods employing
the use of polydextran gel (Sephadex), silica-based (LiChrosorb Diol, LiChrospher RP-18), and
common alkyl packed (Nucleosil 100-7C18, µBondapak C18 10µM) reverse-phase columns.40
Once the mixtures have been separated to an acceptable degree with extraction and filtration
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techniques, one or more of these packing materials could be utilized for further separation. Each
collected fraction can be screened for inhibitory activity, and the compound or mixture of
compounds responsible for the observed ammonia abatement by the whole tannin extract can be
determined.

Experimental

Initial Tannin Extraction with Methanol

Methanol (125 mL) was added to a tannin extract (Q, CN, or Q/CN mixture, 5 g) and the
resulting suspension was allowed to stir at room temperature for 2 days. The suspension was
filtered through an Isolute column filter frit (20 μm). The solid residue was rinsed with methanol
(25 mL) and the combined filtrates were filtered through a buchner funnel equipped with
Fisherbrand filter paper P8 and rinsed with methanol (25 mL). The combined filtrates were
concentrated and dried on a vacuum pump over night at 25 oC. The solids from both filterations
were combined and dried on a vacuum pump over night at 25 oC. Dry deep brown powders were
obtained for each fraction. The lost mass is likely the result of some insoluble matter being stuck
within filters (see Table 6).
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Table 6: Masses Collected for Methanol Extraction of Each Tannin Source
Tannin Source
Quebraco (Q)

MeOH Soluble
4.1610 g (83%)

MeOH Insoluble
0.6233 g (13%)

Mass Losta
0.2156 g (4%)

Chestnut (CN)
Quebracho/Chestnut
Mixture (Q/CN)

4.0994 g (82%)

0.7152 g (14%)

0.1861 g (4%)

3.8166 g (77%)

0.8960 g (18%)

0.2777 g (5%)

a. Lost mass is likely the result of material being stuck within the filter

In vitro Plate-Based JBU Inhibitory Assay

Note: Jack bean urease concentration is recorded in enzymatic units (U). Because different
fractions of isolated urease are found to have significantly differing activities, suppliers often
market JBU powders according to observed enzymatic rate per unit mass of powder, and these
rates are written on reagent bottles. As such, solutions of JBU are generally described in terms of
urease activity rather than actual enzyme concentration. One unit (U) will liberate 1.0 µmole of
ammonia per min at pH 7.0 and 25 oC.

This assay was developed based upon a published procedure describing inhibition of JBU
by small molecule inhibitors.48 Briefly, 25 μL of inhibitor (1:4 DMSO/H2O v/v) was added to 25
μL of jack bean urease (0.75U or 0.03U/µL) in pure water. The mixture was incubated at 37 ºC
for 1 hr. Next, 200 uL of buffer solution consisting of 100 mM HEPES ([N-(2hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid)]), pH 6.8, 500 mM urea, and phenol red
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indicator (0.002% w/v), was added to the enzyme/inhibitor solutions. The final concentrations in
each well were the following: 2% DMSO, 80mM HEPES, 400mM urea, 0.0016% phenol red,
and 0.075U of jack bean urease. The plate was incubated at 37 ºC and ammonia production was
monitored by a microplate reader (570 nm). All determinations were performed in triplicate.
Activity at each inhibitor concentration was determined as the slope of an absorbance vs. time
plot, within the time range of 20 - 30 min.

Dose-Response Curve Fitting Function

The fitting function for the generated dose-response curves was described.51 Curves were
first generated in 2002/2 ORIGIN Version 7.0, and IC50 values were determined by Equation 1:

eqn 1;

where Vmax, Vmin, IC50 and n represent the uninhibited enzyme activity, fully inhibited enzyme
activity, minimum inhibitory concentration for 50% activity reduction, and the Hill coefficient,
respectively.

CHAPTER 3
ANTIMALARIAL ACTIVITY OF QUERCETIN ANALOGS

This chapter is adapted in part from our previous publication52

Introduction

According to the World Health Organization, there were an estimated 660,000 worldwide
deaths caused by malaria in 2010.53 Of these, it is estimated that 86% were children under the
age of 5, the vast majority (79%) residing in Africa. The same report indicates that some 90% of
reported malarial cases worldwide are attributed to Plasmodium falciparum, the most deadly of
the four Plasmodium species infecting humans. Additional reports suggest malarial infection and
mortality are more widespread than previously estimated, with Murray et al. suggesting up to
200 million clinical cases and 1.2 million deaths in 2010 alone.54 Efforts to reduce the spread of
P. falciparum have been hindered by the increasing emergence of drug resistant strains.
Flavonoids, a class of naturally occurring polyphenolic compounds found universally
within the Plantae kingdom, have been shown to inhibit numerous enzymatic pathways
necessary for sustained P. falciparum growth throughout the erythrocytic life cycle stages.
Flavonoids have been shown to inhibit amyloid fibril formation of P. falciparum merozoite
surface protein 2, which suggests a significant decrease in erythrocyte intercalation in vivo.55
Additionally, Dormeyer et al. report that flavonoids, specifically (-)-epigallocatechingallate ((-)-
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ECGC, (12)), inhibit P. falciparum infected erythrocyte cytoadhesion to host small-vessel
endothelial cells via intercellular adhesion molecule 1 (ICAM 1) binding (85-90% inhibition at
50 μM).56 Khalid et al. provided an early report of P. falciparum abatement by flavonoids both
extracted from plant material as well as synthetically prepared natural flavonoids.57 More
recently, flavonoids have been demonstrated to inhibit the type-II fatty acid biosynthesis
pathway (FAS-II) necessary for the development of cellular walls. For example, various
flavonoids extracted from natural sources have been shown to inhibit β-ketoacyl-ACP-reductase
(FabG), β-hydroxacyl-ACP-dehydratase (FabZ), and enoyl-ACP-reductase (FabI).58 Among
these, (-)-EGCG (12) was again shown to strongly inhibit both the various enzymes involved in
the FAS-II pathway (FabG IC50 = 0.3 μM, FabZ IC50 = 0.4 μM and FabI IC50 = 0.2 μM) as well
as exhibit P. falciparum anti-plasmodial activity (PfNF54 IC50 = 25.5 μM, PfK1 IC50 = 9.9
μM).58d Tasdemir et al. suggest the source of the activity is the relative planar conformation of ()-EGCG in comparison to other flavonoids, specifically flavan-3-ols.58d
The drawback to the potential of these compounds as antimalarial agents is two-fold: the
compounds are promiscuous enzyme inhibitors, presumably due to catechol chelation of
metalloenzymes, and the compounds are relatively insoluble in aqueous media. Specifically, the
flavonol quercetin (13) has been shown to exhibit activity not only against P. falciparum, but
also acts as an antiviral,59 anticancer,60 and anti-inflammatory61 agent. Although this compound
clearly has therapeutic potential for various ailments, it is currently limited mainly by solubility.
To address this, it was determined that introduction of amine moieties could increase solubility
due to additional hydrogen bonds with the solvent. Solubility could be increased further by
converting the free amine bases to the corresponding hydrochloride or trifluoroacetate salts.
Additionally, the activity data can be used to develop Comparative Molecular Field Analysis
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(CoMFA) models to predict the activity of novel, structurally similar compounds. We report
herein the synthesis, characterization, solubility, antimalarial activity and CoMFA analysis of 19
novel aminoalkylated quercetin analogs.

Results and Discussion

Compound Synthesis, Structural Elucidation, and Solubility

Based upon the emergence of deadly drug resistant strains of P. falciparum, it is now
imperative that novel classes of antimalarial agents be developed and the mechanisms of action
be determined. Quercetin (13), a naturally occurring flavonoid found in a wide range of plant
life, has been previously reported as exhibiting antimalarial activity and may provide a natural
scaffold for the synthesis of novel antimalarial agents.57 Additionally, (-)-EGCG (12) and (+)catechin (5) have been shown to exhibit antimalarial activity and have been included in this
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study as commercially available flavonoid P. falciparum inhibitors.58d Although quercetin
inhibits the parasitic growth, its clinical application may be limited due to minimal aqueous
solubility. We have therefore integrated basic nitrogen moieties into quercetin via the Mannich
reaction of formaldehyde and various primary and secondary amines. The products (14-31) were
transformed into salts via the addition of hydrochloric or trifluoroacetic acid to a suspension of
each compound in methanol followed by removal of the alcohol. The solubility of the free bases
was determined via UV-spectroscopic solubility assay.62
With the exception of compounds (30) and (31), all compounds were synthesized via the
Mannich reaction of quercetin with formaldehyde and primary amines (Scheme 2). Compounds
(30) and (31) were synthesized by employing secondary instead of primary amines and
compound (31) utilized two rather than one equivalent of both formaldehyde and the amine
(Scheme 3). Due to the minimal solubility of quercetin in ethanol, the reaction is thought to have
progressed slowly with the precipitation of the desired product providing a driving force. The
products were collected by filtration, negating the need for any further chromatographic
purification. Yields ranged from 21 to 85% for the primary aminoalkylated quercetin analogs
(Table 7) and were 65 and 56% for compounds (30) and (31) respectively (Table 8).
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Scheme 2: Synthesis of benzyl and phenethyl aminoalkylated quercetin derivatives

Scheme 3: Synthetic scheme for furfuryl and secondary aminoalkylated quercetin derivatives
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Table 7: Synthetic Yields and Solubility Data of Phenethyl and Benzyl Mannich Analogs

Compound n R1 R2 R3 R4 Yield (%)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
a.

- 2 H
2 Cl
2 H
2 H
2 F
2 H
2 Cl
2 Cl
2 H
1 H
1 H
1 H
1 H
1 H

H
H
Cl
F
H
H
H
H
H
H
Cl
H
H
F

H
Cl
H
H
H
F
H
H
Cl
H
H
Cl
F
H

H
H
H
H
H
H
Cl
H
H
H
H
H
H
H

84.9
47.3
59.4
64.7
71.9
48.5
60.0
21.2
69.9
69.3
24.3
39.1
29.6
42.4

Solubility
(μM)a
44.35
41.00
167.7
198.7
275.2
95.36
135.6
199.2
84.55
98.83
48.60
107.3
110.3
212.3
122.7

Measured as solubility in 2% DMSO/H2O (v/v) at 25 oC;
solution absorbance measured at 280 nm.
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Table 8: Synthetic Yields and Solubility Data of Furfuryl and Secondary Amine Mannich
Products

R2

Yield
(%)

Solubility
(μM)a

Furfuryl Amine

H

37.8

39.60

(29)

Tetrahydrofurfuryl
amine

H

97.6

38.55

(30)

Methylpiperazine

H

64.5

131.13

(31)

Piperidine

56.3

247.3

Compound

Amine

(28)

a.

R1

Measured as solubility in 2% DMSO/H2O (v/v) at 25 oC; solution absorbance measured at
280 nm.

A major pitfall in the discovery of novel therapeutic agents is the lack of compound
solubility in aqueous media. To address this, the solubility of the synthetic compounds, as well as
quercetin, was determined. As expected, all synthesized compounds were determined to exhibit
solubility greater than or comparable to that of the parent compound quercetin (13). However,
the activity of the compounds is clearly structurally-based as demonstrated by the comparison of
the relative activities.
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There has been some discussion in recent years concerning the site of alkylation when
performing Mannich reactions upon flavonoids. Specifically, the 6 and 8 positions on the A-ring
of quercetin are both nucleophilic and thus susceptible to electrophilic aromatic substitution
(Figure 10, left). A study published by Nguyen et al. reports moderate to excellent
regioselectivity for the Mannich reaction of chrysin, a flavone, with various cyclic imines is
achieved by varying the reaction solvent. Up to 99:1 selectivity of positions 6:8 was achieved
with the use of ether as the solvent.63 Zhang et al. report selective alkylation at position 8 with
the use of DMSO.64 Additionally, Kukhareva et al. report selective alkylation at position 6 with
the use of isopropanol as the solvent and dihydroquercetin as the nucleophile.65

Figure 10: Flavonoid numbering scheme and 2D NMR correlation observed. Left: General
numbering scheme for flavonols; Right: Correlation observed in HMBC NMR (see Appendix D,
page 356).

54
Proton, carbon and 2D NMR were employed for structural elucidation. Substitution at the
8 position on the A ring of quercetin was suspected based upon proton NMR (see Appendix C,
page 287). Quercetin exhibits specific proton NMR peaks at 6.18 and 6.40 ppm corresponding to
the 6 and 8 positions respectively. All of the products exhibited peaks around 5.9 ppm with a
notable absence of any peaks within the range of 6.1 to 6.8 ppm suggesting substitution at the 8
position with a slight shift in the proton peak corresponding to the 6 position. This observation is
corroborated by heteronuclear multiple-bond correlation spectroscopy (HMBC) NMR. Proton
and carbon peaks were first assigned by proton, carbon and HSQC NMR (see Appendix D, page
356). Correlation was observed within the HMBC spectrum between protons at the 1 position
and carbon atoms at the 2 and 5 positions (Figure 10, right). Additionally, correlation was
observed between the proton at the 4 position and the carbon atom at the 3 position, strongly
suggesting alkylation at the 8 position.

Antimalarial Activity and CoMFA Analysis

Antimalarial activity of the compounds against three strains of the P. falciparum parasite,
W2 (Chloroquine (CQ) resistant, mefloquine (MFQ) sensitive), D6 (CQ sensitive, MFQ
resistant) and C235 (CQ, MFQ, and pyrimethamine resistant), is shown in Table 9. Extensive
research has been conducted concerning the relationship between various naturally occurring
flavonoids and P. falciparum abatement.58a-c To date, the most potent class of natural flavonoids
has been found to be catechingallate esters.58a-c For reference, three flavonoids have been tested
for P. falciparum inhibitory activity (5,12,13). Of these, only (-)-epigallocatechingallate (12), a
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catechingallate ester, was found to exhibit potent activity (D6 IC50 = 0.073 μM). Three
compounds (15 – 17, IC50 = 0.065 – 0.13μM), exhibited similar activity across all three strains,
including the drug resistant strains against which compound (12) demonstrated reduced activity.
All of the aminoalkylated quercetin analogs exhibit activity superior (up to 160-fold increase) to
that of quercetin (13) and (+)-catechin (5). Phenethyl and benzyl amine derivatives (14 – 27)
were found to have activity within the nanomolar to low micromolar range (IC50 = 0.065 -2.18
μM across all strains) while the secondary amine and furfurylamine derivatives (28-31) were
found to have low micromolar activity (IC50 = 1.2 – 5.3 µM across all strains). None of the
compounds tested were as active as MFQ or arteminisinin (ART) against any strain; however,
many were more potent than CQ against the W2 and C235 strains (14 – 21, 24). Because the W2
and C235 strains are CQ resistant, the observed activity of these compounds may be the result of
a differing mechanism of action than that of CQ.
Among the potent aminoalkylated quercetin analogs, the phenethyl amine derivatives (14
– 22) exhibited greater activity than the benzyl amine derivatives (23 – 27) suggesting that the
increase in chain length leads to favorable interactions within the mechanism of action. The
relationship between the halogen substitution pattern and inhibitory activity of these compounds
was also explored. For the benzyl amine derivatives (23 – 27), chloro substitution exhibits
stronger inhibitory activity than fluoro substitution as evidenced by the inhibition of W2 by
compounds (24) and (27) (W2 IC50 = 0.26 and 0.69 µM, respectively). For the phenethyl amine
derivatives, the difference between chloro and fluoro substitution is generally minimal, with
chloro substitution exhibiting slightly better activity in the case of compounds (16) and (17) (W2
IC50 = 0.079 and 0.13 µM respectively) and fluoro substitution exhibiting better activity in the
case of compounds (18) and (21) (W2 IC50 = 0.24 and 0.29 µM, respectively). However, fluoro
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substitution exhibited a six-fold increase in activity for compounds (19) and (22) (D6 IC50 = 0.14
and 0.83 μM, respectively).
The relationship between substitution positions was also explored. Substitution at the
meta position results in the highest inhibitory activity ((17), D6 IC50 = 0.069 µM), while
substitution at the ortho (18) and para (19) positions generally results in similar inhibitory
activity, with the ortho position being slightly more active (D6 IC50 = 0.11 and 0.14 µM,
respectively). This relationship between ortho and para substitution and activity varies slightly
with P. falciparum strain and compound chain length, however, the activity is generally
comparable, except in the case of para-chloro-phenethylamine (22) where the ortho position (21)
exihibits much greater activity(D6 IC50 = 0.25 and 0.83 μM, respectively). 2,4-Dichlorinated
phenethylamine derivative (15) exhibited the highest inhibitory activity across all strains
suggesting increased halogenation positively contributes to activity. This observation is also
supported by 2,6-dichlorinated phenethyl amine derivative (20), which as higher activity across
all strains than the 2-chloro derivative (21).
Additionally, the most active aminoalkylated quercetin analogs, compounds (15) and
(16), were tested for both early and late stage anti-gametocytocidal activity to ascertain their
potential to impact on transmission (Table 9). It was determined that the compounds were
weakly active against the early gametocyte stages, with inhibition (IC50) values of 9.67 and 6.79
μM for compounds (15) and (16), respectively for early stage (I-III) gametocytes. Both
compounds were considerably less effective against the late (IV-V) stage gametocytes exhibiting
100% inhibition at 40 μM. The reference drugs CQ, Puromycin and Artesunate were
demonstrated to be effective at concentrations routinely illustrated.66 Neither compound (15) nor
(16) exhibited activity comparable to the reference compounds for early stage (I-III)
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gametocytes, or more importantly the late stage (IV-V) gametocytes, indicating the need for
further compound optimization if this quercetin scaffolding is to be explored further as a possible
antimalarial effective against not only the clinical disease but also transmission to the vector (see
Table 9).

Table 9: Antimalarial Activity of Quercetin Analogs Against P. falciparum Strains
Compound

W2 IC50
(μM)a

D6 IC50
(μM)a

C235 IC50
(μM)a

NF54-pfs16-GPF
Early (I-III) gam
IC50 (μM)b

NF54-pfs16-GPF
Late (VI-V) gam
IC50 (μM)b

(5)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
ARTc

5.967
1.43
2.916
>2.12
0.07141
0.07897
0.1294
0.2404
0.2934
0.2274
0.2927
1.85
>2.18
0.2586
0.5923
0.7185
0.6936
>2.23
>2.21
2.39
1.193
0.0067

6.67
0.07277
8.959
2.11
0.06583
0.06865
0.06933
0.1059
0.1364
0.1619
0.2517
0.83
>2.18
0.1861
0.3719
0.4058
0.5146
>2.23
>2.21
2.944
1.735
0.009

5.919
0.6114
13.05
>2.12
0.07982
0.08016
0.08831
0.1837
0.1515
0.1530
0.2584
1.18
>2.18
0.2165
0.4345
0.6989
0.6189
>2.23
>2.21
5.335
3.135
0.01304

9.67
6.79
-

100% at 40 μM
100% at 40 μM
-

a.
b.
c.

Antimalarial activity assay performed by Richard Sciotti at the WRAIR, Silver Spring, MD
Antigametocytal assay performed by Vicky Avery at Griffith University, Nathan, Queensland, AUS;
Gam = gametocyte
From Ref. 67

(Continued on next page)
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Table 9: Continued

Compound

W2 IC50
(μM)a

D6 IC50
(μM)a

C235 IC50
(μM)a

NF54-pfs16-GPF
Early (I-III) gam
IC50 (μM)b

NF54-pfs16-GPF
Late (VI-V) gam
IC50 (μM)b

CQc
MFQc
Puromycin
Artesunate

0.6343
0.0065
-

0.01422
0.01998
-

0.22621
0.06555
-

0.126
0.175
0.003

100% at 120 μM
0.194
0.012

a.
b.
c.

Antimalarial activity assay performed by Richard Sciotti at the WRAIR, Silver Spring, MD
Antigametocytal assay performed by Vicky Avery at Griffith University, Nathan, Queensland, AUS;
Gam = gametocyte
From Ref. 67

The antimalarial activity data obtained for the compounds was used to perform a CoMFA
analysis of the compound test set to produce models capable of predicting the activity of novel
compounds.68 Because the exact target responsible for the observed antimalarial activity is
unknown, target-based (docking) computational methods cannot be employed. Alternatively,
CoMFA analysis uses actual activity data to produce models which determine steric and
electrostatic regions around the quercetin scaffold responsible for the observed activities.
CoMFA models can therefore bue used to predict the antimalarial activity of newly designed
compounds prior to screening.
The test compounds were input into a SYBYL X 1.3 database and aligned by
substructure overlap based upon the quercetin scaffold. The CoMFA steric (Lennard-Jones) and
electronic (Coulombic) fields were generated by first assigning atomic charges based upon the
Gasteiger-Huckel method.68b The CoMFA models were generated by calculating the energy at
lattice points of the compounds placed in a 3D lattice. The energetic cutoff was set at 30
Kcal/mol to minimize the effects of highly energetic steric or electronic regions. The models use
a partial least squares (PLS) method to correlate the energy of the lattice points to activity and
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model effectiveness was quantified by examining the cross-validated q2 values, which are
calculated from the following equation (Equation 2):

eqn 2;

where Yactual, Ypredicted and Ymean are the experimental, predicted and average values of the
antimalarial activity respectively. Models demonstrating a cross-validated q2 value of 0.5 or
greater are considered acceptable.
CoMFA models were made for each of the three P. falciparum strains with all of the
models utilizing the activity data for the entire compound test set ((12) and (14 – 31). The best
model developed, model 1, includes the test compound set based upon the C235 P. falciparum
strain data (Table 10). The model exhibits a cross-validated (CV) q2 value of 0.520 and is based
upon two components. Not surprisingly, the models are dominated by the steric contribution,
with electrostatic interaction accounting for only 2.03% of each model (Table 10). Linear plots
of predicted vs. experimental pIC50 values for each model were constructed (Figure 11). These
plots were constructed to demonstrate the validity of the models and clearly demonstrate that
activity predictions of novel aminoalkylated quercetin analogs should be based upon models 1 or
3. Additionally, predicted and experimental pIC50 values for each P. falciparum strain can be
found in the corresponding table (see Table 11). It should be noted that the CoMFA model
corresponding to the PfW2 inhibitory data (Model 2) is weak. With a cross-validated q2 value of
0.306, this model should not be utilized to predict the activity of structurally similar, novel
compounds.

60

Pred. pIC50 vs Exp. pIC50 for C235
(Model 1)

Pred. pIC50 vs. Exp pIC50 for W2
(Model 2)
7.5

Pred. pIC50

Pred. pIC50

7.5

6.5

5.5

4.5

6.5

5.5

4.5
4.5

5.5

6.5

7.5

4.5

5.5

Exp. pIC50

6.5

7.5

Exp. pIC50

Pred. pIC50 vs Exp. pIC50 for D6
(Model 3)

Pred. IC50

7.5

6.5

5.5

4.5
4.5

5.5
6.5
Exp. pIC50

7.5

Figure 11: Predicted pIC50 vs. experimental pIC50 for all compounds against all malarial strains.
Top: C235. Middle: W2. Bottom: D6. The predicted values were generated from CoMFA models
of each data set. Solid lines designate the situation where predicted and experimental pIC50
values are equal (y = x).
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Table 10: Parameters for CoMFA Models Generated

Model

q

2

2

r

(1) C235 0.520 0.723
(2) W2 0.306 0.491
(3) D6 0.502 0.772

Standard
Error

# of
Components

0.3747
0.3931
0.3384

2
1
3

Steric
Contribution
(%)
97.97
97.97
97.97

Electrostatic
Contribution
(%)
2.03
2.03
2.03

CoMFA analysis generates 3D contour plots demonstrating regions of favorable (green)
and unfavorable (red) steric effects as well as areas of favorable positive (blue) and negative
(red) electrostatic interaction. Figure 12 depicts both quercetin (top) and the entire set oftest
compounds overlaid (bottom) on the contour plot for model 1 (PfC235). The positive steric
contribution (green) relates to region of space occupied by the Mannich addition products;
specifically, the phenethylamine Mannich derivatives fit within this region better than the
benzylamine, secondary amine and furfuryl amine Mannich derivatives (Figure 12, bottom).
Additionally, the unfavorable steric region (yellow) residing adjacent to the 6 position of the A
ring (Figure 12, top) is occupied by the secondary addition product for compound (31),
suggesting that diaminoalkylation will result in decreased activity, even if phenethylamines were
utilized. Concerning electrostatic interactions, a favorable negatively charged region (red) is
shown to reside over the substituted phenethyl rings, suggesting the incorporation of strongly
electron-withdrawing groups (halogens) leads to increased activity. Finally, a region of favorable
positive electrostatic interaction (blue) is observed to reside adjacent to the 7 position of the A
ring.
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Figure 12: Contour plots generated from CoMFA analysis. Top: Contour plot of Model 1
displaying quercetin. The image depicts steric (left) and electrostatic (right) contributions
generated by the CoMFA model. The color scheme is as follows: Favorable (yellow) and
unfavorable (green) steric interactions; positive (blue) and negative (red) favorable electrostatic
contributions. All regions are shown at 95% of the total contribution. Bottom: Contour plot of
Model 1 with all test compounds, (13), (14-31), included. The color scheme and percent
contribution displayed are the same as those described.
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Table 11: CoMFA Analysis of Each P. falciparum Strain

Compound

Exp.
C235
pIC50

Pred. C235
pIC50
(Model 1)

Exp. W2
pIC50

Pred. W2
pIC50
(Model 2)

Exp. D6
pIC50

Pred. D6
pIC50
(Model 3)

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

4.884
5.674
7.098
7.096
7.054
6.736
6.820
6.815
6.588
5.928
5.662
6.665
6.362
6.156
6.208
5.652
5.656
5.273
5.504

4.7041
6.5379
6.6557
6.7214
6.7543
6.5693
6.6931
6.4995
6.5556
6.6258
5.9967
6.2110
6.1424
6.1369
6.1810
5.6586
5.6422
5.4136
5.2628

5.535
5.674
7.146
7.103
6.888
6.619
6.533
6.643
6.534
5.733
5.662
6.587
6.227
6.144
6.159
5.652
5.656
5.622
5.923

5.6620
6.5065
6.6485
6.6391
6.6636
6.5533
6.6112
6.4445
6.5332
6.6141
5.9530
6.0729
5.9323
5.9199
6.0516
5.7830
5.7885
5.7587
5.6786

5.048
5.676
7.182
7.163
7.159
6.975
6.865
6.791
6.599
6.081
5.662
6.730
6.430
6.392
6.289
5.652
5.656
5.531
5.761

4.9459
6.5266
6.7363
6.9272
7.0629
6.7600
6.7199
6.5066
6.6590
6.5963
5.8906
6.1194
6.1731
6.1519
6.1063
5.3422
5.3372
5.4583
5.9477

64

Conclusions

To our knowledge, this is the first report of synthetically modified quercetin being tested
against P. falciparum. Quercetin was subject to Mannich conditions in the presence of
formaldehyde and various amines resulting in regioselective aminoalkylation via electrophilic
aromatic substitution. The reaction resulted in fair yields (21 – 98%) and the products were
subject to a solubility assay, as well as tested against three drug resistant strains of the malaria
parasite, P. falciparum. Among the compounds, phenethyl amine derivatives were found to
exhibit the most potent activity against the asexual life cycle stages. Aromatic halo-substitution
of the phenethyl and benzyl moieties results in greater efficacy, specifically when concerning
chlorination. Substitution at the meta-position was determined to produce the most potent
interactions across all three strains of drug resistant P. falciparum. Additionally, multihalogenation of the phenethyl derivatives resulted even more effective compounds, the most
active being 2,4-dichlorinated phenethyl amine derivative (15).
To evaluate the observed SAR, the compounds were subject to CoMFA analysis for each
of the three strains of P. falciparum. The best model generated (Model 1) includes the data for
PfC235 inhibitory activity, with the entire set of test compounds considered. The model exhibits
a cross-validated q2 value of 0.520 and involves total steric and electrostatic contributions of
97.97 and 2.03%, respectively. The generated contour maps for the model demonstrate regions
of favorable and unfavorable steric and electrostatic contributions, providing structural insight
into the activity observed for these compounds.
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While these results are promising, the mechanism of action is, at this time, unknown.
More research is necessary to determine which pathways, if any, are interacting with the
compounds resulting in microbial abatement. To address the second downside of this class of
compounds (enzymatic inhibition promiscuity), the drug-host interactions must be discovered to
produce a more selective inhibitor.

Experimental

General Methods.

All chemicals were purchased from Sigma Aldrich and were used without any further
purification. Melting points were recorded on a Mel-Temp II apparatus. FTIR were recorded a on
a Mattson ATI Genesis Series outfitted with a Pike Technologies MIRacle ATR. UV-Vis
absorption for the solubility assay was recorded on a Biotek Synergy 2 multi-detection
microplate reader. 1H and 13C NMR were recorded on a BrukerAvance III 500 outfitted with a 5
mm BBFO Z-gradient probe.

Solubility Assay

Compound solubility in aqueous media was determined based upon a modified version of
the UV-spectroscopic assay developed by Hoelkeet et al.62 A 1 mM stock solution of each
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compound as a free base was prepared in DMSO. Calibration curves were generated by first
preparing a 20 µM stock solution of each compound in the media (2% DMSO in water) and
sequentially diluting to various concentrations (4, 8, 12, and 16 µM) with a final volume of 250
µL in a 96-well plate. Concentrated solutions were prepared by suspending each compound in
the media to the saturation point. The suspensions were centrifuged at 8000 rpm for 10 mins and
filtered. Solution absorbance was measured on a 96-well microplate reader at 25 oC and at 280
nm. Concentrations were calculated by extrapolating the best fit line of the calibration curves for
each compound.

Synthesis of Compounds (14-31)

General Procedures.
General Procedure for the synthesis of Compounds (14-29). To a suspension of quercetin (0.35
mmol) in EtOH (5 mL) was added 37% wt formaldehyde in H2O (0.35 mmol) and amine (0.35
mmol). The resulting suspension was allowed to stir for 16h. Product was isolated via vacuum
filtration as a yellow solid.

General Procedure for Preparation of Acid Salts.
Each compound was suspended in methanol and concentrated acid (HCl, 14-29; TFA, 30-31)
was added to the suspension. The solids were observed to dissolve and the methanol was
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removed under vacuum to afford the acid salts of each compound. Yields for all compounds
were quantitative.

8-(phenethylaminomethyl)quercetin (14)

Synthesized according to the general procedure outlined above using phenethylamine; yield:
85%; mp: 171-173 oC (decomp) ; 1H NMR (500 MHz, DMSO-d6, ppm): 2.87 (2H, t, J = 7.70
Hz), 3.00 (2H, t, J = 7.71 Hz), 4.18 (2H, s), 6.01 (1H, s), 6.89 (1H, d, J = 8.50 Hz), 7.20-7.23
(5H, m), 7.54 (1H, dd, J = 3.55 Hz), 7.70 (1H, d, J = 2.20 Hz); 13C NMR (500 MHz, DMSO-d6,
ppm): 34.0, 42.6, 49.0, 99.3, 99.7, 101.6, 115.4, 116.1, 120.2, 122.8, 126.8, 128.9, 129.0, 135.9,
139.0, 145.6, 146.0, 148.0, 154.2, 160.5, 168.9, 175.8; FTIR (cm-1): 637, 698, 1001, 1090, 1108,
1127, 1169, 1253, 1281, 1316, 1378, 1411, 1513, 1559, 1608, 1651, 2768, 2929, 3130.
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8-(2,4-dichlorophenethylaminomethyl)quercetin(15)

Synthesized according to the general procedure outlined above using 2,4dichlorophenethylamine; yield: 47%; mp: 188-191 oC(decomp); 1H NMR (500 MHz, DMSO-d6,
ppm): 2.95 (4H, s), 4.12 (2H, s), 6.03 (1H, s), 6.88 (1H, d, J = 8.45 Hz), 7.33-7.35 (2H, m), 7.527.54 (2H, m), 6.69 (1H, d, J = 2.15 Hz);13C NMR (500 MHz, DMSO-d6, ppm): 32.1, 43.3, 47.8,
99.4, 100.7, 102.2, 115.4, 116.1, 120.1, 122.8, 127.8, 129.1, 132.2, 132.8, 134.4, 135.9, 136.3,
145.6, 146.3, 148.0, 153.9, 160.0, 167.4, 176.1; FTIR (cm-1): 637, 698, 1001, 1090, 1108, 1127,
1169, 1253, 1281, 1316, 1378, 1411, 1513, 1559, 1608, 1651, 2768, 2929, 3130.
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8-(3-chlorophenethylaminomethyl)quercetin(16)

Synthesized according to the general procedure outlined above using 3-chlorophenethylamine;
yield: 59%; mp: 179-182 oC (decomp); 1H NMR (500 MHz, DMSO-d6, ppm): 2.82 (2H, t, J =
7.32), 2.97 (2H, t, J = 6.93 Hz), 4.13 (2H, s), 5.98 (1H, s), 6.88 (1H, d, J = 8.46 Hz), 7.18-7.30
(4H, m), 7.53 (1H, dd, J = 3.55 Hz), 7.68 (1H, d, J = 2.26 Hz); 13C NMR (500 MHz, DMSO-d6,
ppm): 34.1, 43.2, 48.9, 99.6, 100.1, 101.8, 115.4, 116.1, 120.1, 122.8, 126.7, 127.9, 128.0, 129.0,
130.6, 133.4, 133.5, 135.9, 142.1, 145.6, 146.0, 148.0, 153.9, 160.2, 168.4, 175.9; FTIR (cm-1):
683, 699, 787, 842, 882, 983, 1002, 1107, 1122, 1168, 1185, 1245, 1303, 1349, 1416, 1445,
1557, 1604, 1650, 2779, 2960.
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8-(3-fluorophenethylaminomethyl)quercetin(17)

Synthesized according to the general procedure outlined above using 3-fluorophenethylamine;
yield: 65%; mp: 192-193 oC (decomp); 1H NMR (500 MHz, DMSO-d6, ppm): 2.86 (2H, t, J =
7.33 Hz), 2.96 (2H, t, J = 7.35 Hz), 4.14 (2H, s), 5.98 (1H, s), 6.88 (1H, d, J = 8.45 Hz), 7.017.09 (3H, m), 7.29-7.32 (1H, m), 7.32 (1H, dd, J = 3.57 Hz) 7.68 (1H, d, J = 2.20 Hz); 13C NMR
(500 MHz, DMSO-d6, ppm): 34.2, 43.3, 48.9, 99.6, 99.7, 100.1, 101.6, 113.6, 115.3, 115.7,
115.9, 116.1, 116.2, 120.1, 122.8, 125.2, 130.6, 135.8, 142.4, 145.6, 146.0, 148.0, 154.0, 160.2,
161.7, 163.7, 168.8, 175.8; FTIR (cm-1): 686, 743, 786, 876, 982, 1002, 1107, 1123, 1183, 1247,
1304, 1350, 1415, 1446, 1490, 1519, 1557, 1591, 1612, 1650, 2678, 2782, 2952.
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8-(2-fluorophenethylaminomethyl)quercetin(18)

Synthesized according to the general procedure outlined above using 2-fluorophenethylamine;
yield: 72%; mp: 191-192 oC (decomp); 1H NMR (300 MHz, DMSO-d6, ppm): 2.87-2.93 (4H,
m), 4.14 (2H, s), 5.99 (1H, s), 6.88 (1H, d, J = 8.49 Hz), 7.10-7.15 (2H, m), 7.24-7.31 (2H, m),
7.52 (1H, dd, J = 3.55 Hz), 7.68 (1H, d, J = 2.16 Hz); 13C NMR (500 MHz, DMSO-d6, ppm):
28.0, 43.2, 48.1, 99.6, 100.2, 101.8, 115.4, 115.5, 116.1, 120.1, 122.8, 124.9, 126.0, 126.1, 128.9,
131.5, 135.9, 145.6, 146.1, 148.0, 154.0, 160.1, 162.0, 168.5, 175.9; FTIR (cm-1): 685, 699, 757,
791, 838, 881, 942, 982, 1002, 1108, 1125, 1170, 1232, 1253, 1306, 1381, 1415, 1446, 1492,
1514, 1557, 1615, 1650, 2624, 2774, 2945, 3121, 3425, 3519.
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8-(4-fluorophenethylaminomethyl)quercetin(19)

Synthesized according to the general procedure outlined above using 4-fluorophenethylamine;
yield: 49%; mp: 192-195 oC (decomp); 1H NMR (300 MHz, DMSO-d6, ppm): 2.83 (2H, t, J =
6.76 Hz), 2.93 (2H, t, J = 6.97 Hz), 4.14 (2H, s), 5.96 (1H, s), 6.88 (1H, d, J = 8.46 Hz), 7.057.08 (2H, m), 7.23-7.28 (2H, m), 7.52 (1H, dd, J = 3.29 Hz) 7.68 (1H, d, J = 1.56 Hz); 13C NMR
(500 MHz, DMSO-d6, ppm): 33.5, 43.1, 49.2, 99.7, 101.6, 115.3,115.5, 115.6, 115.8, 116.1,
120.1, 122.8, 130.8, 130.9, 135.36, 135.39, 135.8, 145.6, 145.9, 148.0, 154.1, 160.3, 160.4,
162.3, 169.0, 175.8; FTIR (cm-1): 698, 742, 792, 815, 877, 956, 984, 1002, 1108, 1161, 1229,
1255, 1304, 1351, 1380, 1417, 1446, 1509, 1556, 1602, 1650, 2776, 2961, 3122, 3448, 3536.
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8-(2,6-dichlorophenethylaminomethyl)quercetin(20)

Synthesized according to the general procedure outlined above using 2,6dichlorophenethylamine; yield: 60%; mp: 203-205 oC (decomp); 1H NMR (300 MHz, DMSO-d6,
ppm): 2.82 (2H, t, J = 7.76 Hz), 3.12 (2H, t, J = 7.70 Hz), 4.18 (2H, s), 6.05 (1H, s), 6.87 (1H, d,
J = 8.49 Hz), 7.24 (1H, t, J = 8.04 Hz), 7.41 (2H, d, J = 8.22 Hz), 7.54 (1H, dd, J = 3.56 Hz) 7.70
(1H, d, J = 2.16 Hz); 13C NMR (500 MHz, DMSO-d6, ppm): 30.6, 43.0, 46.0, 99.4, 100.5, 102.2,
115.4, 116.1, 120.0, 122.8, 129.0, 129.1, 134.9, 135.1, 135.9, 145.6, 146.3, 148.0, 154.0, 160.1,
167.6, 176.1; FTIR (cm-1): 699, 723, 752, 784, 809, 845, 882, 926, 976, 1000, 1088, 1108, 1162,
1183, 1208, 1231, 1273, 1299, 1345, 1411, 1438, 1555, 1608, 1650, 2650, 2765, 2946, 3204,
3297.
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8-(2-chlorophenethylaminomethyl)quercetin(21)

Synthesized according to the general procedure outlined above using 2-chlorophenethylamine;
yield: 21%; mp: 193-195 oC (decomp); 1H NMR (300 MHz, DMSO-d6, ppm): 2.93 (4H, s), 4.15
(2H, s), 6.00 (1H, s), 6.88 (1H, d, J = 8.49 Hz), 7.23-7.26 (2H, m), 7.33-7.38 (2H, m), 7.52 (1H,
dd, J = 3.56 Hz), 7.69 (1H, d, J = 2.19 Hz); 13C NMR (500 MHz, DMSO-d6, ppm): 32.3, 43.0,
47.6, 99.5, 100.1, 101.9, 115.4, 116.1, 120.1, 122.8, 127.8, 128.8, 129.7, 131.5, 133.5, 135.9,
136.8, 145.6, 146.1, 148.0, 154.2, 160.2, 168.2, 175.9; FTIR (cm-1): 683, 698, 749, 791, 840,
881, 924, 980, 1001, 1106, 1119, 1165, 1183, 1232, 1303, 1347, 1415, 1444, 1556, 1607, 1650,
2774, 2949, 3193, 3468.
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8-(4-chlorophenethylaminomethyl)quercetin(22)

Synthesized according to the general procedure outlined above using 4-chlorophenethylamine;
yield: 70%; mp: 171-173 oC (decomp); 1H NMR (500 MHz, DMSO-d6, ppm): 2.85 (2H, t, J =
7.45 Hz), 3.00 (2H, t, J = 7.45 Hz), 4.17 (2H, s), 6.03 (1H, s), 6.90 (1H, d, J = 8.45 Hz), 7.26
(2H, d, J = 8.45 Hz), 7.33 (2H, d, J = 4.20 Hz), 7.54 (1H, dd, J = 3.55 Hz), 7.70 (1H, d, J = 2.20
Hz); 13C NMR (500 MHz, DMSO-d6, ppm): 33.6, 42.9, 49.0, 99.5, 99.7, 101.8, 115.4, 116.1,
120.2, 122.8, 128.5, 128.8, 128.9, 129.0, 131.0, 131.1, 131.4, 135.9, 138.3, 145.6, 146.1, 148.0,
154.1, 160.3, 168.4, 175.9; FTIR (cm-1): 607, 640, 699, 734, 805, 878, 937, 984, 1001, 1091,
1109, 1123, 1169, 1267, 1302, 1350, 1383, 1421, 1445, 1492, 1556, 1606, 1650, 2770, 2958,
3136, 3515.
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8-(benzylaminomethyl)quercetin(23)

Synthesized according to the general procedure outlined above using benzylamine; yield: 69%;
mp: 175-179 oC (decomp); 1H NMR (300 MHz, DMSO- d6, ppm): 3.89 (2H, s), 4.13 (2H, s),
6.08 (1H, s), 6.84 (1H, d, J = 8.49 Hz), 7.32-7.36 (6H, m), 7.70 (1H, d, J = 2.16 Hz); 13C NMR
(500 MHz, DMSO-d6, ppm): 42.4, 51.4, 99.3, 99.8, 102.2, 115.6, 116.1, 120.0, 122.7, 128.0,
128.9, 129.1, 129.2, 130.1, 135.9, 137.4, 145.5, 146.3, 148.0, 153.9, 160.3, 167.5, 176.1; FTIR
(cm-1): 601, 642, 698, 742, 790, 834, 880, 953, 976, 999, 1107, 1163, 1202, 1252, 1295, 1372,
1427, 1514, 1559, 1608, 1647, 2961, 3200.

77
8-(3-chlorobenzylaminomethyl)quercetin(24)

Synthesized according to the general procedure outlined above using 3-chlorobenzylamine;
yield: 24%; mp: 181-183 oC (decomp); 1H NMR (300 MHz, DMSO-d6, ppm): 3.83 (2H, s), 4.07
(2H, s), 6.12 (1H, s), 6.84 (1H, d, J = 8.46 Hz), 7.31-7.34 (4H, m), 7.43 (1H, s), 7.70 (1H, d, J =
2.16 Hz); 13C NMR (500 MHz, DMSO-d6, ppm): 42.3, 51.1, 99.1, 101.1, 102.6, 115.7, 116.1,
119.8, 122.7, 127.5, 127.6, 128.6, 130.6, 133.5, 136.0, 101.4, 145.5, 146.6, 148.1, 153.9, 160.1,
166.4, 176.2; FTIR (cm-1): 628, 698, 726, 836, 883, 857, 1000, 1027, 1085, 1107, 1162, 1205,
1265, 1299, 1339, 1372, 1426, 1556, 1604, 1648, 2643, 2749, 2957, 3187, 3438.
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8-(4-chlorobenzylaminomethyl)quercetin(25)

Synthesized according to the general procedure outlined above using 3-chlorobenzylamine;
yield: 24%; mp: 181-183 oC (decomp); 1H NMR (300 MHz, DMSO-d6, ppm): 3.83 (2H, s), 4.07
(2H, s), 6.12 (1H, s), 6.84 (1H, d, J = 8.46 Hz), 7.31-7.34 (4H, m), 7.43 (1H, s), 7.70 (1H, d, J =
2.16 Hz); 13C NMR (500 MHz, DMSO-d6, ppm): 42.3, 51.1, 99.1, 101.1, 102.6, 115.7, 116.1,
119.8, 122.7, 127.5, 127.6, 128.6, 130.6, 133.5, 136.0, 101.4, 145.5, 146.6, 148.1, 153.9, 160.1,
166.4, 176.2; FTIR (cm-1): 628, 698, 726, 836, 883, 857, 1000, 1027, 1085, 1107, 1162, 1205,
1265, 1299, 1339, 1372, 1426, 1556, 1604, 1648, 2643, 2749, 2957, 3187, 3438.
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8-(4-fluorobenzylaminomethyl)quercetin(26)

Synthesized according to the general procedure outlined above using 4-fluorobenzylamine; yield:
30%; mp: <250 oC; 1H NMR (300 MHz, DMSO-d6, ppm): 3.82 (2H, s), 4.08 (2H, s), 6.07 (1H,
s), 6.83 (1H, d, J = 8.40 Hz), 7.15 (2H, t, J = 8.85 Hz), 7.33 (1H, dd, J = 3.49 Hz), 7.40 (2H, t, J
= 4.72 Hz), 7.68 (1H, d, J = 2.16 Hz); 13C NMR (500 MHz, DMSO-d6, ppm): 42.4, 50.7, 99.3,
100.4, 102.3, 115.5, 115.6, 115.7, 116.0, 119.9, 122.7, 131.0, 131.1, 134.4, 135.9, 145.5, 146.4,
148.0, 153.8, 160.1, 161.0, 167.2, 176.1; FTIR (cm-1): 698, 730, 791, 820, 840, 882, 954, 979,
1000, 1026, 1107, 1161, 1183, 1204, 1251, 1298, 1340, 1371, 1409, 1445, 1511, 1557, 1602,
1648, 2643, 2753, 2972, 3204, 3393.
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8-(3-fluorobenzylaminomethyl)quercetin(27)

Synthesized according to the general procedure outlined above using 3-fluorobenzylamine; yield:
42%; mp: 190-191 oC (decomp); 1H NMR (300 MHz, DMSO-d6, ppm): 3.84 (2H, s), 4.07 (2H,
s), 6.11 (1H, s), 6.83 (1H, d, J = 8.25 Hz), 7.09 (1H, s), 7.19 (2H, s), 7.32-7.34 (2H, m), 7.69
(1H, s); 13C NMR (500 MHz, DMSO-d6, ppm): 42.4, 51.1, 99.1, 101.1, 102.6, 114.3, 115.3,
115.5, 115.6, 116.1, 119.8, 122.7, 124.9, 130.7, 135.9, 141.8, 145.5, 146.5, 148.0, 153.8, 160.0,
161.7, 163.7, 166.4, 176.4; FTIR (cm-1): 639, 717, 789, 817, 835, 885, 956, 998, 1025, 1105,
1162, 1181, 1204, 1229, 1250, 1297, 1339, 1369, 1424, 1491, 1556, 1605, 1647, 2775, 2959,
3205, 3441, 3517.
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8-(furfurylaminomethyl)quercetin(28)

Synthesized according to the general procedure outlined above using furfurylamine; yield: 38%;
mp: 197-201 oC (decomp); 1H NMR (300 MHz, DMSO-d6, ppm): 3.86 (2H, s), 4.10 (2H, s), 6.14
(1H, s), 6.35 (1H, d, J = 3.03 Hz), 6.40 (1H, dd, J = 1.67 Hz), 6.88 (1H, d, J = 8.48 Hz), 7.45
(1H, dd, J = 3.56 Hz), 7.61 (1H, dd, J = 0.85 Hz), 7.71 (1H, d, J = 2.26 Hz); 13C NMR (500
MHz, DMSO-d6, ppm): 42.1, 44.3, 98.9, 100.9, 102.8, 108.8, 110.9, 115.6, 116.1, 120.1, 122.7,
136.0, 143.1, 145.5, 146.7, 148.1, 153.9, 160.1, 165.8, 176.3; FTIR (cm-1): 641, 698, 747, 790,
885, 919, 954, 999, 1106, 1161, 1183, 1236, 1267, 1299, 1338, 1370, 1411, 1444, 1515, 1559,
1606, 1647, 2586, 2756, 2962, 3200.

82
8-(tetrahydrofurfurylaminomethyl)quercetin(29)

Synthesized according to the general procedure outlined above using tetrahydrofurfurylamine;
yield: 75%; mp: 201-205 oC (decomp); 1H NMR (500 MHz, DMSO-d6, ppm): 1.50 (1H, m),
1.83-1.85 (1H, m), 1.91-1.96 (1H, m), 2.73-2.79 (4H, m), 3.65 (1H, quart, J = 7.30 Hz), 3.743.77 (1H, m), 3.96-3.98 (1H, m), 4.17 (2H, s), 5.98 (1H, s), 6.89 (1H, d, J = 8.45 Hz), 7.53 (1H,
dd, J = 3.57 Hz), 7.68 (1H, d, J = 2.20 Hz); 13C NMR (500 MHz, DMSO-d6, ppm): 25.6, 29.3,
43.8, 51.9, 67.8, 76.8, 99.7, 99.9, 101.4, 115.3, 116.1, 120.0, 122.9, 135.8, 145.6, 145.8, 148.0,
153.9, 160.2, 169.5, 175.8; FTIR (cm-1): 600, 641, 687, 743, 790, 833, 887, 939, 997, 1017,
1106, 1165, 1234, 1272, 1295, 1344, 1370, 1414, 1445, 1561, 1615, 1645, 2871, 2972, 3513.
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8-(1-methylpiperizinomethyl)quercetin(30)

Synthesized according to the general procedure outlined above using 1-methylpiperizine; yield:
65%; mp: 233-235 oC (decomp); 1H NMR (300 MHz, DMSO-d6, ppm): 2.17 (3H, s), 2.37 (4H,
m), 2.59 (4H, m), 3.88 (2H, s), 6.18 (1H, s), 6.90 (1H, d, J = 8.46 Hz), 7.59 (1H, dd, J = 3.42
Hz), 7.71 (1H, s); 13C NMR (500 MHz, DMSO-d6, ppm): 19.0, 45.6, 51.4, 52.2, 54.7, 56.5, 98.6,
100.3, 103.2, 115.5, 116.1, 120.4, 122.7, 136.1, 145.6, 147.0, 148.2, 154.2, 160.1, 164.6, 176.4;
FTIR (cm-1): 639, 681, 796, 935, 1002, 1131, 11162, 1250, 1317, 1370, 1430, 1512, 1562, 1602,
1649, 2573, 3070.
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6,8-(Dipiperidinomethyl)quercetin(31)

To a suspension of quercetin (0.1025 g, 0.3391 mmol) in EtOH (5mL) was added 37% wt
formaldehyde in H2O (60 µL, 0.8058 mmol) and piperidine (70 µL, 0.7086 mmol). The resulting
suspension was allowed to stir for 16h at rt. Product was isolated via vacuum filtration as a
yellow solid; yield: 56%; mp:190-193 oC (decomp); 1H NMR (500 MHz, DMSO-d6, ppm): 1.471.54 (16H, m), 2.73 (4H, s), 3.74 (4H, s), 6.87 (1H, d, J = 8.50 Hz), 7.58 (1H, dd, J = 3.53 Hz),
7.73 (1H, d, J = 2.15 Hz); 13C NMR (500 MHz, DMSO-d6, ppm): 22.2, 22.7, 23.7, 25.6, 44.2,
53.1, 53.5, 99.0, 99.2, 102.8, 115.4, 116.1, 120.3, 122.4, 122.7, 128.7, 129.4, 136.1, 145.6146.6,
148.1, 154.0, 160.1, 166.4, 176.2; FTIR (cm-1): 601, 639, 692, 740, 791, 811, 879, 931, 997,
1034, 1111, 1127, 1164, 1254, 1314, 1368, 1426, 1509, 1557, 1601, 1650, 2858, 2941, 3063.

CHAPTER 4
METHIONINE AMINOPEPTIDASE INHBITITION

The introduction to this chapter is adapted in part from our previous publication69

Introduction

Antibiotic Market Introduction and Resistance

Since the golden age of antibacterial drug discovery (1935 to 1968), where 14 novel
classes of antibiotics were discovered and brought to market, the FDA approved only five
additional classes between 1968 and 2008, two of which are restricted to topical applications.70
The cause of such a drastic decline in antibiotic drug discovery resulting in approved therapies is
primarily financial; bacterial targets are able to rapidly adapt to environmental adjustments,
including the introduction of bactericidal and bacteriostatic chemical agents.71 Colonies are
therefore able to develop resistance mechanisms for the inactivation of antibiotics, rendering
therapies ineffective. Drug discovery pipelines often require significant investments of capital
(hundreds of millions of dollars) and time (up to seven years) prior to being able to market the
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drug as a finalized product.72 Because bacterial species have developed resistance mechanisms as
early as two yearsafter market introduction, major drug companies began to shift discovery
efforts towards more chronic illnesses.73 This has created an underdeveloped therapeutic market
for academic and industrial research groups to explore.
The major contributing factor to difficulties arising from targeting bacterial infection
involves resistance to chemotherapies. According to the CDC, there were an estimated two
million illnesses requiring hospitalization and 23,000 deaths attributed to bacterial and fungal
resistance to approved chemotherapies in 2012.73 As such, a detailed understanding of the
mechanisms involved in resistance must be discovered. Confirmed resistance mechanisms
include: altered drug uptake, overproduction of macromolecular target, altered macromolecular
target, production of a drug-destroying enzyme, overproduction of enzymatic substrate, novel
enzymatic product biosynthesis and efflux pumps.74 Any combination of these resistance
mechanisms can dramatically decrease the therapeutic potential and clinical application of
antibacterial agents. It is therefore imperative that novel chemotherapies focus on
macromolecular targets and biological pathways that have not been previously targeted and had
the opportunity to develop resistance mechanisms. One class of targets that has been identified as
potentially therapeutic is methionine aminopeptidase (MetAP), a ribosomal associated
metalloprotease responsible for the cleavage of N-terminal methionine initiators from nascent
proteins.75

87
Methionine Aminopeptidase

The processes and specific macromolecular structures involved in protein translation
have been determined, with early efforts involving structural elucidation beginning in the
1960’s.76 Frequently, co- or post-translational modification must be made to the polypeptide. The
earliest modifications generally involve proteolytic cleavage of N-terminal initiators or signaling
peptides; to accomplish this, methionine aminopeptidase (MetAP) cleaves methionine initiators
from nascent proteins, or following deformylation of N-formyl methionine in prokaryotes.77 It is
currently unknown if MetAP-mediated cleavage occurs co- or post-translationally, or some
combination of the two, with cleavage generally occurring for peptides of 20-40 residues in
length for eukaryotic cells.77 Catalyzed methionine cleavage is accomplished via the activity of
two divalent metal cofactors bound within the methionine recognition site by five resides found
to be conserved across all species (two Glu, two Asp and His residues). Additionally, catalysis
has been hypothesized to occur via the nucleophilic attack of a cofactor bound hydroxide ion or
water molecule.78 Addition of EDTA to buffered solutions containing MetAP has resulted in the
complete abatement of enzymatic activity, suggesting sequestration of cofactor incorporation
into the protein deactivates catalysis.79
MetAPs are broadly associated with other divalent metalloproteases including
aminopeptidase P and prolidases, all of which include a common fold termed the “pita-bread”
fold.80 MetAP enzymes are divided into two major groups (types 1 and 2) and two additional
subgroups (types a and b), although some species specific derivatives differing from these
commonly defined groups have been found.81 Type 2 is distinguished from Type 1 by the
inclusion of an α-helical extension of the C-terminal domain of around 60 residues in length that
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stretches over the active site and has been suggested to be the source of selectivity for differences
in methionine cleavage for various peptides in eukaryotic cells (Figure 13).80 Additionally,
subgroups a and b refer to the absence or presence, respectively, of an N-terminal extension
suggested to play a role in ribosomal recognition.75 Comparison of the primary, secondary, and
tertiary structures of MetAPs from prokaryotic and eukaryotic sources reveals a high degree of
conservation across all species of MetAP. For example, the identity and orientation observed in
X-ray crystal structures of the five residues responsible for metal cofactor binding is consistent
for all species, as demonstrated for E. coli MetAP1a (EcMetAP1a), HsMetAP1b and
HsMetAP2b (see Figure 14).

Figure 13: Comparison of MetAP1a and MetAP2b isoforms. Top Left: EcMetAP1a (PDB:
1MAT);82 Top Right: HsMetAP2b (PDB: 1BN5).83 The additional N-terminal domain indicative
of type b enzymes is shown in red and the additional C-terminal domain insertion indicative of
type 2 enzymes is shown in green. Cobalt atoms are shown in blue.
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Figure 14: Conservation of residues responsible for metal cofactor binding. Left and Right: Two
different orientations showing overlaid active site residues of HsMetAP1b (PDB: 2B3K),84
HsMetAP2b and EcMetAP1a. Each enzyme is color-coded as follows: cobalt atoms: blue
spheres, HsMetAP1b: yellow, HsMetAP2b: orange, EcMetAP1a (green).

Sequence Alignment of Bacterial and Human MetAPs

The high degree of conservation of MetAPs isolated from various species can be
visualized when examining sequence alignments. For example, the sequence alignment of
Rickettsia prowazekii MetAP1a (RpMetAP1a) with EcMetAP suggests 53% identity
conservation across the two bacterial enzymes (see Figure 15). Additionally, alignment of
RpMetAP1a and HsMetAP1b reveals diminished conservation between the prokaryotic and
eukaryotic species (43%). Representations of the external protein surface of RpMetAP1a colorcoded according to residue similarities reveal the high degree of conservation both among
differing bacterial species and between bacterial and human species. Essentially the entire
binding pocket is conserved in both cases, although a few residues lining the pocket entrance are
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non-conserved, especially for RpMetAP1a and HsMetAP1b; non-conserved residues were also
found to be prevalent at the external protein surface (Figure 16).

Figure 15: Conservation between MetAP species. Top: Sequence alignment of RpMetAP1a and
EcMetAP1a shaded according to alignment (dark = identity; light = similarity; no-shading = nonconserved). Alignment suggests 53% identity between the proteins. Residues responsible for
Figure 14 continued: cofactor binding are marked as X. Middle: Sequence alignment of
RpMetAP1a and HsMetAP1b. Alignment suggests 43% identity between the proteins.
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Figure 16: Surface diagram of RpMetAP1a colored according to sequence alignment. Left:
EcMetAP1a and Right: HsMetAP1b (green = identity; yellow = similarity; magenta = nonconserved). The blue ligand is a bound methionine.

Methionine Aminopeptidase as an Antibacterial Target

The cellular reliance on MetAP enzymatic activity is well established, with inactivation
of the pepM gene in Salmonella typhimurium, the gene coding for StMetAP, resulting in cell
death.85 Additionally, the methionine aminopeptidase gene (map) of E. coli was substituted for
an altered map gene fragment under lac promoter control. Cell growth was only observed in the
presence of lac operon inducer isopropyl-β-thiogalactoside, again suggesting MetAP knockout
results in cell death.86 Thus, the removal of MetAP activity from single cellular organisms
results in growth inhibition and implicates MetAP inhibition as an antibacterial target. Inhibition
of MetAP was therefore suggested as a novel druggable target for antibacterial applications.
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Similarities within the core structure of HsMetAP1, HsMetAP2 and EcMetAP1 are found
when examining the overlaid structures of these three enzymes (Figure 13, bottom left and right),
demonstrating the conservation of the five residues that bind the metal cofactors.82 Due to the
high conservation of the active sites between various isoforms of these enzymes, the discovery of
selective inhibitors targeting a single species of MetAP is paramount and presengs a considerable
challenge inhibitor design. Additionally, most chemical classes capable of inhibiting these
enzymes act via coordination the metal cofactors. This often results in the inherent promiscuous
inhibition of various metalloenzymes, which are extremely prevalent in nature. The discovery of
potent, isoform selective inhibitors of MetAPs from various species is therefore a formidable
task. Currently, most accounts detailing classes of bacterial MetAP inhibitors failed to co-screen
against human isoforms of the enzyme. If any of these classes of compounds are to be advanced
beyond laboratory applications, a detailed understanding of enzymatic selectivity must be
explored. Human inhibitory data are therefore shown and discussed as available within published
reports.

Variability of Metals Activating MetAPs

The design of selective inhibitors of bacterial MetAPs is complicated by the lack of
information regarding the identity of the native metal cofactors found within the active sites of
these enzymes. MetAPs have been shown to exhibit enzymatic activity when utilizing a variety
of metals as cofactors, including Co(II), Fe(II), Mn(II), Zn(II) and Ni(II).87 However, the native
cofactors for most species of MetAP are unknown, although various groups have implicated one
or more of these metallic species. For example, D’souza and Holtz have implicated Fe(II) as the
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native cofactor of EcMetAP1 by examining the metal content of the whole cells with inductively
coupled plasma (ICP) emission analysis; additionally, MetAP was isolated under both aerobic
and anaerobic conditions and screened for activity.88 Because some metals are oxidative under
aerobic conditions, these may be lost under typical enzymatic purification processes, further
demonstrating the difficulty in cofactor determination. Finally, many protein purification
methods employ the use of affinity columns and cation exchange resins, affording the possibility
of MetAP activation by metallic artifacts encountered within purification processes, such as
nickel found within widely used HisTrapTM columns. Therefore, many published reports
detailing MetAP inhibitors screen against enzymes containing the various metal cofactors shown
to afford enzymatic function. Finally, inhibitory values are largely dependent upon the identity of
the metal cofactors, further demonstrating the importance of native cofactor determination.

Classes of MetAP Inhibitors

1,2,4-Triazole Based Inhibitors

Various 1,2,4-triazole motifs have been identified as bacterial MetAP inhibitors.89 The
compounds do not appear to be species specific inhibitors, with inhibition demonstrated against
MetAPs from numerous bacterial strains. The 1,2,4-triazole pharmacophore is also active against
human MetAP2, as demonstrated in a study at GlaxoSmithKline exploring more than 80 3anilino-5-arylthio-1,2,4-triazole derivatives against HsMetAP2.90 The compounds exhibit potent
activity, with binding inhibition constants (Ki) ranging from >10,000 to 0.04 nM against the
Co(II) form of HsMetAP2. The same study also found preferential binding to Co(II) inclusive
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HsMetAP2 over the Mn(II) derivative, and discovered selectivity of HsMetAP2 binding (Ki = 0.5
nM) over HsMetAP1 (Ki = 3900 nM) when screening the original MetAP2 hit compound (5(benzylthio)-N-phenyl-4H-1,2,4-triazol-3-amine) against both enzymes. The compounds are
competitive inhibitors with bridging coordination to both metals in the enzymatic active site, as
demonstrated in the crystal structure of N-(2-isopropylphenyl)-5-((thiophen-2-ylmethyl)thio)4H-1,2,4-triazol-3-amine bound to HsMetAP2 (PDB: 2OAZ).90
A similar binding mode is observed for bacterial MetAPs as demonstrated by the X-ray
crustal structures of triazole species (32) and (33) with Mycobacterium tuberculosis MetAP
(MtMetAP1) (see Figure 17).89d The compounds chelate to the Ni(II) cofactors through the
triazole 1 and 2-N atoms at distances around 2.0 Å for both crystal structures. Additionally,
compound (32) exhibits parallel-displaced π-π stacking with Phe-211 at a distance of 3.4 Å.
Similar interactions with Phe-211 are not observed for the binding of compound (33),
presumably due to the inclusion of an additional Ni(II) metal within the crystal structure. This
third metal is bound to the inhibitor through the triazole 4-N (although this nitrogen should be
protonated) and coordinates with His-114 through the imidazole N-atom. The coordination
sphere of the third metal is filled via coordination to a chloride ion and a water molecule cocrystallized within the enzyme active site. Ye also makes note of the difference in the
coordination number of the metals for each structure; the bis-Ni(II) active site metals present in
both crystal structures are hexacoordinate for compound (32) and pentacoordinate for compound
(33), with the difference in coordination likely arising from the inclusion of the third metal in the
case of inhibition by (33).89d
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Figure 17: Crystalline structures of EcMetAP1a with bound 1,2,4-triazoles. Left: Compound
(32) bound to the active site of MtMetAP1c (PDB: 3IU9).89g Right: Compound (33) bound to the
active site of MtMetAP1c (PDB: 3IU8).89g The color scheme is as follows for both figures: red
spheres = nickel metals; green sphere = chlorine ion; light green compounds = triazole species;
yellow dashes represent coordination to the metals from residues or the inhibitors.
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Most triazole-based chemical series that have been synthesized and screened against a
variety of bacterial MetAPs are of the general structure shown in Table 12. The compounds
exhibit selective binding based upon the identity of the divalent metals in the active site, with the
best activity observed for enzymes with Ni(II) and Co(II) cofactors, followed by Mn(II) and
Fe(II), respectively.89c-e, 89g This trend is present for all of the triazole inhibitors, regardless of
MetAP species reported. Compound (32) was found to exhibit the most potent inhibition across
all metals and MetAP species. The source of the activity of (32) is not readily apparent when
examining the crystal structures shown in Figure 17. No interactions are observed between any
residues within the active site and the chlorine atoms at positions 2 and 4 of derivative (32). With
compounds (32) and (38) being the only triazole species screened containing ortho-substitution
on the benzyl ring, any conclusions drawn concerning this substitution pattern are premature.
However, for some bacterial strains, 4-fluoro-benzyl derivative (34) demonstrated comparable
activity to that of 2,4-dichloro-benzyl derivative (32). For example, the difference in the
inhibition of Co(II) bound A. baumannii MetAPx (AbMetAPx) by (32) and (34) is only 0.1 µM,
while the difference for the Co(II) form of MtMetAP1c is 0.48 µM, with (32) being more active
against both forms. Additionally, the inclusion of amines at the 2-position of the triazole ring
appears to be beneficial, with a 2.5-fold increase in activity for compounds (33) and (34) against
MtMetAP1c. Alkylated-phenyl derivatives (35-37) exhibit weak inhibition of B. pseudomallei
MetAP1 (BpMetAP1) (IC50 = >250 – 3.1 µM, Co(II) cofactors) as compared with the other
screened inhibitors suggesting that aryl alkylation in the 4-position produces detrimental effects
to binding. Although p-methyl-benzyl derivitive (35) is more active than p-fluoro-benzyl
derivative (34) against BpMetAP1 (IC50 = 3.1 and 7.0 µM, respectively), this trend is not
observed across different bacterial strains (see Table 12).
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Table 12: Activity of Various Triazole Based Inhibitors Against Bacterial MetAPs

Cmpd

R1

R2

R3

R4

Enzymea

(32)

Cl

H

Cl

NH2

(33)

(34)

(35)

F

F

Me

H

H

H

H

H

H

H

NH2

NH2

Cob,c Mnb,c

Feb,c

Nib,c

MtMetAP1a

>250

>250

>250 >250

MtMetAP1c

0.26

2.0

40

0.24

89d,89g

AbMetAPxd

0.78

64

128

4.9

89e

AbMetAPyd

0.38

14

94

0.40

89e

BpMetAP1

1.0

-

-

-

89c

MtMetAP1a

>250

>250

>250 >250

MtMetAP1c

2.0

143

>500

MtMetAP1a

>250

>250

>250 >250

MtMetAP1c

0.74

18

>500

1.3

89d,89g

AbMetAPx

0.88

303

>500

23

89e

AbMetAPy

0.64

34

>500

2.2

89e

BpMetAP1

7

-

-

-

89c

MtMetAP1a

>250

>250

MtMetAP1c

0.69

26

>500

2.5

89d,89g

AbMetAPx

2.1

145

>500

44

89e

AbMetAPy

3.8

14

94

0.40

89e

BpMetAP1

3.1

-

-

-

89c

0.58

Refd
89d

89d
89d,89g
89d

89d

>250 >250

(36)

i-Pr

H

H

NH2

BpMetAP1

>250

-

-

-

89c

(37)

t-Bu

H

H

NH2

BpMetAP1

>250

-

-

-

89c

(38)

H

F

F

NH2

BpMetAP1

>250

-

-

-

89c

a.
b.
c.
d.

MtMetAP1a/ MtMetAPc = Mycobacterium tuberculosis , AbMetAPx/ AbMetAPy =
Acinetobacter baumannii, BpMetAP1 = Burkholderia pseudomallei
The different metal headings correspond to the various MetAP cofactors (divalent)
IC50 values are expressed in units of µM
MetAPx and MetAPy refer to two enzymes expressed in different genes from A. baumannii
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Oefner explored the effect of differing 3-substituted triazoles on the activity of S.
typhimurium MetAP1 (StMetAP1).89a They found that compounds (39) and (40) exhibited strong
binding (StMetAP1 IC50 = 0.599 and 0.044 µM, respectively; Co(II) cofactors), where the
increase in activity for compound (40) is attributed to the inclusion of the 3-(methylthio)-1propanamine substituent. The authors present crystal structures of (39) and (40) bound to the
StMetAP1 active site and report a similar binding mechanism to that reported earlier in Figure
17, with the triazole 1 and 2-N atoms bridging the Co(II) cofactors. This remains the only study
to date exploring the effect of substitution at the 3-position of the triazole ring on bacterial
MetAP1 activity.

The exploration of this class of compounds on bacterial MetAP inhibition is limited, with
only a few publications reporting activity, and with most screening the same compounds against
various species of MetAP. The effect of chain length between the benzyl and triazole rings
should be probed in the future to explore potent favorable interactions with the various lipophilic
side chains (such as MtMetAP1c Phe-211) residing within the active site of these enzymes.
Additionally, the amino moiety at the 3-position of the triazole ring should be derivitized and
screened against bacterial MetAPs, as demonstrated for compound (40). These compounds
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should also be co-screened against HsMetAP1 and HsMetAP2 to determine the selectivity for
enzymatic inhibition. Although some triazole species exhibit potent activity against bacterial
MetAPs, similar triazole species have demonstrated preferential binding to HsMetAP2 over
HsMetAP1, possibly foreshadowing selectivity challenges for bacterial targets.

Biaryl Chelating Inhibitors

Various groups have implicated compounds consisting of biaryl ring systems capable of
metal chelation as inhibitors of MetAPs from both human and bacterial sources, with the most
common scaffolding including 2,2’-bipyridyl,91 2-(2-pyridine)-benzimidazole,92 or
thiabendazole92-93 motifs. Thiabendazole (41) was crystallized with EcMetAP1 containing three
Co(II) cofactors, with the inhibitor chelating to the auxiliary Co ion closest to the entrance of the
active site (Figure 18, right). Interestingly, this third Co(II) cofactor is not present in the crystal
structure of EcMetAP1 without bound inhibitors (PDB: 2MAT)94 (Figure 18, left). A series of
similar inhibitors (pyridinylpyrimidines and pyridinylquinazolines) have been crystallized with
HsMetAP1, with the chelation of a third Co(II) cofactor as the mode of binding for each
structure (PDB: 2G6P,95 4IU6,91d 4HXX,91e 4IKR,91a 4IKS,91a 4IKT91a). Zhang provides an
excellent discussion of these crystal structures and the source of the auxiliary Co(II) ion present
in the active site.91d The crystal structures were generated by first crystallizing the enzyme, then
soaking the crystals in a solution containing inhibitor and cobalt(II) chloride. The inclusion of
the auxiliary Co(II) cofactor, which is not suggested to be present in the native enzyme as
demonstrated by the E. coli MetAP1 (EcMetAP1) crystalline structure (PDB: 2MAT)94 (Figure
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18, left), is therefore thought to be a result of the method of crystallization. However, these
compounds exhibit structure-based activity and selectivity of HsMetAP1 over HsMetAP2.91d, e

Figure 18: Crystalline structures of EcMetAP1a with bound biaryl chelator. Left: EcMetAP1
with no inhibitors (Co(II) cofactors) (PDB: 2MAT).94 Right: Compound (41) bound to the active
site of EcMetAP1 (PDB: 1YVM).93 The color scheme is as follows for both images: blue spheres
= nickel metals; light green compound = thiabendazole; yellow dashes represent coordination to
the metals from residues or the inhibitors.
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Kishor reports a series of pyridinylpyrimidine based inhibitors of E. faecalis MetAP1a
(EfMetAP1a) and MtMetAP1c, where compounds were co-screened against HsMetAP1b to
elucidate selectivity for the bacterial forms of the enzyme.91a The compounds are all of the
general structure shown below, where a wide variety of substituents were employed at the
positions indicated. Generally, the most active compounds utilized small donating or
withdrawing groups at R1 (Me, CF3, NH2, OH), R2 (H, Cl, CN, n-pentyl, CH2-cyclopropyl,
CH2CO2Et) and R3 (H, CH3, OH, SH, SMe). For example, compound (42) was determined to be
the most active against EfMetAP1a (IC50 = 1.56 µM, Co(II) cofactors), while compound (43)
was determined to be the most active against MtMetAP1c with (IC50 = 1.67 µM, Co(II)
cofactors). However, these compounds are also active against HsMetAP1b (IC50 = 0.95 and 0.66
µM for (42) and (43), respectively, Co(II) cofactors), suggesting selectivity shortcomings.

2-(2-Pyridine)-benzimidazole scaffolds have been utilized in the design of bacterial
MetAP inhibitors.92 The compounds are of the general structure shown below where R1 and R2
are generally H, Alkyl, Cl, F, NH2, CN, NO2 or phenyl ketones.92b, c Of these possible
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derivatives, compound (44) was the most active compound exhibiting activity better than that of
the parent compound 2-(2-pyridyl)benzimidazole (R1 = R2 = H) with IC50 values of 0.162 and
0.574 µM, respectively, against EcMetAP1 with Co(II) cofactors.92c Additionally, converting the
imidazole NH to an N-benzyl derivative resulted in a slight decrease in activity (IC50 = 0.992
µM), while utilizing a 2-pyrazine instead of the 2-pyridyl biaryl system resulted in a drastic
decrease in activity (2-(2-pyrazine)-benzimidazole EcMetAP1 IC50 = 4.59 µM, Co(II) cofactors).
The effect of introducing fused imidazole-heterocycle rings was also explored and resulted in a
notable increase in activity. For example, 4-azabenzimidazole derivative (45) exhibits a five-fold
increase in activity (EcMetAP1 IC50 = 0.105 µM, Co(II) cofactors) over the parent (2-(2pyridyl)benzimidazole) compound.92c For other azabenzimidazole derivatives (2-(2-pyridine)-5azabenzimidazole, 2-(2-pyridine)-4,6-diazabenzimidazole and 2-(2-pyridine)-4,7diazabenzimidazole) the increase in activity is to a lesser extent, although all exhibit better
activity than the benzimidazole parent compound. Concerning selectivity, compounds (44) and
(45) were co-screened against HsMetAP types 1 and 2 and were found to be more potent against
the bacterial enzyme than both human enzymes ((44), IC50 = 28.8 µM, HsMetAP1; (45), IC50 =
27.6 and 26.7 µM, HsMetAP 1 and 2, respectively, Co(II) cofactors).92b
The most active biaryl chelating inhibitors of bacterial MetAPs are species bearing a
thiabendazole (41) motif.92-93 The general structure of thiabendazole derivatives is shown below,
where R1 and R2 were H, Alkyl, Cl, F, NH2, CN, NO2 or phenyl ketones.92c Unlike the similar 2(2-pyridine)-benzimidazole derivatives, where some substitution patterns produced compounds
of activity greater than that of the 2-(2-pyridine)-benzimidazole parent compound, all
substitution patterns explored at R1 and R2 for thiabendazole derivatives produced species
exhibiting less potent activity than thiabendazole (41) (EcMetAP1 IC50 = 0.472 µM, Co(II)
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cofactors).92a, 92c However, N-benzyl derivative (46) and N-methyl-thiabendazole both exhibited
activity comparable to that of thiabendazole (EcMetAP1 IC50 = 0.461 and 0.497 µM,
respectively, Co(II) cofactors).92c Like the 2-(2-pyridine)-benzimidazole derivatives, the
introduction of fused imidazole-heterocycle rings was explored for thiabendazole derivatives.92c
Interestingly, 4-azabenzimidazole derivative (47) was found to be the most active compound of
this series (EcMetAP1 IC50 = 0.078 µM, Co(II) cofactors), while the related 5-azabenzimidazole
derivative exhibited less potent activity than the thiabendazole parent compound (EcMetAP1
IC50 = 1.724 µM, Co(II) cofactors). Finally, compounds (46) and (47) were screened against
HsMetAP types 1 and 2. Compound (46) exhibited no activity against HsMetAPs at a stock
concentration of 25 µM, while compound (47) was determined to exhibit selectivity for the
bacterial enzyme over HsMetAP1 (IC50 = 39.8 µM, Co(II) cofactors).92b

Aryl Carboxylic Acid Inhibitors

Aryl carboxylic acid derivatives, usually 5-aryl-2-furoic acid or 5-aryl-2-thiophenic
acids, have been demonstrated as potent inhibitors of bacterial MetAPs.89c-e, 89g, 96 The
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compounds bind via chelation to one of the active site metals, as shown in the numerous crystal
structures of these compounds bound to MetAPs from bacterial sources (PDB: 1XNZ,96f
2EVM,96d 2Q92,96g 2Q93,96g 2Q94,96g 2Q95,96g 2Q96,96g and 3IU789g). For example, 5-(2chlorophenyl)-2-furoic acid (48) was crystallized with EcMetAP1 containing Mn(II) cofactors
(PDB: 1XNZ)96f (Figure 19). The crystal structure clearly demonstrates (48) chelating to one of
the Mn(II) cofactors, with additional binding interactions to His-178 (3.3 Å) and distorted Tshaped π-π stacking with Tyr-62. Similar modes of binding are observed for the crystal structures
of other aryl-furoic acid inhibitors, with the PDB codes listed earlier (see Figure 19).

Figure 19: 5-(2-Chlorophenyl)-2-furoic acid (48) bound to the active site of EcMetAP1. The
color scheme is as follows: purple spheres = manganese metals; light green compound = (48);
yellow dashes represent coordination to the metals from residues or the inhibitors (PDB:
1XNZ).96f
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The general structure of these furoic acid and thiophenic acid derivatives is shown below.
This class of inhibitors has been demonstrated to bind preferentially to MetAPs containing
Mn(II) cofactors over other cofactors, as demonstrated by the differences in activity for
compound (48) when screened against various metalloforms of EcMetAP1 (IC50 = 0.511, 138,
141 and 116 µM; Mn(II), Co(II), Ni(II) and Fe(II), respectively).96a Additionally, (48) was
screened against AbMetAPx and AbMetAPy, with preferential binding again observed for the
Mn(II) loaded forms of the enzymes (AbMetAPx IC50 = 13, 394, 188, 358 µM; Mn(II), Co(II),
Ni(II) and Fe(II), respectively; AbMetAPy IC50 = 0.92, 381, 186, 288; Mn(II), Co(II), Ni(II) and
Fe(II), respectively).89e Compound (48) was also screened against MtMetAP1c and was found to
be active against the Mn(II) loaded form of the enzyme only (MtMetAP1c IC50 = 14 µM; Mn(II);
IC50 = >500 µM; Co(II), Ni(II) and Fe(II))96h where inhibition of BpMetAP1 with Co(II)
cofactors by (48) was not observed (IC50 = >250 µM).89c
Furoic acid derivatives appear to be more active than thiophenic acid derivatives, as
demonstrated by the activity of 5-(2-chlorophenyl)thiophenic acid derivative (49) (EcMetAP1
IC50 = 3.5, 45.3, 50.0 and 50.0 µM, Mn(II), Co(II), Ni(II) and Fe(II), respectively).96b
Concerning phenyl furoic acid derivatives, substitution at the 2-position of the phenyl substituent
generally resulted in the most active compounds, with motifs usually including Cl, Me, MeO,
EtO and CF3 substituents.96a, b For example, 5-(2-trifluoromethylphenyl)-2-furoic acid (50) was
found to exhibit the most potent activity against EcMetAP1 (IC50 = 0.15 µM, Mn(II) cofactors)
of any test compounds.96b Substitution at two positions of the phenyl ring increases activity,
except in the case of 2,3-disubstituted derivatives, with 2,5-disubstituted motifs generally having
the most pronounced increase in activity. For example, 5-(2,3-dichlorophenyl)-2-furoic acid (X =
O, R1 = R2 = Cl, R3 = R4 = H), 5-(2,4-dichlorophenyl)-2-furoic acid (X = O, R1 = R3 = Cl, R2 =
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R4 = H) and 5-(2,5-dichlorophenyl)-2-furoic acid (X = O, R1 = R4 = Cl, R2 = R3 = H) all
demonstrated superior activity to that of (48) against EcMetAP1 with Mn(II) cofactors (IC50 =
0.94, 0.44, and 0.25 µM, respectively).96b This trend is observed for all derivatives with these
substitution patterns, regardless of the substituent identity. Additionally, derivatives with aryl
substituents other than substituted phenyl rings are also potent inhibitors, as in the case of 5-(21H-indolyl)-2-furoic acid (51) (EcMetAP1 IC50 = 0.46 µM, Mn(II) cofactors).

The conversion of the acid chelating group to a hydroxamic acid has been shown to
increase activity against EcMetAP1, with the most pronounced increases resulting for Co(II) and
Fe(II) cofactors. For example, conversion of (48) to hydroxamic acid derivative (52) results in
dramatic activity increases when screened against these cofactors (EcMetAP IC50 for (48) =
>200, 94 and 2.9 µM; Co(II), Fe (II), Mn(II) cofactors, respectively; EcMetAP IC50 for (52) =
3.5, 1, 1.3 µM; Co(II), Fe (II), Mn(II) cofactors, respectively).96i Additionally, (52) was
crystallized with EcMetAP1 bearing Mn(II) cofactors (PDB: 4A6W);96h the crystal structure
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demonstrates bridging interactions to both active site metals as opposed to chelation
demonstrated for the crystal structure of (48) (Figure 19). Finally, other 5-aryl-2-heterocyclic
carboxylic acids (i.e. oxazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole, and imidazole) were screened
against EcMetAP1 and were found to exhibit comparable or worse inhibitory activity.96i
Furoic acids have also been screened for bacterial growth inhibition against E. coli cells
with recombinant MtMetAP1c.96h Although the in vitro activity of these compounds against
bacterial MetAPs has been established, compound (48) was ineffective at inhibiting E.coli
growth. Because these furoic acid derivatives have only demonstrated activity for Mn(II) forms
of MetAPs, this lack of activity may suggest the native form of MtMetAP1c does not contain
Mn(II) cofactors when excluding physicochemical parameter considerations.96h Unfortunately,
compounds of this class have not been screened against HsMetAPs and selectivity data are
therefore not discussed.

Quinoline Inhibitors

Compounds bearing 8-hydroxy or 8-amino quinoline motifs have been demonstrated to
inhibit bacterial MetAPs in vitro. As observed within the crystal structure of N-(8quinolinyl)methanesulfonamide (53) bound to EcMetAP1 with Mn(II) cofactors (PDB: 2BB7),97
the compounds bind to an auxiliary metal atom imbedded within the active site via chelation
from the quinoline N and sulfonamide N atoms, with hydrophobic interactions to Tyr-62, His-79
and His-178 (see Figure 20).97 This binding mechanism is similar to that demonstrated by the
biaryl chelating inhibitors discussed previously. Again, because the crystal structure was
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obtained by mixing the enzyme and inhibitor in a buffered solution containing MnCl2, the
inclusion of the auxiliary Mn(II) is likely the result of the method of crystallization and the
compounds may act in a mechanism not observed within this crystal structure.

Figure 20: N-(quinolin-8-yl)methanesulfonamide (53) bound to the active site of EcMetAP1.
The color scheme is as follows: purple spheres = manganese metals; light green compound =
(53); yellow dashes represent coordination to the metals from residues or the inhibitors and Hbonding (PDB: 2BB7).97

The chemical structures and bacterial MetAP inhibitory activity for various quinoline
based inhibitors is below in Table 13. Species bearing sulfonamide groups at the 8-position (R1)
were found to be selective for MetAPs with Co(II) or Ni(II) cofactors, and are less potent for
enzymes bearing Mn(II), Fe(II) and Zn(II) metals. Generally, nitroxoline (58) derivatives (R1 =
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OH, R2 = H, R3 = NO2) were found to be more active than compounds bearing chloro or sulfuric
acid groups at R2 (compare: (57) and (58); (59) and (60)) against BpMetAP1 bearing Co(II)
cofactors. Additionally, morpholine and piperidine Mannich products of 5-chloro-8-quinolinol
(59) and nitroxoline ((60) and (62)) have demonstrated activity against BpMetAP1 (IC50 = 9.0,
0.1 and 0.03 µM, respectively). However, these derivatives, specifically (60), do not exhibit
superior activity to that of the parent compound nitroxoline (58). Although dimethylamino
derivative (61) and piperidine derivative (62) do exhibit slightly better activity than nitroxoline
(58) against BpMetAP1, the increases in activity are marginal, indicating that drastic
improvements upon the activity of these derivatives will likely not be achieved with Mannich
products of the 7-position on the quinoline scaffolding (see Table 13).

Table 13: General Structures and Enzymatic Inhibitory Activity of Quinoline Inhibitors

R2

R3

(53)

H

H

EcMetAP1 0.137

2.14

3.74 0.184

(54)

H

Cl

EcMetAP1 0.154

1.64

3.93 0.171 0.806

97

(55)

H

H

EcMetAP1

18.5

13.8

97

Cmpd

R1

Enzyme

Coa,b Mna,b Fea,b

1.69

Nia,b

7.42

Zna,b Ref
1.11

11.3

97

(Continued on next page)
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Table 13: (Continued)

Cmpd
(56)
(57)
(58)
-

R1
OH
OH
OH
-

(59)

OH

-

-

(60)

R2
H
H
H
-

R3
H
SO3H
NO2
-

Enzyme
Coa,b Mna,b Fea,b
EcMetAP1 11.0
SaMetAP1 22.9
HsMetAP1 44.9
HsMetAP2 39.8
EcMetAP1 0.77
SaMetAP1 18.3
HsMetAP1 >15
HsMetAP2
2.03
BpMetAP1 213
HsMetAP1 >15
HsMetAP2
>15
BpMetAP1 0.06
HsMetAP1 >15
HsMetAP2
0.055
-

Nia,b
-

Zna,b Ref
92b
92b
92b
92b
92b
92b
98
98
89c
98
98
89c
98
98
-

Cl

BpMetAP1

9

-

-

-

-

89c

-

HsMetAP1
HsMetAP2

>50
-

2.66

-

-

-

98

OH

NO2

BpMetAP1

0.10

-

-

-

-

89c

(61)

OH

NO2

BpMetAP1

0.04

-

-

-

-

89c

(62)

OH

NO2

BpMetAP1

0.03

-

-

-

-

89c

a.
b.

-

98

The different metal headings correspond to the various MetAP cofactors (divalent)
IC50 values are expressed in units of µM

(Continued on next page)
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Table 13: (Continued)

Cmpd
(63)
(64)
a.
b.

R1
OH
OH
-

R2
Br
I
-

R3
Cl
Cl
-

Enzyme
Coa,b Mna,b Fea,b
MtMetAP1 5.44
MtMetAP1 4.92
HsMetAP1 105
HsMetAP2 112
MtMetAP1 9.25
MtMetAP1 11.1
HsMetAP1 84.7
HsMetAP2 80.4
-

Nia,b
-

Zna,b Ref
99
99
99
99
99
99
99
99
-

The different metal headings correspond to the various MetAP cofactors (divalent)
IC50 values are expressed in units of µM

Some of these compounds have shown activity against HsMetAP1 and HsMetAP2 ((58)
IC50 = 44.9 and 39.8 μM, HsMetAP1 and HsMetAP2, respectively), demonstrating potential
selectivity shortcomings (Table 13).92b Nitroxoline (58) also exhibits potent activity against
HsMetAP2 (IC50 = 0.055 μM) that is comparable to the activity observed for BpMetAP1 (IC50 =
0.06 μM), providing further evidence of promiscuous MetAP inhibition. Additionally,
compounds of this class have been identified as pan-assay interference compounds (PAINS) for
their ability to break down under normal assay conditions to species capable of affording false
hit signals.100 The compounds have been identified as redox cyclers and protein covalent
modifiers, suggesting selectivity issues against various MetAP isoforms and other host (human)
proteins.100 While some compounds were potent inhibitors of various bacterial MetAPs, this
chemical class is unlikely to progress further than in vitro studies against MetAPs and inhibitory
studies against bacterial colonies.
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Fumagillin Derivatives

A landmark in the inhibition of HsMetAP came in 1997 with the discovery that the antiangiogenic properties observed for fumagillin (65) were due to MetAP2 inhibition.101 A later
report details the mechanism of binding, with the epoxide covalently binding to an active site
histidine (His-79) residue of EcMetAP1.94 Additionally, the difference of a single residue in the
active sites of HsMetAP1 as compared with HsMetAP2 is responsible for the selectivity of
ovalicin (66), a fumagillin derivative, for the latter enzyme.102

Concerning the inhibition of bacterial MetAPs by fumagillin and its derivatives, only the
parent compound fumagillin (65) has been screened (EcMetAP1 IC50 = 9.15 µM; Co(II)
cofactors).92c Additionally, fumagillin (65) was shown to covalently bind to HsMetAP2101 and a
derivative (Ovalicin) exhibits selectivity between HsMetAP1 and HsMetAP2.102 Although this
class of inhibitors has exhibited potent activity against HsMetAP2, a diverse collection of
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derivatives has not been screened against bacterial targets. More research is necessary to
determine MetAP potency against bacterial targets.

Peptide-Based Inhibitors

Peptide-based inhibitors of bacterial MetAPs are designed according to two motifs:
modified methionine moieties103 and 3-amino-2-hydroxy amino acid (bestatin) derivatives.89b, 89f,
94, 103a, 104

Compounds of this class have been crystallized with MetAP (PDB: 2GG0,89b 2GG9,89b

2GGB,89b 2GG889b). As demonstrated in Figure 21, hydroxy amino acid derivatives bind to the
MetAP active site via chelation to both metal centers from the primary amine, secondary alcohol
and adjacent amide carbonyl to form a tridentate complex.89b Additionally, the p(trifluoromethyl)phenyl substituent of (67) exhibits hydrophobic interactions with Tyr-62 and
His-63 (not shown), maximizing binding to the catalytic domain (see Figure 21).
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Figure 21: Bestatin derivative (67) bound to the active site of EcMetAP1. The color scheme is as
follows: blue spheres = cobalt metals; light green compound = (67); yellow dashes represent
coordination to the metals from residues or the inhibitors and H-bonding interactions (PDB:
2GG0).89b

Generally, compounds of this class do not exhibit binding specificity based upon the
identity of the active site metals. For example, (2S,3R)-3-amino-2-hydroxyheptanoic acid (68)
does not exhibit drastic changes in activity for EcMetAP1 with Co(II), Mn(II), Zn(II), or Ni(II)
cofactors (IC50 = 12.3, 11.5, 9.3 and 22.3 µM, respectively).103a Changing the free acid to a short
peptide chain, as in the case of Ala-Leu-OMe derivative (69), results in compounds with similar
activity that still bear the same nonselective character as free acid (68) against the various
EcMetAP1 metalloforms (IC50 = 22.9, 25.2, 16.7 and 12.5 µM; Co(II), Mn(II), Zn(II), and Ni(II),
respectively).103a Although (69) demonstrates better inhibitory activity against EcMetAP1 with
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Ni(II) than free acid (68), the activities of these two derivatives are comparable for all
metalloforms, suggesting binding contacts involving nonspecific hydrophobic interactions to
auxiliary binding pockets play a larger role in enzymatic inhibition than chelation to the active
site metals. Conversion of the n-butyl chain to p-(trifluoro)phenyl substituent, as in the case of
(67), results in an increase in activity against EcMetAP1 with Co(II) cofactors (IC50 = 1.7
µM)89b as compared with similar derivative (69).

Some peptide-based inhibitors of bacterial MetAPs incorporate methionine residues for
enzymatic recognition of the natural substrate. For example, pyridine derivative (70) was found
to inhibit EcMetAP1 (IC50 = 2.5 µM; Co(II) cofactors) and even displayed selectivity for the
bacterial isoform over HsMetAP1 and HsMetAP2 (IC50 = 48 and 91 µM, respectively), although
the source of the isoform selectivity is not discussed.103c Additionally, conversion of the
methionine sulfur to a methylene to form an n-butyl chain results in a decrease in activity against
EcMetAP1 (IC50 = 59 µM; Co(II) cofactors) demonstrating the advantage of substrate
recognition. Some peptide-based inhibitors exhibiting activity against bacterial MetAP isoforms
incorporate both methionine and amino alcohol motifs. For example, compound (71) was shown
to potently inhibit EcMetAP1 (IC50 = 2.5 µM; Co(II) cofactors) while incorporating both
methionine recognition and the chelating ability of amino-alcohol motifs. Interestingly,
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conversion of the N-terminal cysteine of (71) to a valine residue results in a slightly less active
species (EcMetAP1 IC50 = 4.3 µM; Co(II) cofactors).103c

Thiazole Containing Inhibitors

Inhibitors containing thiazole rings are generally composed of N-(2thiazolyl)picolinamide,105 N-(2-thiazolyl)oxamide,96d, 96f, 96j, k or N-(2-thiazolyl)thiazole-4carboxamide motifs.106 The sole crystal structure of EcMetAP1 utilizing thiazole inhibitors
contains N1-cyclopentyl-N2-(2-thiazolyl)oxalamide (72) bound to an auxiliary Co(II) atom
crystallized near the active site of EcMetAP1 (PDB: 2EVO)96d (see Figure 22). Like similar
crystal structures containing auxiliary metal atoms, (72) coordinates in a bidentate fashion, with
the thiazole amide nitrogen and cyclopentyl amide carbonyl groups coordinating to the metal
center. The coordination sphere of the auxiliary cobalt atom is filled by coordination to His-79
and three water atoms. Additionally, (72) exhibits π-π stacking with Tyr-65 via the thiazole ring.
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Figure 22: Oxalamide derivative (72) bound to the active site of EcMetAP1. The color scheme is
as follows: blue spheres = cobalt metals; light green compound = (72); yellow sashes represent
coordination to the metals from residues or the inhibitors and H-bonding interactions (PDB:
2EVO).96d
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Compounds bearing a (2-thiazolyl)picolinamide scaffolding are of the general structure
shown below. Components of this series contain the (2-thiazolyl)picolinamide core (73) with
substitution at various positions around the pyridine ring, with the most active compounds
utilizing amides or esters at the 3-position.96b, 105c Additionally, any substitution pattern appears
to enhance activity as compared with the picolinamide core (73), which was found to inhibit
EcMetAP1 (IC50 = 5.0; Co(II) cofactors). For example, 3-propionamido (R1 = propionamide, R2
= R3 = R4 = H) derivative exhibits potent activity against EcMetAP1 with Co(II) cofactors (IC50
= 0.26), while similar 4-acetylamido (R2 = acetylamide, R1 = R3 = R4 = H) and 5-but-3-eneamido
(R3 = but-3-eneamide, R1 = R2 = R4 = H) derivatives exhibited less potent activity.105c
Interestingly, all compounds bearing substitution at the 6-position (R4) of the pyridine ring were
found to be inactive against both EcMetAP1, except in the case of 6-hydroxymethyl substitution
(R1 = R2 = R3 = H, R4 = CH2OH; IC50 = 5.82 µM; Co(II) cofactors).105c
Compounds containing ester or amide motifs at the 3-position (R1) exhibit the best
activity of this class, with amides generally exhibiting superior activity than the corresponding
esters. For example, phenyl ester derivative (74) exhibits weaker activity than the corresponding
amide (75) against EcMetAP1 (IC50 = 1.22 and 0.89 µM, respectively; Co(II) cofactors).105a
Interestingly, phenyl ester (74) is significantly more active than amide (75) against S. cerevisiae
MetAP1 (IC50 = 1.03 and >100 µM, respectively; Co(II) cofactors), demonstrating the selectivity
of amide derivatives for bacterial MetAPs over fungal MetAPs. Concerning phenyl esters and
amides, only compounds bearing 2-substituted phenyl esters were found to be active against
ScMetAP1, although the source of this activity is not discussed.105a However, this is an important
observation; the most difficult problem to overcome in the search for bacterial MetAP inhibitors
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is enzymatic selectivity. Because these enzymes are highly conserved across numerous lifeforms,
the selective inhibition of isoforms from a single kingdom is paramount.
As stated previously, compounds bearing alkyl esters and amides at the 3-position (R1) of
the pyridyl ring generally exhibit more potent activity than aryl derivatives against various
MetAPs. Additionally, the incorporation of alkyl amines greatly improves MetAP inhibitory
activity; for example, 3-(2-(diethylamino)acetamido derivative (76) exhibits potent activity
against EcMetAP1 (IC50 = 0.049 µM; Co(II) cofactors).105c Various other alkyl amine derivatives
(dimethyl, pyrrolidinyl, piperadinyl, and morpholino) were screened against EcMetAP1,
although none were as active as (76).
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Compounds of this class have been screened in bacterial whole-cell assays and the
activities can be found in Table 14.105a While compound (73) exhibits activity against both
EcMetAP1 and was shown to be active against some bacterial cell lines (S. aureus and E. coli),
all ester and amide inhibitors. Considering the fact that derivatives of (73) exhibit more potent
activity against EcMetAP1 than parent compound (73), it is surprising to see that the compounds
are essentially ineffective as antibacterial agents. The authors of the study provide two
hypotheses to explain this observation: first, the compounds may not be able to penetrate cell
walls as effectively as (73) and second, the physiological active site metals for MetAPs from the
various bacterial species may not be cobalt. Because the physicochemical parameters of this
class of compounds have not been determined and due to the fact that the natural cofactors of
bacterial MetAPs are unknown, either of these hypotheses could be responsible for the observed
lack of cell growth abatement for these derivatives.
Finally, compounds of this class have been screened against HsMetAPs to elucidate
isoform selectivity. For example, compound (73) was found to be less active against HsMetAP1
(IC50 = 10.4 µM; Co(II) cofactors), than EcMetAP1 (Table 14).107 Although (73) only exhibits a
two-fold increase in inhibition favoring the bacterial isoform, the incorporation of lipophilic
amide functionalities at the 3 position of the picolinamide scaffold affords compounds inactive
against HsMetAPs. When employing a benzamide at postion 3, a potent inhibitor of EcMetAP1
with selectivity over HsMetAP1 results (IC50 = 0.89 and >100 µM; Co(II) cofactors,
respectively)107 (see Table 14).
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Table 14: Whole-Cell Inhibition of Various Bacteria by (2-Thiazolyl)picolinamide Derivatives

Cmpd

R

(73)

H

EcMetAP1
S. aureusb,c E. colib,c P. aeruginosab,c
IC50a,c
5.0

2

12.5

250

(77)

0.13

62.5

125

500

(78)

0.33

62.5

125

500

(79)

0.28

15.6

250

250

(80)

5.4

125

250

500

a.
b.
c.

IC50 values are expressed in units of µM
MIC values are expressed in units of µg/mL
From Ref. 105a

In addition to (2-thiazolyl)picolinamide derivatives, N-(2-thiazolyl)oxamide derivatives
have been shown to inhibit bacterial MetAPs. Based upon the crystal structure of EcMetAP1
containing cyclopentylamide derivative (72), the compounds inhibit the enzyme via coordination
to an auxiliary Co(II) atom not found within the native enzyme. As stated previously, the
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incorporation of this third metal atom in the active site of MetAPs is likely the result of the
method of crystallization; because metal salts are included in the crystallization mother liquor
with both the enzyme and the inhibitors present, it is impossible to know if the inhibitor is
chelating to the auxiliary metal atom prior to enzyme coordination.
Only three oxamide derivatives have been screened against bacterial MetAPs and are
shown in Table 15. These compounds were screened against EcMetAP1 containing the various
cofactors shown in the table and were found to be selective for MetAPs containing Co(II)
cofactors. Slight activity was observed for EcMetAP1 with Ni(II) cofactors, while the
compounds are essentially inactive against both the Mn(II) and Fe(II) forms of the enzyme.
Interestingly, the compounds were found to be inactive as bacterial growth inhibitors of E.coli.96k
Such observed lack of activity in the bacterial whole-cell assay is noteworthy, as the compounds
clearly inhibit some metalloforms of the enzyme. However, because the native cofactor has not
been assigned (although Chai suggests the native cofactor for E. coli is Fe(II)96j), the compounds
may not be active against the natural form of the enzyme. Additionally, the physicochemical
parameters of these compounds have not been evaluated and any conclusions drawn regarding
the observed lack of activity against E. coli in the whole-cell assay are premature. Finally, a
wider test set of these compounds must be screened to determine if progression from hit-to-lead
is feasible. To date, species bearing an oxamide scaffold have not been screened against
HsMetAPs to determine isoform selectivity (see Table 15).
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Table 15: Oxamide Based MetAP Inhibitors

Compound

a.
b.

E. coli AS19
Co(II)a Mn(II)a Ni(II)a Fe(II)a Cell-Growth
Inhibitionb

Ref.

0.067

53

1.0

46

>1000

96f, 96k

0.073

54

2.0

65

>1000

96f, 96k

0.28

108

3.4

118

-

96f

Inhibition of EcMetAP1 with indicated cofactors; expressed as IC50 (µM)
Expressed as IC50 (µM)

Species bearing a N-(2-thiazolyl)thiazole-4-carboxamide core are active against
EcMetAP1, although their activity has not been verified in whole-cell assays.106 Derivatives of
this class of inhibitors utilize functionalization at the 4-position of the central thiazole ring. They
are isosteric with the (2-thiazolyl)picolinamide derivatives discussed previously and exhibit
similar activity, although the selectivity for bacterial (E. coli) MetAPs over fungi (S. cerevisiae)
MetAPs is not as pronounced. Generally, these compounds utilize alkyl, aryl and amide
functionalization at the 4-position of the thaizole ring.108 Essentially any substitution at this
position results in potent inhibitors of EcMetAP1 (IC50 = <1.0 µM), while the parent compound,
N-(2-thiazolyl)thiazole-4-carboxamide (R = H), was found to be less potent (IC50 = 1.97 µM,
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Co(II) cofactors).106b Because drastic changes in activity are not observed for these inhibitors, a
true structure-activity relationship is difficult to deduce. However, the activity of piperidine
derivatives (83 – 85) appears to follow a logical SAR, with activity increasing with decreasing
length between the piperidine and thiazole rings. For example, amide (83) was found to be a
potent inhibitor of EcMetAP1 (IC50 = 0.14 µM, Co(II) cofactors),106b while removal of the amide
N and carbonyl to afford (84) results in a three-fold increase in activity (IC50 = 0.045 µM, Co(II)
cofactors),106a and shortening of the alkyl chain by a methylene, (85), results in an additional
four-fold increase in activity (IC50 = 0.010 µM, Co(II) cofactors)106b to afford the most potent
compound of this class screened against EcMetAP1 to date. Although compound (85) is a potent
inhibitor of EcMetAP1, it has also been demonstrated as a potent inhibitor of ScMetAP1 (IC50 =
0.075 µM, Co(II) cofactors), demonstrating possible selectivity issues not observed for similar
(2-thiazolyl)picolinamide derivatives. Finally, compounds of this class have not been coscreened against HsMetAPs and isoform selectivity against human enzymes is therefore
unknown.
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Other Inhibitors

In addition to the classes of bacterial MetAP inhibitors discussed, other classes of
inhibitors have been identified, such as barbiturates,109 salicylate derivatives,96a, 110 catechols,96k,
108, 111

and bengamide derivatives.112 In general, the barbiturate based inhibitors exhibit moderate

activity against EcMetAP1 (Ki = 4 – 517 µM, Co(II) cofactors),109 with only one compound
exhibiting potent activity (Ki = 0.05 µM) and were found to be nonselective inhibitors of
MetAPs, as demonstrated by comparable activity with HsMetAP1. Because the compounds are
not very active against MetAPs, exhibit nonselective inhibition and only one report exists
detailing their activity, a detailed overview has been excluded.
Some salicylate derivatives have demonstrated activity in a bacterial whole-cell assay
when screened against E. coli AS19. The compounds contain biaryl systems between the
salicylate core and thiophene rings, with the most active compounds against bacterial growth
utilizing 4-(2-thiophene)-benzoic acid motifs. Unlike most other classes of MetAP inhibitors,
salicylate derivatives do not exhibit metalloform selectivity in the inhibition of MetAPs. For
example, compound (86) was shown to inhibit E. coli AS19 growth (IC50 = 34.1 µM; MIC = 28
mg/L),96e although potent inhibition of EcMetAP1 is not observed (IC50 = 87.7, 62.7 and 73.0
µM; Co(II), Mn(II) and Fe(II), respectively). (86) was the most potent compound screened
against E. coli AS19 growth, with all salicylate derivatives exhibiting similar activity (IC50 =
48.5 to >1000 µM; MIC = 30 to >248 mg/L).
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Species bearing various substitution patterns were screened for both enzymatic and
antibacterial activity, although the activities were generally too close to determine SAR effects.
However, the authors were able to show the 2-hydroxybenzoic acid substitution pattern is
necessary for potent activity, which would facilitate metal chelation.
Catechol based inhibitors have been implicated as possible antibacterial agents which
target MetAP, as demonstrated by both their potent in vitro enzymatic activity and antibacterial
activity.96k, 108, 111 Generally, this class of inhibitors consists of catechol – heterocycle biaryl
systems, with the most potent heterocycles usually consisting of thiophene, furan or thiazole
rings, and pyridine, pyrimidine, 1,2,3-triazole, imidazole, or oxazole rings usually producing less
active species. Thiophene derivative (87) has been crystallized with EcMetAP1 and was found to
exhibit the expected binding mode, with the catechol moiety chelating one of the active site
metals (PDB: 3D27)108a (Figure 23). Like the similar aryl carboxylic acid derivatives, the
thiophene ring exhibits T-shaped π- π stacking interactions with Tyr-62 (see Figure 23).
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Figure 23: Catechol derivative (87) bound to the active site of EcMetAP1. The color scheme is
as follows: blue spheres = cobalt metals; light green compound = (87); yellow dashes represent
coordination to the metals from residues or the inhibitors and H-bonding interactions (PDB:
3D27).108a

The general structure of catechol based inhibitors of bacterial MetAPs is shown in Table
16. Compounds of this class of inhibitor exhibit selectivity for MetAPs with Fe(II) cofactors and
have been screened against various bacterial species to determine antibacterial activity. Species
utilizing heterocycles other than thiophene have been excluded from the table as they generally
exhibit less activity against both the enzyme in vitro and against cell growth inhibition, with the
exception of furan derivatives containing alkyl amides, as in the case of compound (93).
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Generally, 3-catechol thiophene derivatives are more active than 2-catechol thiophenes against
both EcMetAP1 and the various bacterial strains, as demonstrated by the difference in activity
for compounds (88) and (89). Additionally, functionalization at any position of the thiophene
ring results in an increase in antibacterial activity; for example, compounds (90) – (92) exhibit
activity comparable or better than parent compound (88) against the various bacterial strains.
However, these compounds generally do not exhibit more potent activity than (88) in the
enzymatic assay, suggesting a mechanism of action other than MetAP inhibition when excluding
cell-permeability considerations.
Although these compounds initially appear to be selective inhibitors of bacterial MetAPs,
they have been implicated as pan-assay interference compounds.100 Species bearing catechol
rings are known promiscuous inhibitors of metalloenzymes and often exhibit false positive
responses in assays. Therefore, any future studies utilizing this class of inhibitors should be
diligent in their investigations and rigorously question the result (see Table 16).

Table 16: Catechol Based Inhibitors

R

a.
b.
c.

Coa,b

Mna,b

Fea,b

E. coli
AS19c

E. coli
D22c

B.
subtilisc

B.
megateriumc

63

56

13

15 (5)

12 (6)

21.8 (7)

27.8 (11)

Refc

96k, 108a

The different metal headings correspond to the various MetAP cofactors (divalent)
IC50 values are expressed in units of µM
Inhibition of bacterial growth (IC50 = µM); Numbers in parenthesis are MIC (µg/mL)

(Continued on next page)
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Table 16: (continued)

R

a.
b.
c.

Coa,b

Mna,b

Fea,b

E. coli
AS19c

E. coli
D22c

B.
subtilisc

B.
megateriumc

40

28

3.8

30 (15)

2.0 (2)

15.7 (9)

19.2 (10)

96k, 108a

24

16

5.1

33

4.0 (3)

16.1 (7)

21.2 (9)

96k, 108a

>100

>100

7.4

19 (9)

3.7 (4)

16.5 (5)

16.0 (5)

96k, 108a

2.4

2.1

3.1

11 (5)

7.7 (9)

12.8 (8)

17.5 (10)

96k, 108a

62

49

20

6.1 (3)

7.3 (2)

6.0 (2)

5.0 (1)

96k, 108a

30

12

0.9

23 (19)

-

-

-

108b

The different metal headings correspond to the various MetAP cofactors (divalent)
IC50 values are expressed in units of µM
Inhibition of bacterial growth (IC50 = µM); Numbers in parenthesis are MIC (µg/mL)

Refc
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Finally, bengamide derivatives have demonstrated activity against MtMetAP1a and
MtMetAP1c and have been crystallized with MtMetAP1 (PDB: 3PKC,112a 3PKD,112a
3PKE112a).112 The general structure of these inhibitors is shown below and the compounds
chelate both active site metals via the 1,2,3-triol chain. Other enzyme-inhibitor interactions
involve numerous H-bonding and hydrophobic coordination. As demonstrated by compounds
(95) and (96), derivatives of this class of inhibitors utilize the same side chain as the natural
product (94) with functionalization involving the conversion of the caprolactam ring to other
lipophilic ring systems. Although these compounds exhibit potent activity against MetAP in
enzymatic assays ((95): MtMetAP1c IC50 = 39, 0.40, 150 and 61 µM; Co(II), Mn(II), Ni(II) and
Fe(II) cofactors, respectively), they do not exhibit large differences in activity for the various
substitution patterns, as demonstrated by the differences in activity for compounds (95) and (96)
(MtMetAP1c IC50 = 52, 0.2, >250 and 68 µM; Co(II), Mn(II), Ni(II) and Fe(II) cofactors,
respectively).112a Additionally, they are essentially inactive against M. tuberculosis in a
microplate Alamar Blue (MABA) cellular growth inhibition assay ((95) % inhibition at 128 µM
= 15%; (96) % inhibition at 128 µM = 48%).112a Therefore, more research must be conducted to
maximize activity if these compounds are to progress from hit identification to lead refinement.
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Experimental Design

Efforts involving the development of potential antibiotic chemotherapies for the
treatment of infection should focus on enzymatic or cellular pathways that are both necessary for
cellular proliferation and, to avoid preexisting resistance mechanisms, have not been previously
targeted by commercially available drugs. Because the cellular reliance on MetAP activity is
well established,85-86 the inhibition of this class of ubiquitous enzymes could provide a novel
antibacterial mechanism of action. Following an extensive review of published reports involving
the inhibition of bacterial MetAPs by small molecules (see Classes of MetAP Inhibitors, page
93), several potent classes of inhibitory species accessible by facile synthetic routes were
discerned. To discover novel, potent inhibitory chemical entities, published scaffolding can be
utilized as a starting point for further optimization.
Once compounds are obtained through synthetic or commercially available sources,
inhibitory activities must be discovered to determine SARs for each chemical series. Following
protein expression and purification, enzymatic inhibitory assays can be utilized for this purpose,
which typically monitor substrate consumption or product formation as a function of enzymatic
activity.3 The specific enzymatic species is also significant and should be selected according to
availability, structural elucidation (and deposition within the PDB), and access to the
corresponding whole-cell assays. We therefore selected Rickettsia prowazekii MetAP1a for our
enzymatic inhibitory assay, as our collaborators (Bart Staker, SSGCID) had previously isolated
the protein and determined the sequence and crystalline structure (PDB: 3MX6, 3MR1). An
additional collaborator (Jonathon Audia, USA) had previously optimized a host-cell viability
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assay capable of determining antirickettsial activity in the presence of endothelial cells. We were
thus able to screen compounds against the target enzyme to determine potent species prior to
cellular screening.
Members of the genus Rickettsia are responsible for epidemic typhus. Early symptoms
include headache, fever, and a spotted rash indicative of Rickettsial infection, with many patients
experiencing neurological effects (delirium, hysteria) and some falling into a coma as a result of
a lowering in blood pressure, although cases are rarely fatal (10 – 30% mortality).113 The
pathogen is carried by the human body louse and transmitted through fecal matter deposited on
hosts. Scratching of louse bites facilitates bacterial introduction even days after the initial bite, as
Rickettsiae are able to survive in feces for extended periods of time. Bacterial infection quickly
spreads between host species, as individual lice eventually succumb to infection.113
Rickettsiae are obligate intracellular pathogens and are therefore unable to survive for
extended periods outside of cellular hosts.114 As such, the pathogen was originally difficult to
obtain in laboratory settings and early treatment efforts progressed slowly.115 Although once
epidemic and therefore currently considered Category B bioterrorism agent,116 Rickettsial
infection of the populous can be treated with common antibiotics (tetracyclines or
chloramphenicol) and systematic mortality is no longer widespread, although species have been
isolated with resistances to these antibiotics.117
The structure of RpMetAP1a contains the characteristic “pita-bread” fold indicative of
this class of enzymes, and was determined to have significant sequence alignment with
EcMetAP1a (53%) and HsMetAP1b (43%) (see Sequence Alignment of Bacterial and Human
MetAPs, page 89). The majority of conserved residues line the catalytic binding pocket and the
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five residues responsible for cofactor binding are conserved across all three species. Regarding
selectivity, inhibitory compounds should target residues within the active site that are unique to
the species targeted. For example, a histidine near the active site in both Ec and Hs MetAPs was
found to be a lysine in RpMetAP1a. Although this residue is spatially far from the active site
metals generally utilized as an anchor for inhibitory species, enzymatic selectivity of these
isoforms could be achieved by specifically targeting this residue (see Figure 24).

Figure 24: Active site of RpMetAP1a. The residue colored green (Lys-61) demonstrates the only
major non-conserved active site residue between RpMetAP1a, EcMetAP1a and HsMetAP1b
(PDB: 3MX6).
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Inhibitors, based upon furoic acid, 1,2,4-triazole, quinoline, and anthranilic acid
scaffolds,89c were selected as starting points for optimization against bacterial MetAPs.
Additionally, a library of 294 compounds based upon published inhibitory motifs was purchased
and screened against RpMeAP1a in the hope of discovering novel chemical space for bacterial
MetAP inhibition. The most potent inhibitors were submitted to collaborators (Jonathon Audia)
for antirickettsial screening in a host-cell viability assay. Finally, computational modeling was
employed to aid in SAR determination and to guide hit modification efforts.

Results and Discussion

Compound Synthesis and Enzymatic Inhibitory Activities

Prior to the synthesis of compounds based upon published bacterial MetAP inhibitors, it
was necessary to develop and optimize a suitable enzymatic activity assay. The assay employed
was adopted from published reports,89d where MetAP activity was monitored using methionyl
aminomethylcoumarin (Met-AMC) as the substrate, which upon enzymatic cleavage of the
peptide bond between the methionine and AMC moieties produces free AMC, a fluorescent
compound with emission at 460nm (Scheme 4). Initially, compounds are incubated with
RpMetAP1a (1 µM) for one hr in the assay buffer. Next, substrate is added to initiate the
reaction, and the fluorescence is monitored for 90 mins. Inhibitory activities are calculated in the
same manner as described previously for urease inhibition studies (see Figure 9, page 36), except
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enzymatic activity was calculated as the slope of fluorescence vs. time plots over the 30 – 40 min
range (see Scheme 4).

Scheme 4: Reaction monitored for the MetAP in vitro assay

To begin the optimization of published bacterial MetAP inhibitors, compounds based
upon the furoic acid scaffold were purchased (Sigma Aldrich). The compounds were chosen
based upon published SAR against other bacterial species, and representative compounds have
been crystallized as bound structures against EcMetAP1a (see Aryl Carboxylic Acid Inhibitors,
page 103). As with other reports detailing the inhibition of bacterial MetAPs by furoic acids and
thiophenic acids,89c, d, 89g, 96a, b, 96d, 96f, 96h-j, 118 the most potent compounds contain small
substituents at the ortho (R1) position. Xie et al., attribute this observed increase in activity to the
elevation in the rotational barrier energy of the biaryl system, resulting in a twisted conformation
that is favored for maximal binding.96d This conformation is observed in all crystal structures of
these compounds bound to MetAPs (PDB: 1XNZ,96f 2EVM,96d 2Q92,96g 2Q93,96g 2Q94,96g
2Q95,96g 2Q96,96g and 3IU789g). Generally, the compounds bind via bidentate coordination
through the carboxylate to one of the active site metals, with one of the oxygen atoms also
exhibiting coordination to the other cofactor (PDB: 3MAT94).96f This results in a competitive
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mechanism of inhibition where the catalytic site is blocked by inhibitor coordination, effectively
eliminating access by substrate.
As with other reports,96b 5-phenyl-2-thiophenic acid (97) was found to exhibit weaker
activity than that of the corresponding furan (98) (IC50 = 74 and 37 μM, respectively).
Compound (50) utilizes a trifluoromethyl substituent at the ortho (R1) position and was observed
to be the most active compound of this chemical series (IC50 = 0.50 μM). Such activity was
essentially mirrored by other compounds utilizing substitution at R1, namely (48), (99) and (100),
with inhibitory values of 0.61, 0.91, and 0.64 μM, respectively. The exact electronic character of
the substituents was found to play a minimal role on activity, as species bearing both donating
and withdrawing groups were active (Cl vs. Me; (48) and (99), respectively). Only one species
containing meta (R2) substitution, 3-methyl derivative (101), exhibited superior activity to that of
unsubstituted 5-phenyl-2-furoic acid (98), with inhibitory values of 26 and 37 μM respectively.
All other 3 and 4 substituted aryl furoic acids were found to only weakly inhibit enzymatic
activity (see Table 17).
Species bearing the 1,2,4-triazole scaffold have been shown to inhibit MetAPs from both
bacterial89a, 89c, d, 89g, 118b, 119 and human120 sources. These species have been shown to most
effectively inhibit MetAPs utilizing Co(II) or Ni(II) cofactors, with weaker inhibition observed
for Mn(II) cofactors. Interestingly, MetAP species bearing Fe(II) cofactors exhibit essentially no
reduction in enzymatic turnover in the presence of triazole inhibitors (see 1,2,4-Triazole Based
Inhibitors, page 93). Crystal structures detailing the binding of these compounds to bacterial
MetAP targets exist (PDB: 3IU8,89g 3IU989g). The compounds bind via coordination of the 1N
and 2N atoms of the triazole ring to the divalent metal cofactors embedded within the active site

137
of MetAPs. Additional binding contacts generally include π-π stacking with aromatic
(phenylalanine, histadine, and tyrosine) residues occupying adjacent space to the substrate
binding pocket. A similar binding mechanism is observed for HsMetAP2, with coordination to
the metal cofactors by the triazole ring and additional π-π stacking to aromatic residues (PDB:
2OAZ90).120 Additionally, compounds with substituents at the 3-amino position of the 1,2,4triazole scaffold have been demonstrated to potently inhibit HsMetAP2b;90 we therefore sought
to explore the effects of derivatization at both the 3-amino and 5-thio positions of the 3-amino1,2,4-triazole-5-thiol starting material.

Table 17: Activity of Furoic Acid Species Against RpMetAP1a

Cmpd
(97)
(98)
(48)
(50)
(99)
(100)
(101)
(102)
(103)
(104)
(105)
a.
b.

X
S
O
O
O
O
O
O
O
O
O
O

R1
H
H
Cl
CF3
Me
Cl
H
H
H
H
H

R2
H
H
H
H
H
H
Me
CF3
NO2
H
H

R3
H
H
H
H
H
H
H
H
H
Me
Br

R4
H
H
H
H
H
Cl
H
H
H
H
H

IC50a,b
74 ± 7
37 ± 3
0.61 ± 0.04
0.50 ± 0.01
0.91 ± 0.03
0.64 ± 0.02
26 ± 1
46 ± 2
77 ± 4
57 ± 2
60 ± 5

IC50 values are expressed in units of µM; Mn(II) cofactors
Enzymatic inhibitory assay performed by Congling Chen and
Phumvadee Wangtrakuldee of the Horn and Hagen labs at NIU
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Concerning the chemical synthesis of our desired compounds, substitution at the 5position is easily accomplished by abstraction of the acidic thiol proton and introduction of
various electrophilic species; this reaction can be performed under aqueous conditions if the
electrophile is unable to undergo E2 eliminations, as in the case of benzyl bromides.89c As such,
compounds (32), (34 – 37), (39) and (106 – 107) were synthesized utilizing 1:2 water to ethanol
as the solvent mixture with hydroxide as the base; products were obtained in acceptable yield in
most cases (47 – 92%), especially considering the compounds were purified by recrystallization
(see Scheme 5).

Scheme 5: Synthesis of benzyl-thioether derivatives of 1,2,4-triazole class of MetAP inhibitors

Because all published inhibitors of bacterial MetAPs utilize benzyl-thioether substituents
at the 5-position of the 1,2,4-triazole core, we were interested in varying the chain length
between the sulfur and aryl rings. However, alkyl halides will undergo E2 eliminations under the
conditions utilized for benzyl bromides and an alternative synthetic route was necessary. The
reaction was therefore carried out with DMF as the reaction solvent and TEA as a weak base to
afford the desired product in good yield (93%) (see Scheme 6).
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Scheme 6: Synthesis of phenylpropyl-thioether derivative (108)

A published report regarding the inhibition of HsMetAP2b by 1,2,4-triazole species
suggests compounds containing substituents of the amine at the 3-position are potent;90 we
therefore wished to explore derivatization of the amino substituent. Following addition of benzyl
or phenylpropyl groups to the 5-thio position, the compounds were subject to typical amide
synthesis conditions utilizing carbodiimide mediated cross-coupling and various alkyl and aryl
carboxylic acids. Initial attempts utilized a DMF solvent system with catalytic DMAP and TEA
as the base, and EDC as the coupling reagent. However, product was isolated in poor yield
(12%). Additionally, proton NMR of the product suggested primary amine protons remained
intact during the course of the reaction and the addition occurred instead at one of the triazole N
atoms. Following HSQC, HMBC and COSY 2-dimensional NMR analysis, the reaction was
determined to have occurred at the 2-N of the triazole core. This is corroborated by published
reports;121 based upon the published inhibitory mechanism of action, it was hypothesized that
compounds with 2-N substitution patterns could coordinate to one or both active site metals
through the 3-amino N and triazole 4-N atoms, resulting in the retention of inhibitory activity.
We therefore decided to synthesize and screen a small number of these compounds. To improve
the chemical synthesis, the reaction solvent was changed to DCM, the catalyst to HOBT and the
temperature was increased. Yields were found to significantly increase utilizing this synthetic
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procedure (65 – 99%), and compounds (109 – 119) were therefore synthesized accordingly (see
Scheme 7).

Scheme 7: Synthesis of 4-methybenzyl-thioether derivatives (109 – 119)

We were also interested in exploring the effect of other substituents at either the 2-N of
the triazole core or the 3-amino N atom. Sulfonamide groups are widely distributed within the
chemical space encompassing currently available drugs, especially concerning early sulfa
antibiotics.74 We therefore elected to also synthesize 4-chlorophenyl sulfonamide (120) by
dissolving the 1,2,4-triazole starting material (35) in DCM, followed by the addition of base
(TEA) and the corresponding sulfonyl chloride. Following purification, the desired compound
was obtained in nearly quantitative yield (99%). Finally, we attempted to synthesize compounds
bearing substitution at the 3-amino N atom by first protecting the heterocyclic nitrogen
nucleophile as a BOC carbamide. However, subjecting the resulting species to amide coupling
conditions resulted in the recovery of the starting materials. No further attempts to react at the 3amino N were performed (see Scheme 8).
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Scheme 8: Synthesis of 2-N-(4-chlorophenyl) sulfonamide derivative (120)

The most potent compounds utilizing the 1,2,4-triazole scaffold are of the structure
shown in Table 18. The inclusion of electron-withdrawing groups (Cl or F) at the R1 and R2
position has been shown to have a positive effect on binding.89d, 118b However, the most potent
compound containing benzyl thioethers employed in our study was found to be unsubstituted
derivative (39) with an IC50 value of 6.6 µM, although 2,4-dichloro derivative (32) exhibited
comparable activity (IC50 = 7.7 µM). Interestingly, no group to date has explored the effect of
chain length between the triazole ring and the aryl thioether on inhibitory activity. We therefore
synthesized and screened phenylpropyl derivative (108) and found a three-fold increase in
activity (IC50 = 2.1 µM) when compared to benzyl derivative (39). This was the strongest
inhibitory activity found for species utilizing the 1,2,4-triazole scaffold. However, the exact
source of this increase in activity has not been discerned, although we suspect the increase in
chain length between the phenyl and triazole groups allows for stronger hydrophobic interactions
with aromatic active site residues (see Table 18).
Compounds bearing substitution of the triazole core ring (109 – 116) were also
synthesized and screened for inhibitory activity against RpMetAP1a. We expected the
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compounds would exhibit weak activities against the target, as the binding mechanism predicted
by crystallographic methods (PDB: 3IU8)89g was disrupted. None of the compounds screened
exhibited activities superior than the cutoff of >50% inhibition at 10 µM, regardless of the
specific ester identity. Interestingly, sulfonamide derivative (117) was found to exhibit the
weakest inhibitory activity, although conclusions regarding the relative activities of amide versus
sulfonamide substitution cannot be made with such a small compound test set (see Table 18).

Table 18: Activity of Triazole Species Against RpMetAP1a

Cmpd
(39)
(34)
(35)
(36)
(37)
(106)
(107)
(32)
(108)

n
1
1
1
1
1
1
1
1
3

R1
H
H
H
H
H
H
Cl
Cl
H

R2
H
F
Me
iPr
tBu
Cl
H
Cl
H

(109)

1

H

(110)

1

H

a.
b.
c.
d.

R3
H
H
H
H
H
H
H
H
H

92
93

-d
90

IC50b,c
6.6 ± 1.0
24 ± 19
23 ± 2.7
14 ± 0.5
14 ± 1.2
30 ± 1.5
15 ± 1.5
7.7 ± 0.9
2.1 ± 0.1

Me

82

38

-

Me

81

38

-

% Yield

% Inhiba,b
-d

47
67
85
55

-d
-d
-d
-d
-d
-d

Percent inhibition of enzyme activity at 10 µM versus uninhibited control, Mn(II) cofactors
Enzymatic inhibitory assay performed by Congling Chen and Phumvadee Wangtrakuldee
of the Horn and Hagen labs at NIU; see ref 11
IC50 values are expressed in units of µM; Mn(II) cofactors
Compound synthesized by Phumvadee Wangtrakuldee of the Horn and Hagen labs at NIU

(Continued on next page)
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Table 18: Continued

Cmpd

n

R1

R2

(111)

1

H

(112)

1

(113)

% Yield

% Inhiba,b

IC50b,c

Me

79

40

-

H

Me

80

41

-

1

H

Me

55

41

-

(114)

1

H

Me

65

41

-

(115)

1

H

Me

97

43

-

(116)

1

H

Me

99

44

-

(117)

1

H

Me

97

31

-

a.
b.
c.
d.

R3

Percent inhibition of enzyme activity at 10 µM versus uninhibited control; Mn(II) cofactors
Enzymatic inhibitory assay performed by Congling Chen and Phumvadee Wangtrakuldee
of the Horn and Hagen labs at NIU
IC50 values are expressed in units of µM; Mn(II) cofactors
Compound synthesized by Phumvadee Wangtrakuldee of the Horn and Hagen labs at NIU

Compounds composed of the 8-quinolinol scaffold have been screened against MetAPs
from B. pseudomallei,89c M. tuberculosis,99 E. coli,92b, 97, 122 Staphylococcus aureus,92b and
against those of human origin.92b The chelating ability of 8-quinolinol derivatives affords an
interesting mechanism of binding for metalloenzymes; a sole crystal structure of an 8-quinolinol
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derivative bound to a bacterial (E. coli) MetAP exists (PDB: 2BB7)97 (see Quinoline Inhibitors,
page 107). The crystal structure exhibits binding to a tertiary Mn(II) cofactor found within the
active site, with the presence of this additional cofactor likely being the result of inhibitor-metal
complex formation in solution prior to enzyme binding.97 Because assay conditions require a
high (> 1 µM) concentration of free metal in solution, it is probable that this complex formation
precedes inhibition. However, given the structure-activity relationship previously discovered for
the inhibition of B. pseudomallei,89c we felt it was appropriate to screen a class of aminoalkylated
quinolinol analogues against R. prowazekii MetAP.
Compounds were synthesized based upon published reports123 describing the
aminoalkylation of 8-quinolinols via the nucleophilic attack of imines generated in situ (Mannich
reaction). Quinoline starting materials were mixed with formaldehyde and various amines in
EtOH and heated to reflux for 24 hrs. Products were found to precipitate upon cooling and were
purified by recrystallization from EtOH and water (1:1). Isolated reaction yields were acceptable
(>70%) in all but two cases ((59) and (62)) (see Scheme 9).

Scheme 9: Synthesis of aminoalkylated 8-quinolinol derivatives
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An independent screening against Plasmodium falciparum (PfMetAP2) conducted by our
group revealed similar benzylbenzamide quinolinols exhibit potent activity against the protozoan
enzyme. Additionally, compounds of this general structure were screened against
Cryptosporidium parvum in a cellular growth inhibitory assay and were found to be potent
bactericidal agents,124 although a macromolecular target was not identified. We therefore
hypothesized compounds of this general structure could be potent inhibitors accessible by the
same route optimized for the aminoalkylated quinolinols, where benzamide and benzaldehyde
are utilized for imine generation. However, combining these species with nitroxoline (58) and
refluxing in EtOH did not afford the desired compound and starting materials were recovered. A
literature report detailed the successful reaction of 2-naphthol with benzamide and benzaldehyde
in EtOH when heating is applied by microwave irradiation;125 however, the reaction proved to be
minimally successful (30% conversion by 1H NMR) when translating to 8-quinolinol
nucleophiles.
An additional report126 suggested the neat reaction of 2-naphthols with benzamide and
benzaldehyde progressed under microwave irradiation with the addition of an acid catalyst
(trichloroacetic acid). These reaction conditions were found to translate to 8-quinolinols when
TFA is substituted as the acid catalyst. Various 8-quinolinol species were therefore subjected to
these reaction conditions with a variety of substituted benzamide and benzaldehyde derivatives.
Interestingly, the reaction was found to progress only when a withdrawing group is present at the
5-position of the 8-quinolinol nucleophile; this suggests the increased acidity of the 8-phenol
increases the nucleophilicity of the quinoline ring. However, addition of a sulfonic acid at the 5position results in the loss of substrate conversion, presumably due either to the acidity of the
sulfonic acid group or the predicted elevation in melting point when compared to nitroxoline (58)
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and 5-chloro-8-quinolinol (118). Reaction yields were found to be highly variable (5 - 99%)
when utilizing these two nucleophiles (see Scheme 10).

Scheme 10: Synthesis of benzylbenzamide 8-quinolinol derivatives

A recent study published by the Hagen group regarding the inhibition of BpMetAP189c
found 8-quinolinol derivatives utilizing NO2 groups para to the hydroxyl group exhibited the
most potent activity. Species bearing Cl groups at the same position were essentially inactive. In
this study, the opposite appears to be true, with all Cl derivatives being more potent inhibitors
than the corresponding NO2 derivatives. However, the metals employed as cofactors for this
study were Mn(II), while Co(II) was used previously in the study of B. pseudomallei MetAP
inhibitors; this may explain the observed difference in activity regarding Cl or NO2 substitution,
as observed activities have been documented to be highly dependent upon the identity of the
metallic cofactors.97
Unsubstituted quinolinol derivatives exhibited superior activity than any aminoalkylated
species. For example, the most active species was found to be 5-chloro-8-quinolinol (118), with
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an IC50 value of 0.9 µM. All other derivatives (8-quinolinol (56), nitroxoline (58), and 2-methyl8-quinolinol (119)), exhibited comparable activity to that of (121) except for 5-sulfonic acid
derivative (57), with an IC50 value of 66 µM. The large reduction in inhibitory activity is likely
the result of the increased acidity of the phenol due to the strong withdrawing ability of the
sulfonate. Concerning aminoalkylated derivatives, all were inferior inhibitors than the
corresponding quinolinol fragments, although 5-chloro-8-quinolinol derivatives ((59), (120–
122)) were significantly more active than nitroxoline derivatives ((60 – 62) and (126 – 128)) (see
Table 19).
A variety of benzylbenzamide 8-quinolinol species were synthesized and screened
against RpMetAP1a to determine inhibitory activity. Only one compound was found to exhibit
greater than 50% inhibition of enzymatic activity at a stock concentration of 10 µM ((146), 57%
inhibition). In general, nitroxoline derivatives (X = NO2) were more potent than corresponding
5-chloro-8-quinolinol (X = Cl) derivatives, although neither series was found to potently inhibit
RpMetAP1a activity. Although the substitution pattern of the benzyl and benzamide aryl rings
was explored for substituents at the meta and para positions, inhibitory activities appear to be
largely independent of the substitution pattern. Regardless, the compounds were essentially
inactive against RpMetAP1a and were therefore excluded from future consideration as bacterial
MetAP1 inhibitors (see Table 20).
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Table 19: Activity of Aminoalkylated Quinolinol Species Against RpMetAP1a

Cmpd
(56)
(57)
(58)
(118)
(119)

R1
H
H
H
H
CH3

R2
H
SO3H
NO2
Cl
H

(59)

H

(120)

% Yielda
-

IC50a,b
1.0 ± 0.3
66 ± 12
1.3 ± 0.7
0.9 ± 0.1
1.4 ± 0.1

Cl

68

2.5 ± 0.1

H

Cl

95

4.7 ± 0.1

(121)

H

Cl

74

7.1 ± 0.9

(122)

H

Cl

80

3.9 ± 0.7

(60)

H

NO2

91

16 ± 4.0

(61)

H

NO2

89

22 ± 3.1

(62)

H

NO2

43

73 ± 38

(123)

H

NO2

73

10 ± 0.7

(124)

H

NO2

91

116 ± 17

(125)

H

NO2

74

8.4 ± 2.2

a.
b.

R3
H
H
H
H
H

Compound synthesis and enzymatic inhibitory assay performed by Phumvadee Wangtrakuldee of
the Horn and Hagen labs at NIU; see reference 11
IC50 values are expressed in units of µM; Mn(II) cofactors
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Table 20: Activity of Benzylbenzamide Quinolinol Species Against RpMetAP1a

Cmpd
(126)
(127)
(128)
(129)
(130)
(131)
(132)
(133)
(134)
(135)
(136)
(137)
(138)
(139)
(140)
(141)
(142)
(143)
(144)
(145)
(146)
(147)
(148)
(149)
(150)
(151)
(152)
(153)
(154)
a.
b.

X
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
NO2
NO2
NO2
NO2
NO2
NO2
NO2
NO2
NO2
NO2
NO2

R1
H
H
H
H
H
H
H
H
H
H
Me
Me
Me
Me
Me
OMe
OMe
OMe
H
H
H
H
H
H
H
H
Me
Me
OMe

R2
H
Me
OMe
OMe
OMe
Me
Me
H
H
H
H
H
H
H
H
H
H
H
H
Me
Me
Me
Me
OMe
H
H
H
H
H

R3
H
H
H
Me
Cl
Me
Cl
Me
H
H
H
Me
Cl
H
H
Me
Cl
H
H
H
Cl
Me
H
Cl
Me
H
H
Cl
Cl

R4
H
H
H
H
H
H
H
H
Me
Cl
H
H
H
Cl
Me
H
H
Me
H
H
H
H
Me
H
H
Me
H
H
H

% Yield
>99
51
6
5
16
29
74
60
63
58
76
79
81
73
75
71
74
10
81
51
34
20
15
16
66
19
67
57
24

% Inhiba,b
39
37
36
20
30
19
34
34
18
29
40
37
26
26
19
24
34
19
42
37
57
28
27
33
44
41
39
33
32

Percent inhibition of enzyme activity at 10 µM versus uninhibited control;
Mn(II) cofactors
Enzymatic inhibitory assay performed by Congling Chen of the Horn and
Hagen labs at NIU
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Various anthranilic acid sulfonamides have been implicated as potent inhibitors of
HsMetAP2b.127 Crystalline structures of these compounds with HsMetAP2b (PDB: 2GA2,127a
1YW7,127b 1YW8,127b 2EA2,127c and 2EA4127c) reveal the binding mechanism; specifically, 4chlorobenzene sulfonamide derivative (155) was crystallized and found to coordinate to an active
site metal through one of the O atoms, while simultaneously H-bonding with His-231 via the
other (PDB: 2GA2).127a Because this His residue is conserved across most MetAP species, it was
hypothesized that a similar binding mechanism is possible when targeting MetAPs isolated from
bacterial sources. Additionally, reports involving anthranilic acid based inhibitors of MetAPs
have determined that increasing the lipophilicity of the aryl ring results in increased inhibitory
activity; introducing halogens at 5 position of the aryl core has been found to accomplish this by
bromination at this position. Based upon these published reports, a series of anthranilic
sulfonamides was therefore synthesized and screened for inhibitory activity against RpMetAP1a
(see Figure 25).
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Figure 25: Binding mode of anthranilic acid sulfonamides with HsMetAP2b. Anthranilic acid
sulfonamides have been found to bind via coordination to one metal cofactor and H-bonding
with His-231through the two carbonyl oxygen atoms. Specifically, 4-chlorobenzene sulfonamide
derivative (155) was found to bind according to this mechanism, with additional hydrophobic
interactions from Ile-338 and His-339 contributing to binding efficiency (PDB: 2GA2).127a

According to a published procedure for the related methyl 3-methylanthranilate starting
material,128 methyl anthranilate was first halogenated with elemental bromine in acetic acid to
afford (156). The common side reaction involves the addition of an additional bromine to the 3position of the anthranilic acid core, resulting in compound (157). The separation of these two
species was found to be difficult and was accomplished by column chromatography. Although

152
the compounds were found to have similar retention and therefore overlapped collection, only
fractions displaying a single spot by TLC were collected, resulting in the low isolated yield
(28%) of the desired compound (see Scheme 11).

Scheme 11: Synthesis of methyl 5-bromoanthranilate

Once methyl 5-bromoanthranilate was obtained in acceptable quantity for use as a
starting material, various sulfonamides were synthesized according to a reported method.129
Utilizing DCM as the solvent, the starting material was mixed pyridine followed by the addition
of various sulfonyl chlorides. Products were isolated following workup and column
chromatography in acceptable yield (40 – 85%). Interestingly, this reaction occurred when
utilizing mesyl chloride as the sulfonamide to afford (158), although starting materials were
recovered when employing the corresponding iso-propyl and n-butyl sulfuryl chlorides; the
difference in reactivity for alkyl sulfuryl chlorides was not explored further. Finally, free acids
were obtained under base-catalyzed ester hydrolysis conditions in excellent yield (86 – 97%)
(see Scheme 12).
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Scheme 12: Synthesis of 5-bromoanthranilic acid sulfonamides

In total, 9 compounds were synthesized and screened for inhibitory activity against
RpMetAP1a. It was found that all of the compounds exhibited weak inhibition of enzymatic
turnover. Although our compound test set included a fairly diverse variety of sulfonamides
including alkyl (158), benzyl (159) and aryl ((155), (160 – 166)) substituents, the specific
identity of the sulfonamide had no effect on activity. This suggests the binding mechanism of
these compounds with RpMetAP1a does not involve interactions with sulfonamide side chains
(see Table 21).
Aryl halides (specifically, bromides and iodides) are important reagents for a variety of
cross-coupling reactions; as such, biaryl carboxylic acids are easily prepared from methyl 5bromoanthranilate (156) when employed as a starting material. It was therefore hypothesized that
furoic acid bioisosteres could be obtained via the Suzuki coupling of (156) with various aryl
boronic acids. Utilizing published methods detailing similar transformations,130 the palladium
catalyzed cross-coupling was accomplished utilizing a toluene/H2O solvent system, aqueous
carbonate as the base, and 10 mol percent of the transition metal catalyst. Products were isolated
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and purified to afford desired products in decent yield (59 – 61%), which were converted to free
acids under basic ester hydrolysis conditions (see Scheme 13).

Table 21: Activity of 5-Bromoanthranilic Acid Sulfonamides Against RpMetAP1a

% Yielda
70, 94

% Inhibb,c
44

(159)

40, 86

42

(160)

56, 94

38

(161)

54, 97

39

(155)

83, 96

36

(162)

82, 93

32

(163)

48, 92

39

(164)

85, 88

36

(165)

83, 93

39

Cmpd
(158)

a.
b.
c.

R

Yields are listed as sulfonamide formation and ester hydrolysis, respectively; see Scheme 12
Percent inhibition of enzyme activity at 10 µM vs. uninhibited control; Mn(II) cofactor
Enzymatic inhibitory assay performed by Congling Chen of the Horn and Hagen labs at NIU
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Scheme 13: Synthesis of 5-arylanthranilic acids

The compounds were then screened for enzymatic inhibition and were unfortunately
found exhibit poor activities. Three species were synthesized, including 4-chloro (166), 4-nitro
(167), and 3-nitro (168) aryl anthranilic acids, and were all found to exhibit roughly 40%
inhibition of enzymatic turnover at 10 µM stock concentrations (see Table 22). This suggests
either the inclusion of the 2-analine or conversion of the central furan ring to the larger benzene
isostere is detrimental to enzyme binding.
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Table 22: Activity of 5-Arylanthranilic Acids Against RpMetAP1a

% Yielda

% Inhibb,c

(166)

59

37

(167)

61

41

(168)

61

38

Cmpd

a.
b.
c.

R

Yields are listed according to sulfonamide formation; ester hydrolysis proceeded in
quantitative yield in each case; see Scheme 13
Percent inhibition of enzyme activity at 10 µM versus uninhibited control; Mn(II)
cofactors
Enzymatic inhibitory assay performed by Congling Chen of the Horn and Hagen labs
at NIU

Computational Modeling of RpMetAP1a

To aid in the design of potential bacterial MetAP inhibitors, computational docking can
be employed, where co-crystal structures of target proteins containing bound inhibitors can be
prepared in silico. Different inhibitory compounds can be introduced into the protein binding site
and manipulated to discern the minimum energy conformation. Docking software rank sampled
ligand poses based upon predicted binding energies, which can help identify compounds with
potentially potent inhibitory activities against the target. A wide variety of software packages are
available, both for as opensource and licensed access. For our study, AutoDock131 was chosen as
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the software because it is freely available to any interested user and has been validated for a large
number of targets, including metalloenzymes.132
To validate the scoring function of AutoDock against a particular target of interest,
research efforts generally begin by removing the ligand from a crystal structure containing a
bound inhibitor and docking the ligand back into the target to compare actual and predicted
binding modes. Here, we used furoic acid (48) and a crystal structure of EcMetAP1a, which was
previously determined using X-ray crystallography (PDB: 1XNZ).96f Prior to docking, the
protein crystal structure must be cleaned up and prepared for docking. This includes removal of
water, buffer, inhibitor, or other molecules that have been crystallized with the protein and
observed/modeled into the electron density. Additionally, AutoDock only tolerates specific
atoms that are commonly found within biological macromolecules and organic compounds; the
program does not automatically recognize atoms with less conventional labels (such as
manganese) and will not assign charges to these atoms. Consequently, the charges on the metal
cofactors of the EcMetAP1a structure must be manually set. Additionally, the specific charge of
the Mn(II) cofactors plays a major role in predicted binding interactions. It is therefore useful to
screen a number of metal charges and compare the docking output scores and poses to actual
inhibitory activities and solved crystal structures.
To discern the optimal charge to be assigned to the metal cofactors, a variety of charges
were incrementally assigned and (48) was docked into the substrate binding site. Charges were
applied as 0.3, 0.5, 1.0, and 1.5 elementary charge units for each manganese atom and the output
docking poses and predicted binding affinities were evaluated for each run. The optimal charge
was found to be 0.5; this gave the ligand a larger degree of flexibility between each docking
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pose, where the ligand was predicted to bind through the acid to the metal cofactors in numerous
conformations, while still scoring the actual docking pose favorably. Additionally, the predicted
binding affinities (Ki) were of the same order of magnitude as the actual inhibitory activities
(IC50). From the in vitro screening of RpMetAP1a, 2-chloro furoic acid derivative (48) was found
to potently inhibit enzymatic activity (IC50 = 0.61 µM); as shown in Table 23, the predicted Ki at
0.5 elementary charge units was within an order of magnitude of the experimental IC50. As
shown in Equation 3, Ki is a function of IC50 and the other factors being constant for a given set
of conditions, Ki and IC50 are proportionally related, where the substrate concentration and
Michaelis constant are denoted as [S] and Km, respectively. The equation also demonstrates how
Ki values will only be lower than those expressed as IC50, as Ki is the quotient of IC50 and a
value always greater than or equal to 1 (see Equation 3; see Table 23).

eqn 3

Table 23: Predicted Binding Affinity of (48) with RpMetAP1a at Various Cofactor Charges
Assigned Charge
0.3
0.5b
1.0
1.5
a.
b.

Predicted Kia
1.6 x 10-6
1.1 x 10-7
7.9 x 10-11
1.7 x 10-14

Predicted affinities are expressed in units of M
Charge used for docking studies
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Once the ideal metal charge was determined, the docking poses were evaluated and
compared to the binding mechanism predicted by the crystallographic structure of (48) bound to
EcMetAP1a. The most important interactions between the ligand and receptor involve
coordination to both the metal cofactors via the carboxylate, π- π interactions with Tyr-62 and
hydrophobic interactions with His-63, Tyr-65, His-79, Phe-177, His-178 and Trp-221 (Table 24).
Additionally, the furoic acid inhibitor exhibits a dihedral angle of 40.6o between the furan and
aryl ring. As previously stated, this rotated bi-aryl ring system is necessary for potent inhibition,
with the result being maximized coordination to Tyr-62. Thus, the incorporation of large
substituents at the ortho position affords hindered rotation about the bi-aryl axis, resulting in an
increase in the dihedral angle which serves as the basis for the observed increase in activity for
this substitution pattern (see Table 24).

Table 24: Comparison of Binding Interactions for (48) in Crystal and Docked Structures
Distancea,b
EcMetAP1a Actual RpMetAP1a Docked
Mn(II) Chelation
2.2, 2.3
1.7, 2.1
Mn(II) Coordination
2.0
1.8
π – π Stacking (Tyr62)
4.0
3.1
Hydrophobic (His63)
3.5
6.9c
Hydrophobic (Tyr65)
3.6
3.5
Hydrophobic (His79)
3.6
3.9
Hydrophobic (Phe177)
4.0
3.3
Hydrophobic (His178)
3.3
3.6
Hydrophobic (Trp221)
3.4
3.1
Angle
Mn(II) – OL – Mn(II) Angle
107o
155o
o
(48) Dihedral
41
18o
a.
b.

c.

Distances correspond to closest observed interaction and are reported in Å
Residue numbering corresponds to EcMetAP1a (PDB: 1XNZ)96f
This is a non-conserved residue and exists as Lys in RpMetAP1a
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Examination of the highest scored docking pose against RpMetAP1a suggests a
mechanism of inhibition similar to that observed in the actual crystal structure of the (48) and
EcMetAP1a complex (see Figure 26). As demonstrated in Table 24, protein-ligand bond
distances for the various observed interactions ranged from 0.1 – 0.9 Å. However, the most
obvious difference between the docked and actual structures is the dihedral angle between the
ring systems of the furoic acid inhibitor. The dihedral angle for the docked structure was
observed to be significantly reduced, at 18o, compared to that of the actual pose. Examination of
the Mn-O-Mn bond angle and Mn-O bond distances demonstrates the closer spatial orientation
of the inhibitor in the docked pose as compared to that of the actual crystal structure. The large
Mn-O-Mn bond angle (155o) and shortening of the chelation distance between the Mn and
carboxylate for the docked pose reveals stronger predicted interactions than actually observed.
This results in the inhibitor being docked closer to the metal ion cofactors, which minimizes the
π- π interactions between the inhibitor and Tyr62. Although the inhibitor is spatially closer to
Tyr62 in the docked structure (3.1 Å), the two ring systems are not perpendicular to one another;
this would not allow for key the π- π interactions that presumably contribute to the SAR
observed for this class of inhibitors. The chloride substituent was also found to point into the
middle of the substrate binding pocket, rather than coordinate to residues lining the active site as
seen in the actual crystal structure (see Table 25, see Figure 26).
The entire furoic acid test set, consisting of 11 compounds, was screened in silico against
RpMetAP1a to determine the relationship between predicted and actual affinities. Unfortunately,
the predicted affinities were found to correlate poorly with the experimentally determined
inhibitory activities. Although the SAR of this series of inhibitors has been well established, the
docking program could not predict that compounds bearing substituents at the 2-position of the
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aryl ring are more potent by orders of magnitude. However, the specific poses of the inhibitors
were correctly predicted, as each adopted essentially the same conformation as shown in Figure
26.

Figure 26: Comparison of docked and observed binding interactions of (48) bacterial MetAPs.
Top Left: Crystal structure of (48) with EcMetAP1a (PDB: 1XNZ).96f Top Right: Docked pose
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Figure 26 continued: of (48) with EcMetAP (PDB: 1XNZ).96f Bottom: Docked pose of (48) with
RpMetAP1a (PDB: 3MX6).

Table 25: Predicted Versus Actual Activity Against RpMetAP1a

Cmpd
(97)
(98)
(48)
(50)
(99)
(100)
(101)
(102)
(103)
(104)
(105)
a.
b.

X
S
O
O
O
O
O
O
O
O
O
O

R1
H
H
Cl
CF3
Me
Cl
H
H
H
H
H

R2
H
H
H
H
H
H
Me
CF3
NO2
H
H

R3
H
H
H
H
H
H
H
H
H
Me
Br

R4
H
H
H
H
H
Cl
H
H
H
H
H

IC50a
74
37
0.61
0.50
0.91
0.64
26
46
77
57
60

Pred Kib
0.07
0.09
0.11
0.29
0.04
0.15
0.28
0.40
0.02
0.33
0.20

Enzymatic inhibitory assay performed by Congling Chen and
Phumvadee Wangtrakuldee of the Horn and Hagen labs at NIU
Inhibitory activities and predicted binding affinities are
expressed in units of µM

In addition to docking the furoic acid compound test set against RpMetAP1a, the
representatives from the 1,2,4-triazole series of inhibitors were screened in silico using
AutoDock. However, none of the compounds were predicted to bind according to the mechanism
revealed by crystalline structures where the triazole 1-N and 2-N atoms coordinate to both of the
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cofactors (PDB: 3IU9).89g Additionally, crystal structures of quinolinol derivatives against
EcMetAP1a suggest the compounds bind to a tertiary metal at the entrance to the active site
(PDB: 2BB7).97 This class of compounds was therefore not docked against RpMetAP1a. Because
the docking output did not correlate with the experimentally determined SAR for the furoic acid
series of inhibitors, this docking method should not be used without additional modification in
the design of new inhibitors. However, the general predicted binding mechanism of the class as a
whole was acceptable. It is therefore suggested that this method of docking should only be used
to screen compounds with large structural differences, rather than simply differing substitution
patterns of a single aromatic ring.

Comparison of Inhibitory Activities for RpMetAP1a and HsMetAPs

Of the species screened for RpMetAP1a inhibitory activity, compounds bearing the
quinolinol scaffold have been screened against HsMetAP1b and HsMetAP2b.98 As previously
stated, inhibitory activity greatly depends upon the identity of the metal cofactors bound to
MetAP species. Because HsMetAP1b was determined to be most activated by Co(II) cofactors,
this metal was employed in the screening of quinolinol compounds.98 Additionally, Mn(II) has
been suggested as the native cofactor for HsMetAP2b and this metal was employed in the
corresponding assay.98, 133 Interestingly, the compounds exhibit selective inhibition of
RpMetAP1a over HsMetAP1b, with the compounds generally being inactive against the latter
enzyme. This result is curious, as quinolinol species have been demonstrated to inhibit MetAP
species utilizing Co(II) cofactors over species utilizing Mn(II) cofactors.134 The compounds were
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not as selective against HsMetAP2b, with the observed activities being comparable to
RpMetAP1a. However, HsMetAP2b inhibition has been suggested as a treatment for tumor
growth regulation (antiangiogenic properties)135 and a lack of specificity regarding these two
targets may not be of striking clinical significance (see Table 26).

Table 26: Comparison of Activity (IC50) Against RpMetAP1a and HsMetAPs
Cmpd
(56)
(57)
(58)
(118)
(119)
(120)
(121)
a.
b.
c.
d.

RpMetAP1aa
1.0 ± 0.3
66 ± 12
1.3 ± 0.7
0.9 ± 0.1
1.4 ± 0.1
4.7 ± 0.1
7.1 ± 0.9

HsMetAP1ba,b,c
>15
>15
>15
12.9 ± 1.0
>15
>50
>50

HsMetAP2b a,b,d
2.03 ± 0.3
>15
0.055 ± 0.02
1.27 ± 0.6
>15
7.68 ± 1.2
3.81 ± 0.74

IC50 values expressed in units of µM
In cases where analysis is limited by compound solubility, the minimum
estimate of IC50 is provided, Values from Bhat et al.98
Co(II) cofactors employed in assay
Mn(II) cofactors employed in assay

Host-Cell Viability Assay

To determine the antirickettsial activity of the inhibitors possessing inhibitory activity
against RpMetAP1a, the compounds were sent to our collaborator Prof. Jonathon Audia
(University of Southern Alabama) for screening in a host-cell viability assay. Because
Rickettsiae are obligate intercellular pathogens, assays screening for antirickettsial activity must
utilize host cells to maintain bacterial homeostasis. As such, primary pulmonary vascular
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endothelial cells (ECs) from rat sources were utilized as host-cells. The assay measured cellular
proliferation via a WST-1 (water-soluble tetrazolium salt) absorbance assay, where the tetrazole
ring is reduced by cellular processes to afford formazans; because cleavage occurs only for
proliferating cells, formazan formation can be monitored by spectroscopic methods as a function
of cellular viability and toxicity.136
Uninfected EC host cells are first grown and monitored under the assay conditions to
establish a proliferation baseline. Infected cell lines are then monitored and the reduction in
proliferation versus the control is determined. Inhibitory compounds can then be mixed with
infected EC host cells and monitored to establish viability. If cells are found to grow at a
comparable rate to uninfected controls, the compounds are suggested to exhibit antirickettsial
activity, allowing the ECs to prosper when they would otherwise succumb to infection.
In total, 24 compounds based upon furoic acid, 1,2,4-triazole, quinolinol, and
anthranilic acid sulfonamide scaffolds were screened in the host-cell viability assay. Of these,
only 10 compounds were found to inhibit cellular death and allow for proliferation in the
presence of R. prowazekii. The compounds were first screened at the concentrations indicated in
Table 27, followed by a series of dilutions of an order of magnitude at a time. The compounds
were found to lose activity after dilution, indicating that the optimum inhibitory concentration for
each compound was the highest screened (see Table 27).
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Table 27: RpMetAP Inhibitory Compounds Tested in EC Culture Infection Modela,b

Cmpd

Stockc

Test Ranged

RpMetAP
IC50e

Growth
Inhib

(34)

100

300, 30, 3, 0.3

24

Yes

(35)

100

300, 30, 3, 0.3

23

Yes

(39)

100

300, 30, 3, 0.3

6.6

Yes

(56)

100

30, 3, 0.3, 0.03

1.0

Yes

(60)

100

3, 0.3, 0.03, 0.003

16

Yes

(106)

100

300, 30, 3, 0.3

30

Yes

(107)
(118)

100
100

300, 30, 3, 0.3
30, 3, 0.3, 0.03

15
0.9

Yes
Yes

(122)

13

39, 3.9, 0.39, 0.039

3.9

Yes

(124)

40

1.2, 0.12, 0.01

116

Yes

a.
b.
c.

d.

e.

Host-cell viability assay performed by Jonathon Audia at University of Southern Alabama
Compounds were tested against R. prowazekii-infected ECs by addition to the cell culture
medium at 24-hrs post-infection.
Stock inhibitor solutions were initially prepared in 100% DMSO to achieve a 100 mM
concentration. Additional DMSO was added to any compound that was insoluble and the
final volume adjusted until solubility was achieved. Concentrations expressed in mM.
All compounds were initially tested for toxicity against uninfected ECs based on an
experimentally-determined optimal DMSO final concentration (0.3%) that was not inhibitory
to either ECs or R. prowazekii. Working concentration ranges for testing were adjusted to
produce no EC toxicity. Concentrations expressed in µM.
IC50 values are expressed in units of µM; Mn(II) cofactors

Concerning the compounds found to inhibit Rickettsial induced host cell death, only
species bearing quinolinol ((56), (60), (118), (122) and (124)) and 1,2,4-triazole ((34), (35), (39),
(106), and (107)) scaffolds were suggested to be active. The most potent compound, (124), was
found to restore host EC growth at a concentration of 1.2 µM; interestingly, (124) was able to not
only restore host-cell proliferation, but boosted EC growth by at least 1.2 times that of the
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uninfected control. This suggests the compound is successful at inhibiting Rickettsial infection
while exhibiting no detrimental effects on EC growth. However, the exact mechanism of action
of this compound was not confirmed and we therefore cannot conclude that the inhibition of
RpMetAP is responsible for Rickettsial death.

Library Screening against RpMetAP1a

To discover novel classes of bacterial MetAP inhibitors, a library of suspected inhibitors
can be screened to rapidly determine inhibitory activities of diverse chemical sets. A library of
294 compounds was therefore purchased (OTAVA Ltd., CAN) and screened against
RpMetAP1a. Species included in the screening library were based upon reported hit motifs,
including furoic acid, 1,2,4-triazole, and quinolinol derivatives. Additionally, various species that
have not been reported but are structurally similar and therefore possibly bioisosteric were also
included in the screening library. The compounds were first screened at stock concentrations of
10 µM to establish single-point inhibitory activities; then, compounds exhibiting >50%
inhibition were screened at 10 different concentrations to construct dose-response curves for the
determination of IC50 values. Initially, 35 compounds were identified as hits in the single-point
screening (see Figure 27).
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% Inhibition at 10 µM
% Inhibition

100

50

0

Cmpds with >50% Inhibition
% Inhibition

95

70

45

Figure 27: Representation of single point inhibition for all compounds and compounds with
>50% inhibition. Top: Inhibitory activities for all compounds. Bottom: Compounds exhibiting
>50% inhibition.

Of the 35 original hits, only eleven exhibited inhibitory activities >10µM. These species
represent three major motifs, including furoic, indole, and thiophenic carboxylic acids (169 –
173), a biaryl chelator (174), and 1,2,4-traizoles (175 – 179) (Table 28). The most potent
compound was found to be 5-(methylsulfonamide)-2-furoic acid (169) with an IC50 value of 0.27
µM. Sulfonamides of the furoic acid based inhibitors have not been previously reported in the
literature. Additionally, 5-phenylisoxazole-3-carboxylic acid (170) was determined to exhibit
potent RpMetAP1a inhibitory activity (IC50 = 1.4 µM). This is noteworthy, as the corresponding
furoic acid (99) was found to only weakly inhibit enzymatic turnover (IC50 = 37 µM), and (170)
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is therefore more active by roughly 26-fold. Employing the SAR for the furoic acid series of
inhibitors, it is expected that the incorporation of substituents at the 2-position of the aryl ring
should afford sub-micromolar inhibitors of RpMetAP1a. Finally, structures related to indole and
thiophenic carboxylic acids (171 – 173) have not been previously reported as MetAP1a
inhibitors (see Table 28).
Biaryl chelating inhibitors have been extensively reported as inhibitors of bacterial
MetAPs (see Biaryl Chelating Inhibitors, page 99). The potent inhibitory activity of (174) was
therefore not surprising (IC50 = 1.1 µM). Crystal structures of compounds of this class bound to
MetAPs have determined a binding mechanism in which the chelators bind to a tertiary metal
cofactor. Additionally, the crystallization conditions utilize metal salts dissolved in the
crystallization medium; it is therefore unknown if the compounds coordinate to this cofactor
prior to protein incorporation. However, these compounds exhibit notable SAR and this binding
mechanism is therefore potentially misleading (see Table 28).
Finally, various 1,2,4-triazole species were found to potently inhibit RpMetAP1a activity
(175 – 179). The most potent species utilize 1-phenylethanone thioethers (175 – 177) as opposed
to the benzyl and propylphenyl thioethers utilized in essentially all other published reports;
specifically, 2,4-dimethyl and 3-nitro derivatives (175) and (176) were found to exhibit IC50
value of 0.40 and 1.2 µM, respectively; these compounds were the most potent 1,2,4-triazole
derivatives screened against RpMetAP1a to date. This suggests the incorporation of 1phenylethanone thioethers to the 1,2,4-triazole core can afford potent inhibitors. Related 1naphthyl (178) and cyclohexyl propionyl (179) were found to be only marginally active (IC50 =
5.0 and 9.4 µM, respectively) (see Table 28).
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Table 28: Library Screening Hit Compound Inhibitory Activities
% Inhiba

IC50b

(169)

67 ± 34

0.27 ± 0.01

(170)

82 ± 2

1.4 ± 0.1

(171)

54 ± 37

3.7 ± 0.2

(172)

50 ± 5

3.1 ± 0.3

(173)

50 ± 40

8.3 ± 0.9

(174)

85 ± 6

1.1 ± 0.1

(175)

61 ± 10

0.40 ± 0.07

(176)

78 ± 4

1.2 ± 0.1

(177)

89 ± 1

10.0 ± 1.5

(178)

78 ± 7

5.0 ± 0.6

(179)

64 ± 5

9.4 ± 0.7

Cmpd

Structure

a.
b.

Percent inhibition of enzyme activity at 10 µM versus uninhibited control; Mn(II)
cofactors; measured in duplicate
IC50 values are expressed in units of µM; Mn(II) cofactors
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Conclusions

Because of the global health crisis regarding antibiotic resistance,73 required
hospitalization and mortality from bacterial infection are dramatically increasing and rapidly
outpacing novel drug discovery efforts. To develop novel antibiotics, research efforts should
focus on ubiquitous cellular processes necessary for bacterial proliferation that have not been
previously targeted and therefore had the opportunity to develop resistance mechanisms. One
such target is MetAP, which is responsible for the cleavage of methionine initiators from nascent
proteins.
Based upon with published inhibitors of MetAPs isolated from bacterial sources, a series
of compounds were synthesized or purchased and screened for enzymatic inhibitory activity
against R. prowazekii MetAP; compounds were based upon furoic acid, 1,2,4-triazole,
quinolinol, and anthranilic acid motifs. Suspected RpMetAP1a inhibitory compounds were first
screened against the enzyme in a fluorescence based activity assay, with Mn(II) utilized as the
enzymatic cofactors. Once potent inhibitory compounds were discovered, the most active species
were subjected to a host-cell viability assay to determine anti-Rickettsial activity in the presence
of host endothelial cells of rat origin. Finally, a library of potential RpMetAP1a inhibitory
compounds was screened for activity to determine novel inhibitory species.
From the initial screening of RpMetAP1a inhibitory compounds, it was determined that
compounds based upon furoic acid, quinolinol, and 1,2,4-triazole scaffolds exhibited potent
inhibitory activity. However, only quinolinol-based inhibitors were determined to be active at
reasonable concentrations in the host-cell viability assay, which measured anti-Rickettsial
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activity in the presence of host endothelial cells of rat origin. Although these MetAP inhibitors
appear to have antibacterial activity in vivo, we cannot explicitly conclude that the observed
activity is the result of MetAP inhibition; compounds of this general class have been determined
to exhibit promiscuous inhibition of metalloenzymes, which may be responsible for the observed
antibacterial activity.
The screening of a library of 294 suspected MetAP inhibitors to discern novel classes of
inhibitors found 35 compounds exhibiting >50% inhibition of enzymatic activity at a stock
concentration of 10 μM. These compounds were rescreened to construct 10-point dose-response
curves to determine inhibitory activity (IC50). Only 11 compounds were determined to exhibit
IC50 values less than 10 μM, and of these, only three were based upon unreported motifs (171 –
173). However, the other compounds, based upon furoic acid, biaryl chelator, 1,2,4-triazole
motifs, did not occupy the same chemical space as published inhibitors. This is noteworthy, as
the library screening results provide additional information regarding SAR of published
inhibitory scaffolds which can be utilized in the design of new inhibitors.
Future efforts involving the development of novel MetAP inhibiting antibacterial agents
should focus on expanding currently reported inhibitory motifs that have been expanded upon
with the library screening. For example, furoic acid sulfonamide (169) and aryl isoxazolic acid
(170) were determined as potent inhibitory species and have not been reported in the literature.
These compounds were among the most potent we screened and further SAR determination
could afford a potent lead compound. Additionally, the SAR determined for the corresponding
furoic acid based MetAP inhibitors (e.g. substitution at the 2-position of the aryl ring is
necessary for potent activity) should translate to the isoxazolyl acids.
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Experimental

General Methods.

All chemicals were purchased from Sigma Aldrich and were used without any further
purification. Melting points were recorded on a Mel-Temp II apparatus. Purity was measured
with an Agilent HPLC utilizing a C-18 column (Waters Nova-Pak; 3.9 x 100 mm) with the
following method: Solvent A = H2O (0.1% TFA), Solvent B = Methanol; 0 to 20 min, (10 to
90% B), 20 to 25 min (90 to 10% B); detection was set at two wavelengths (245 and 280 nm). 1H
and 13C NMR were recorded on a BrukerAvance III 500 outfitted with a 5mm BBFO Z-gradient
probe.

RpMetAP1a Enzymatic Activity Assay

The assay utilized is similar to that which we reported earlier.89c The fluorogenic peptide
substrate, methionine-aminomethylcoumarin was purchased from Enzo Life Sciences
(Farmingdale, NY). Purified RpMetAP1a was obtained from the Seattle Structural Genomics
Center for Infectious Disease (SSGCID) and was used as received. Enzyme stock solutions were
prepared by diluting RpMetAP1a into assay buffer (6.25 mM HEPES, 0.1 mM MnCl2, 125 mM
NaCl, pH 7.0) and adjusting enzyme concentration to 4 µM, where concentration was
determined from solution absorbance at 250 nm (measured with a Thermo Scientific NanoDrop
2000c, extinction coefficient = 30,370 M-1 cm-1). Enzymatic activity of RpMetAP was followed
using a Synergy 2 Plate reader (Biotek, Winooski, Vt). All kinetic experiments were carried out
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on Nunc flat-bottom maxisorp 96-well plates (Thermo Fisher Scientific, Rochester, NY). Each
well contained 80 µL of assay mixture with final concentrations of 6.25 mM HEPES, 0.1 mM
MnCl2, 125 mM NaCl, pH 7.0, 200 µM Met-AMC, 0.100 µM RpMetAP1, and 1% DMSO at
various inhibitor concentrations. First, enzyme from prepared stock solutions (20 µL) and
inhibitors at variable concentrations (20 µL, 4% DMSO) in assay buffer was centrifuged (4 oC,
2000 rpm, 5 min) and incubated for 1 h at 4oC. Then, substrate (40 µL, 400 µM) in assay buffer
was added to each well, centrifuged (4 oC, 2000 rpm, 5 min) and incubated at 30 oC for 30 min in
the plate reader. Following incubation, fluorescence was monitored (Excite: 360 nm, Read: 460
nm) for 90 min. Relative activities of enzyme/substrate solutions were determined as the slope of
inhibited enzyme divided by the slope of free enzyme. The first 30 minof data were discarded as
this was considered condition equilibration. Inhibitory activities were calculated as the ratio of
inhibitied and uninhibited enzyme activity (vi / vo) and dose-response curves were fit according
to published methods.

Compound Synthesis

1,2,4-Triazoles Derivatives

5-((3-phenylpropyl)thio)-4H-1,2,4-triazol-3-amine (108)
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3-Amino-1,2,4-triazole-5-thiol (2.0020 g, 17.24 mmol) was suspended in a solution of DMF (20
mL) and triethylamine (2.68 mL, 19.21 mmol). The resulting mixture was purged in inert
atmosphere (N2) and was allowed to stir at room temperature for 30 min. (3Bromopropyl)benzene (2.90 mL, 19.08 mmol) was then added to the light yellow solution and
the resulting mixture was allowed to stir at room temperature overnight under inert atmosphere
(N2). The solution was then poured over H2O (100 mL) and was extracted with ethyl acetate (2 x
100 mL). The combined organic extract was rinsed with brine (200 mL) and dried over sodium
sulfate. Removal of the solvent in vacuo afforded an off white solid of mass 4.4119 g. The
sample was dissolved in ethyl acetate and subjected to flash chromatography (100% EtOAc) to
afford desired product as an off-white solid of mass 3.7654 g; Yield: 93%; mp: 85 – 87 oC;
Purity (HPLC): 254 nm: 97% (TR = 9.88 min, H = 1843 mAU, W = 0.22 min), 280 nm: Neg.
Abs.; 1H NMR (300 MHz, DMSO-d6, ppm): 1.91 (quintet, 2H, J = 7.34 Hz), 2.67 (t, 2H, J = 7.55
Hz), 2.94 (t, 2H, J = 6.84 Hz), 6.02 (s, 2H), 7.15-7.19 (m, 3H), 7.25-7.30 (m, 2H), 11.91 (s, 1H);
13

C NMR (300 MHz, DMSO-d6, ppm): 30.8, 31.6, 34.5, 126.3, 128.76, 128.79, 141.75, 156.5,

157.8; IR (cm-1): 632, 698, 721, 781, 808, 825, 946, 1039, 1072, 1151, 1199, 1216, 1278, 1367,
1413, 1467, 1502, 1587, 1648, 3122, 3448.

General Procedure A: Synthesis of Compounds (109 – 116)

A mixture of a carboxylic acid (0.50 mmol), HOBT (0.23 mmol), triethylamine (0.50 mmol), and
EDC hydrochloride (0.50 mmol) in methylene chloride (5 mL) was prepared and allowed to stir
at room temperature for 10 min. Then, 5-((4-methylbenzyl)thio)-4H-1,2,4-triazol-3-amine (35)
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(0.45 mmol) was added and the mixture was heated to 40 oC and allowed to stir overnight at
elevated temperature. The heating element was removed and the mixture was allowed to cool to
room temperature. The mixture was poured over water (40 mL) and extracted with ethyl acetate
(2 x 40 mL). The combined organic extract was rinsed with brine (100 mL) and dried over
sodium sulfate. The solution was concentrated to dryness and the resulting mixture purified by
column chromatography (0 to 100%; EtOAc:Hexanes).

1-(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)ethanone (109)

Synthesized according to general procedure A using acetic acid; Yield: 82%; mp: 144 – 145 oC;
Purity (HPLC): 245 nm: 88% (TR = 17.82 min, H = 789 mAU, W = 0.12 min), 280 nm: >99%
(TR = 17.82 min, H = 675 mAU, W = 0.12 min); 1H NMR (300 MHz, DMSO-d6, ppm): 2.27 (s,
3H), 2.49 (s, 3H), 4.26 (s, 2H), 7.11 (d, 2H, J = 7.86 Hz), 7.29 (d, 2H, J = 8.01 Hz), 7.61 (s, 2H);
13

C NMR (300 MHz, DMSO-d6, ppm): 21.1, 23.5, 34.4, 129.32, 129.41, 135.1, 136.9, 157.4,

160.6, 170.9; IR (cm-1): 663, 742, 759, 794, 890, 970, 1022, 1037, 1087, 1108, 1159, 1189, 1240,
1270, 1326, 1371, 1425, 1496, 1513, 1650, 1720, 3104, 3203, 3295, 3434.

177
[1,1'-biphenyl]-4-yl(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)methanone
(110)

Synthesized according to general procedure A using 4-phenylbenzoic acid; Yield: 81%; mp: 176
– 177 oC; Purity (HPLC): 254 nm: >99% (TR = 20.76 min, H = 64 mAU, W = 0.11 min), 280 nm
>99% (TR = 20.76 min, H = 106 mAU, W = 0.11 min); 1H NMR (300 MHz, DMSO-d6, ppm):
2.26 (s, 3H), 4.26 (s, 2H), 7.12 (d, 2H, J = 7.89 Hz), 7.28 (d, 2H, J = 7.89 Hz), 7.42-7.55 (m,
3H), 7.77 (d, 2H, J = 7.14 Hz), 7.83-7.88 (m, 4H), 8.14 (d, 2H, J = 8.46 Hz); 13C NMR (300
MHz, DMSO-d6, ppm): 21.1, 34.4, 126.6, 127.5, 128.9, 129.2, 129.4, 129.6, 131.1, 131.9, 135.0,
136.9, 139.3, 144.8, 159.1, 161.4, 166.8; IR (cm-1): 609, 661, 696, 742, 788, 806, 854, 931, 993,
1087, 1130, 1184, 1253, 1272, 1340, 1405, 1492, 1606, 1643, 1679, 3095, 3193, 3430.

178
1-(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)-2-methylpropan-1-one (111)

Synthesized according to general procedure A using isobutyric acid; Yield: 79%; mp: 121 – 123
o

C; Purity (HPLC): 254 nm: 97% (TR = 20.80 min, H = 1321 mAU, W = 0.12 min), 280 nm:

>99% (TR = 20.80, H = 1225 mAU, W = 0.12 min); 1H NMR (300 MHz, DMSO-d6, ppm): 1.16
(d, 6H, J = 6.90 Hz), 2.26 (s, 3H), 3.50 (q, 1H, J = 6.89 Hz), 4.25 (s, 2H), 7.11 (d, 2H, J = 7.83
Hz), 7.30 (d, 2H, J = 8.01 Hz), 7.65 (s, 2H); 13C NMR (300 MHz, DMSO-d6, ppm): 18.7, 21.1,
33.4, 34.4, 129.3, 129.4, 135.1, 136.9, 157.8, 160.9, 177.1; IR (cm-1): 665, 690, 738, 794, 815,
995, 1093, 1159, 1240, 1257, 1276, 1359, 1388, 1467, 1492, 1646, 1710, 2983, 3100, 3291,
3424.

1-(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)-2-phenylethanone (112)

Synthesized according general procedure A using phenylacetic acid; Yield: 80%; mp: 139 – 140
o

C; Purity (HPLC): 254 nm: 75% (TR = 21.32 min, H = 703 mAU, W = 0.12 min), 280 nm: 96%

(TR = 21.32 min, H = 649 mAU, W = 0.12 min); 1H NMR (300 MHz, DMSO-d6, ppm): 2.28 (s,
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3H), 4.26-4.30 (m, 4H), 7.12 (d, 2H, J = 7.89 Hz), 7.30-7.33 (m, 7H), 7.65 (s, 2H); 13C NMR
(300 MHz, DMSO-d6, ppm): 21.2, 34.4, 41.6, 127.4, 128.8, 129.3, 129.4, 130.3, 134.0, 135.1,
136.9,157.7, 161.0, 171.3; IR (cm-1): 630, 674, 694, 721, 742, 769, 809, 1022, 1078, 1147, 1243,
1265, 1284, 1355, 1454, 1494, 1644, 1704, 3436.

1-(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)-3-phenylpropan-1-one (113)

Synthesized according to general procedure A using 3-phenylpropanoic acid; Yield: 55%; mp:
143 – 144 oC; Purity (HPLC): 254 nm: 71% (TR = 22.04 min, H = 1441 mAU, W = 0.12 min),
280 nm: 95% (TR = 22.04 min, H = 1363 mAU, W = 0.12 min); 1H NMR (300 MHz, DMSO-d6,
ppm): 2.23 (s, 3H), 2.94 (t, 2H, J = 7.61 Hz), 3.23 (t, 2H, J = 7.61 Hz), 4.24 (s, 2H), 7.08 (d, 2H,
J = 7.86 Hz), 7.17-7.32 (m, 7H), 7.64 (s, 2H); 13C NMR (300 MHz, DMSO-d6, ppm): 21.1, 29.5,
34.4, 36.7, 126.6, 128.75, 128.83, 129.32, 129.35, 135.1, 136.8, 140.9, 157.5, 160.8, 172.5; IR
(cm-1): 669, 701, 734, 771, 794, 825, 842, 981, 991, 1058, 1162, 1182, 1243, 1272, 1322, 1375,
1402, 1448, 1494, 1513, 1635, 1718, 3106, 3191, 3272, 3450.

180
(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)(4-(dimethylamino)phenyl)
methanone (114)

Synthesized according to general procedure A using 4-(dimethylamino)benzoic acid; Yield:
65%; mp: 137 – 139 oC; Purity (HPLC): 254 nm: 98% (TR = 20.49 min, H = 1779 mAU, W =
0.16 min), 280 nm: >99% (TR = 20.49 mAU, H = 774 mAU, W = 0.14 min); 1H NMR (300
MHz, DMSO-d6, ppm): 2.26 (s, 3H), 2.93 (s, 6H), 4.23 (s, 2H), 6.98-7.11 (m, 3H), 7.22-7.38 (m,
5H), 7.83 (s, 2H); 13C NMR (DMSO-d6, ppm): 21.1, 34.5, 114.3, 117.0, 118.6, 128.95, 129.24,
129.39, 133.0, 134.9, 136.9, 150.2, 159.1, 161.2, 167.9; IR (cm-1): 615, 671, 744, 771, 819, 852,
929, 987, 1006, 1062, 1093, 1174, 1236, 1272, 1305, 1332, 1432, 1492, 1571, 1600, 1639, 1681,
3108, 3189, 3272, 3430.

181
[1,1'-biphenyl]-3-yl(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)methanone
(115)

Synthesized according to general procedure A using 3-phenylbenzoic acid; Yield: 42%; mp: 191
– 192 oC; Purity (HPLC): 254 nm: >99% (TR = 20.26 min, H = 349 mAU, W = 0.29 min), 280
nm: >99% (TR = 20.26 min, H = 89 mAU, W = 0.30 min); 1H NMR (300 MHz, DMSO-d6,
ppm): 2.23 (s, 3H), 4.22 (s, 2H), 7.00 (d, 2H, J = 7.86 Hz), 7.21 (d, 2H, J = 8.01 Hz), 7.37-7.51
(m, 3H), 7.64 (t, 1H, J = 7.79 Hz), 7.71 (d, 2H, J = 6.99 Hz), 7.89 (s, 2H), 7.96 (t, 2H, J = 7.47
Hz), 8.31 (s, 1H); 13C NMR (300 MHz, DMSO-d6, ppm): 21.1, 34.3, 127.3, 128.4, 129.09,
129.17, 129.35, 129.57, 129.81, 131.4, 133.4, 135.0, 136.8, 139.7, 140.3, 159.1, 161.5, 167.2; IR
(cm-1): 613, 663, 676, 700, 717, 738, 765, 821, 838, 906, 937, 991, 1022, 1093, 11262, 1178,
1238, 1268, 1286, 1346, 1498, 1531, 1583, 1639, 1691, 3095, 3181, 3280, 3424.

182
(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)(phenyl)methanone (116)

Synthesized according to general procedure A using benzoic acid; Yield: 99%; mp: 132 – 134
o

C; Purity (HPLC): 254 nm: 97% (TR = 20.97 min, H = 1164 mAU, W = 0.12 min), 280 nm:

>99% (TR = 20.97 min, H = 556 mAU, W = 0.11 min); 1H NMR (300 MHz, DMSO-d6, ppm):
2.27 (s, 1H), 4.22 (s, 2H), 7.10 (d, 2H, J = 7.86 Hz), 7.25 (d, 2H, J = 8.01 Hz), 7.55 (t, 2H, J =
7.55 Hz), 7.67 (t, 1H, J = 7.40 Hz), 8.00 (s, 2H), 8.02 (dd, 2H, 3.15 Hz); 13C NMR (300 MHz,
DMSO-d6, ppm): 21.1, 34.4, 128.5, 129.2, 129.4, 131.0, 132.5, 133.3, 135.0, 136.8, 159.0, 161.3,
167.2; IR (cm-1): 609, 661, 676, 692, 742, 790, 823, 840, 917, 939, 993, 1087, 1133, 1178, 1199,
1243, 1267, 1348, 1376, 1409, 1448, 1498, 1644, 1687, 3099, 3193, 3284, 3440.

1-((4-chlorophenyl)sulfonyl)-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-5-amine (117)

Triethylamine (0.54 mmol), 5-((4-methylbenzyl)thio)-4H-1,2,4-triazol-3-amine (35) (0.45
mmol), and 4-chlorobenzenesulfonyl chloride (0.45 mmol) were dissolved in methylene chloride
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(5 mL). The resulting mixture was allowed to stir at room temperature overnight, under inert
atmosphere (N2). The mixture was then poured over water (20 mL) and extracted with ethyl
acetate (3 x 20 mL). The combined organic extract was rinsed with brine (80 mL) and dried over
sodium sulfate. Removal of the solvent in vacuo afforded (117) as a white solid; Yield: 97%;
mp: 148 – 149 oC; Purity (HPLC): 254 nm: >99% (TR = 20.13 min, H = 845 mAU, W = 0.12
min), 280 nm: >99% (TR = 20.13 min, H = 460 mAU, W = 0.12 min): 1H NMR (300 MHz,
DMSO-d6, ppm): 2.26 (s, 3H), 4.15 (s, 2H), 7.05 (d, 2H, J = 7.92 Hz), 7.16 (d, 2H, J = 8.04 Hz),
7.55 (s, 2H), 7.76 (d, 2H, J = 8.76 Hz), 9.95 (d, 2H, J = 8.76 Hz); 13C NMR (300 MHz, DMSOd6, ppm): 21.1, 34.2, 129.1, 129.3, 129.9, 130.6, 134.9, 135.2, 136.8, 140.9, 158.2, 163.0; IR
(cm-1): 619, 636, 703, 732, 752, 777, 790, 823, 835, 871, 979, 1008, 1043, 1087, 1151, 1184,
1245, 1276, 1373, 1394, 1490, 1513, 1558, 1581, 1654, 3153, 3224, 3303, 3459.

Quinolinol Derivatives

General Procedure A: Synthesis of Compounds (126 – 143)
5-Chloro-8-quinolinol (118) (0.55 mmol), a benzamide (0.83 mmol), a benzaldehyde (0.83
mmol), and TFA (0.06 mmol) were sealed in a microwave tube. The mixture was then heated to
130 oC via microwave irradiation for 45 min. After cooling to room temperature, the resulting
solid was suspended in methylene chloride and heated to reflux. The suspension was allowed to
cool to room temperature and settle. Finally, the supernatant was decanted until only half
remained, and the resulting suspension was filtered via gravity filtration to afford desired
products.
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General Procedure B: Synthesis of Compounds (144 – 154)
5-Nitro-8-quinolinol (58) (0.55 mmol), a benzamide (0.83 mmol), a benzaldehyde (0.83 mmol),
and TFA (0.06 mmol) were sealed in a microwave tube. The mixture was then heated to 130 oC
via microwave irradiation for 45 min. After cooling to room temperature, the resulting solid was
suspended in methylene chloride and heated to reflux. The suspension was allowed to cool to
room temperature and settle. Finally, the supernatant was decanted until only half remained, and
the resulting suspension was filtered via gravity filtration to afford desired products.

N-((5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl)benzamide (126)

Synthesized according to general procedure A using benzaldehyde and benzamide; Yield: >99%;
mp: 242 – 245 oC; Purity (HPLC): 254 nm: 97% (TR = 19.76 min, H = 1780 mAU, W = 0.16
min), 280 nm: >99% (TR = 19.76 min, H = 92 mAU, W = 0.13 min); 1H NMR (300 MHz,
DMSO-d6, ppm): 7.01 (d, 1H, 8.73 Hz), 7.27 (m, 1H), 7.34 (m, 4H), 7.46-7.56 (m, 3H), 7.73 (dd,
1H, J = 4.25 Hz), 7.75 (s, 1H), 7.93 (dd, 2H, J = 4.20 Hz), 8.49 (dd, 1H, J = 3.36 Hz), 8.97 (dd,
1H, J = 1.91 Hz), 9.27 (d, 1H, J = 8.76 Hz), 10.35 (s, 1H); 13C NMR (300 MHz, DMSO-d6,
ppm): 50.5, 119.0, 123.5, 125.4, 125.5, 127.3, 127.5, 127.6, 128.1, 128.7, 128.9, 131.9, 132.9,
134.7, 139.1, 142.1, 149.7, 150.0, 166.5; IR (cm-1): 631, 656, 690, 704, 723, 756, 783, 875, 941,
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1049, 1085, 1108, 1159, 1201, 1238, 1261, 1278, 1321, 1351, 1400, 1463, 1488, 1525, 1579,
1598, 1637, 3316, 3399.

N-((5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl)-3-methylbenzamide (127)

Synthesized according to general procedure A using benzaldehyde and 3-methylbenzamide;
Yield: 51%; mp: 220 – 223 oC; Purity (HPLC): 254 mn: 94% (TR = 20.35 min, H = 1819 mAU,
W = 0.15 min), 280 nm: >99% (TR = 20.35 min, H = 121 mAU, W = 0.11 min);1H NMR (300
MHz, DMSO-d6, ppm): 2.37 (s, 3H), 7.00 (d, 1H, J = 8.73 Hz), 7.26-7.37 (m, 8H), 7.71-7.76 (m,
3H), 7.85 (s, 1H), 8.48 (dd, 1H, 3.36 Hz), 8.97 (dd, 1H, J = 1.91 Hz), 9.21 (d, 1H, J = 8.76 Hz);
13

C NMR (300 MHz, DMSO-d6, ppm): 21.4, 50.6, 119.0, 123.5, 125.3, 125.4, 125.6, 127.3,

127.5, 127.6, 128.5, 128.6, 128.9, 132.4, 133.0, 134.7, 138.0, 139.1, 142.1, 149.7, 150.0, 166.5;
IR (cm-1): 632, 669, 684, 698, 723, 752, 792, 811, 856, 889, 910, 946, 1031, 1051, 1155, 1191,
1230, 1280, 1330, 1349, 1371, 1400, 1461, 1498, 1529, 1583, 1631, 3293.

186
N-((5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl)-3-methoxybenzamide (128).

Synthesized according to general procedure A using benzaldehyde and 3-methoxybenzamide;
Yield: 6%; mp: 191 – 193 oC; Purity (HPLC): 254 nm: >99% (TR = 20.13 min, H = 1794 mAU,
W = 0.14 min), 280 nm: >99% (TR = 20.13 min, H = 131 mAU, W = 0.12 min); 1H NMR (300
MHz, DMSO-d6, ppm): 3.81 (3H, s), 7.00 (1H, d, J = 8.70 Hz), 7.12 (1H, dd, J = 1.66 Hz), 7.267.31 (1H, m), 7.33-7.35 (4H, m), 7.38-7.43 (1H, m), 7.47 (1H, t, J = 1.98 Hz), 7.53 (1H, dt, J =
1.99 Hz), 7.73 (1H, dd, J = 4.24 Hz), 7.85 (1H, s), 8.49 (1H, dd, J = 3.36 Hz), 8.97 (1H, dd, J =
1.91 Hz), 9.25 (1H, d, J = 8.73 Hz), 10.40 (1H, s); 13C NMR (300 MHz, DMSO-d6, ppm): 50.6,
55.8, 113.3, 117.6, 119.0, 120.3, 123.5, 125.4, 125.5, 127.3, 127.5, 127.6, 128.9, 129.9, 133.0,
136.1, 139.1, 142.0, 149.7, 150.1, 159.6, 166.2; IR (cm-1): 632, 665, 682, 703, 723, 752, 792,
813, 858, 890, 948, 1051, 1126, 1155, 1193, 1238, 1282, 1330, 1400, 1461, 1498, 1531, 1583,
1631, 3299.

187
N-((5-chloro-8-hydroxyquinolin-7-yl)(p-tolyl)methyl)-3-methoxybenzamide (129)

Synthesized according to general procedure A using 4-methylbenzaldehyde and 3methoxybenzamide; Yield: 5%; mp: 195 – 197 oC; Purity (HPLC): 254 nm: >99% (TR = 20.76
min, H = 1935 mAU, W = 0.17 min), 280 nm: >99% (TR = 20.75 min, H = 202 mAU, W = 0.12
min); 1H NMR (300 MHz, DMSO-d6, ppm): 2.27 (s, 3H), 3.80 (s, 3H), 6.96 (d, 1H, J = 8.67 Hz),
7.10-7.22 (m, 4H), 7.40 (t, 1H, J = 7.92 Hz), 7.47 (t, 1H, J = 1.67 Hz), 7.52 (dt, 1H, J = 2.00),
7.73 (dd, 1H, J = 4.25 Hz), 7.83 (s, 1H), 8.47 (dd, 1H, J = 3.37 Hz), 8.97 (dd, 1H, J = 1.91 Hz),
9.19 (d, 1H, J = 8.73 Hz); 13C NMR (300 MHz, DMSO-d6, ppm): 20.6, 49.9, 55.3, 112.8, 117.1,
118.4, 119.8, 122.9, 124.9, 125.2, 126.8, 129.4, 132.5, 135.7, 136.1, 138.5, 138.6, 149.1, 149.5,
159.1, 165.6; IR (cm-1): 624, 684, 721, 792, 862, 887, 946, 1049, 1126, 1155, 1191, 1240, 1284,
1334, 1371, 1400, 1463, 1498, 1533, 1583, 1635, 3291.

188
N-((5-chloro-8-hydroxyquinolin-7-yl)(4-chlorophenyl)methyl)-3-methoxybenzamide (130)

Synthesized according to general procedure A using 4-chlorobenzaldehyde and 3methoxybenzamide; Yield: 45%; mp: 229 – 230 oC; Purity (HPLC): 254 nm: 94% (TR = 20.97
min, H = 1886 mAU, W = 0.17 min), 280 nm: >99% (TR = 20.98 min, H = 266 mAU, W = 0.12
min); 1H NMR (300 MHz, DMSO-d6, ppm): 3.81 (s, 3H), 6.94 (d, 1H, 8.61 Hz), 7.12 (ddd, 1H, J
= 1.67 Hz), 7.35-7.42 (m ,5H), 7.46 (t, 1H, J = 1.90 Hz), 7.52 (dt, 1H, J = 2.07 Hz), 7.73 (dd, 1H,
J = 4.25 Hz), 7.82 (s, 1H), 8.49 (dd, 1H, J = 3.37 Hz), 8.98 (dd, 1H, J = 1.91 Hz), 9.24 (d, 1H, J
= 8.65 Hz); 13C NMR (300 MHz, DMSO-d6, ppm): 50.2, 55.8, 113.4, 117.6, 119.1, 120.3, 123.6,
124.9, 125.5, 127.0, 128.9, 129.6, 129.9, 132.1, 133.0, 136.0, 139.1, 141.0, 149.7, 150.1, 159.6,
166.2; IR (cm-1): 638, 682, 719, 792, 829, 865, 950, 1016, 1043, 1093, 1157, 1191, 1245, 1278,
1328, 1373, 1400, 1463, 1496, 1527, 1589, 1627, 3286.

189
N-((5-chloro-8-hydroxyquinolin-7-yl)(p-tolyl)methyl)-3-methylbenzamide (131)

Synthesized according to general procedure A using 4-methylbenzaldehyde and 3methylbenzamide; Yield: 29%; mp: 222 – 224 oC; Purity (HPLC): 254 nm: 88% (TR = 20.96
min, H = 1970 mAU, W = 0.24 min), 280 nm: >99% (TR = 20.23 min, H = 327 mAU, W = 0.14
min); 1H NMR (300 MHz, DMSO-d6, ppm): 2.26 (s, 3H), 2.36 (s, 3H), 6.96 (d, 1H, J = 8.70 Hz),
7.13-7.23 (m, 4H), 7.35-7.37 (m, 2H), 7.70-7.75 (m, 3H), 7.84 (s, 1H), 8.48 (dd, 1H, J = 3.37
Hz), 8.96 (dd, 1H, J = 1.92 Hz), 9.15 (d, 1H, J = 8.76 Hz), 10.37 (s, 1H); 13C NMR (300 MHz,
DMSO-d6, ppm): 20.6, 20.9, 49.8, 118.4, 122.9, 124.7, 124.9, 125.3, 126.8, 127.1, 128.0, 128.1,
128.9, 131.9, 132.5, 134.3, 136.1, 137.5, 138.6, 149.1, 149.4, 166.0; IR (cm-1): 624, 676, 698,
721, 782, 792, 809, 863, 887, 946, 1049, 1157, 1189, 1228, 1280, 1332, 1373, 1400, 1461, 1498,
1529, 1583, 1633, 3301.

190
N-((5-chloro-8-hydroxyquinolin-7-yl)(4-chlorophenyl)methyl)-3-methylbenzamide (132)

Synthesized according to general procedure A using 4-chlorobenzaldehyde and 3methylbenzamide; Yield: 74%; mp: >250 oC; Purity (HPLC): 254 nm: >99% (TR = 21.28 min, H
= 1355 mAU, W = 0.13 min), 280 nm: >99% (TR = 21.28 min, H = 64 mAU, W = 0.13 min); 1H
NMR (DMSO-d6, ppm): 2.37 (s, 3H), 6.97 (d, 1H, J = 8.61 Hz), 7.35-7.43 (m, 6H), 7.72-7.85
(m, 4H), 8.48 (d, 1H, J = 3.36 Hz), 8.97 (dd, 1H, J = 1.92 Hz), 9.25 (d, 1H, J = 8.67 Hz); 10.46
(s, 1H); 13C NMR (300 MHz, DMSO-d6, ppm): 20.9, 49.7, 118.6, 123.1, 124.5, 124.8, 125.0,
126.6, 128.0, 128.2, 128.4, 129.0, 131.6, 132.0, 132.5, 134.1, 137.6, 138.7, 140.6, 149.2, 149.6,
166.1; IR (cm-1): 638, 680, 719, 792, 804, 829, 863, 885, 948, 1014, 1052, 1093, 1108, 1157,
1193, 1220, 1280, 1334, 1373, 1400, 1463, 1500, 1529, 1589, 1600, 1633, 3288.

191
N-((5-chloro-8-hydroxyquinolin-7-yl)(p-tolyl)methyl)benzamide (133)

Synthesized according to general procedure A using 4-methybenzaldehyde and benzamide;
Yield: 60%; mp: 244 – 247 oC; Purity (HPLC): 254 nm: 90% (TR = 20.46 min, H = 1961 mAU,
W = 0.23 min), 280 nm: >99% (TR = 20.46 min, H = 175 mAU, W = 0.14 min); 1H NMR
(DMSO-d6, ppm): 2.26 (s, 1H), 6.97 (d, 1H, 8.70 Hz), 7.13-7.23 (m 4H), 7.48-7.55 (m, 3H), 7.73
(dd, 1H, J = 4.25 Hz), 7.85 (s, 1H), 7.93 (dt, 1H, J = 1.93 Hz), 8.48 (dd, 1H, J = 3.36 Hz), 8.96
(dd, 1H, J = 1.91 Hz), 9.21 (d, 1H, J = 8.76 Hz), 10.34 (s, 1H); 13C NMR (300 MHz, DMSO-d6,
ppm): 21.1, 50.3, 118.9, 123.4, 125.4, 125.8, 127.3, 127.5, 128.0, 128.7, 129.4, 131.8, 133.0,
134.8, 136.6, 139.1, 149.6, 149.9, 166.4; IR (cm-1): 622, 663, 674, 690, 719, 792, 829, 887, 910,
946, 1049, 1155, 1189, 1230, 1278, 1330, 1371, 1400, 1461, 1498, 1529, 1579, 1629, 3318.

192
N-((5-chloro-8-hydroxyquinolin-7-yl)(m-tolyl)methyl)benzamide (134)

Synthesized according to general procedure A using 3-methybenzaldehyde and benzamide;
Yield: 63%; mp: 240 – 241 oC; Purity (HPLC): 245nm: 98% (TR = 20.76 min, H = 1558 mAU,
W = 0.14 min), 280 nm: 88% (TR = 20.76 min, H = 233 mAU, W = 0.14 min); 1H NMR
(DMSO-d6, ppm): 2.27 (s, 3H), 6.98 (d, 1H, J = 8.73 Hz), 7.06-7.16 (m, 3H), 7.23 (t, 1H, J =
7.44 Hz), 7.46-7.58 (m, 3H), 7.73 (dd, 1H, J = 4.24 Hz), 7.87 (s, 1H), 7.93 (dt, 2H, J = 1.91 Hz),
8.48 (dd, 1H, J = 3.36 Hz), 8.97 (dd, 1H, J = 1.91 Hz), 9.24 (d, 1H, J = 8.76 Hz); 13C NMR (300
MHz, DMSO-d6, ppm): 21.6, 50.5, 119.0, 123.5, 124.8, 125.4, 125.6, 127.3, 128.1, 128.2, 128.7,
128.8, 131.8, 133.0, 134.7, 138.0, 139.1, 142.1, 149.6, 149.9, 166.4; IR (cm-1): 632, 669, 692,
707, 773, 790, 811, 889, 943, 1051, 1155, 1191, 1228, 1278, 1330, 1371, 1400, 1461, 1498,
1531, 1579, 1604, 1635, 3299.

193
N-((5-chloro-8-hydroxyquinolin-7-yl)(3-chlorophenyl)methyl)benzamide (135)

Synthesized according to general procedure A using 3-chlorobenzaldehyde and benzamide;
Yield: 58%; mp: 242 – 243 oC; Purity (HPLC): 254 nm: >99% (TR = 18.53 min, H = 1626 mAU,
W = 0.19 min), 280 nm: >99% (TR = 18.53 min, H = 56 mAU, W = 0.17 min); 1H NMR (300
MHz, DMSO-d6, ppm): 6.99 (d, 1H, J = 8.64 Hz), 7.32-7.39 (m, 4H), 7.47-7.59 (m, 3H), 7.73
(dd, 1H, J = 4.25 Hz), 7.87 (s, 1H), 7.92 (dt, 2H, J = 1.91 Hz), 8.48 (dd, 1H, 3.36 Hz), 9.98 (dd,
1H, J = 1.91 Hz), 9.31 (d, 1H, J = 8.70 Hz); 13C NMR (300 MHz, DMSO-d6, ppm): 49.8, 118.7,
123.1, 124.3, 125.1, 126.0, 126.4, 126.8, 127.1, 127.6, 128.3, 130.4, 131.5, 132.5, 133.1, 134.0,
138.6, 144.1, 149.3, 149.6, 166.0; IR (cm-1): 619, 634, 692, 777, 790, 813, 850, 877, 917, 944,
970, 1049, 1079, 1157, 1191, 1228, 1278, 1330, 1373, 1400, 1463, 1500, 1523, 1579, 1600,
1631, 3311.

194
N-((5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl)-4-methylbenzamide (136)

Synthesized according to general procedure A using benzaldehyde and 4-methylbenzamide;
Yield: 76%; mp: 244 – 247 oC; Purity (HPLC): 254 nm: 96% (TR = 17.73 min, H = 1977 mAU,
W = 0.19 min), 280 nm: >99% (TR = 17.73 min, H = 1172 mAU, W = 0.13 min); 1H NMR (300
MHz, DMSO-d6, ppm): 2.36 (s, 3H), 7.01 (d, 1H, J = 8.76 Hz), 7.28-7.34 (m, 7H), 7.73 (dd, 1H,
J = 4.24 Hz), 7.84-7.87 (m, 3H), 8.48 (dd, 1H, J = 3.36 Hz), 8.97 (dd, 1H, J = 1.91 Hz), 9.18 (d,
1H, J = 8.82 Hz), 10.20 (s, 1H); 13C NMR (300 MHz, DMSO-d6, ppm): 21.4, 50.5, 119.0, 123.5,
125.4, 125.6, 127.3, 128.1, 128.9, 129.3, 131.9, 133.0, 139.1, 141.8, 142.2, 149.6, 150.0, 166.3;
IR (cm-1): 638, 653, 680, 700, 717, 750, 790, 811, 835, 889, 917, 944, 966, 1027, 1049, 1157,
1189, 1230, 1280, 1330, 1373, 1400, 1461, 1498, 1533, 1631, 3293.

195
N-((5-chloro-8-hydroxyquinolin-7-yl)(p-tolyl)methyl)-4-methylbenzamide (137)

Synthesized according to general procedure A using 4-methylbenzaldehyde and 4methylbenzamide; Yield: 76%; mp: > 250 oC; Purity (HPLC): 254 nm: >99% (TR = 21.04 min,
H = 1216 mAU, W = 0.14 min), 280 nm: >99% (TR = 21.04 min, H = 61 mAU, W = 0.13 min);
1

H NMR (300 MHz, DMSO-d6, ppm): 2.26 (s, 3H), 2.35 (s, 3H), 6.96 (d, 1H, J = 8.7- Hz), 7.12-

7.15 (m, 2H), 7.20-7.22 (m, 2H), 7.28 (d, 2H, 8.01 Hz), 7.72 (dd, 1H, J = 4.24 Hz), 7.83-7.86 (m,
3H), 8.47 (dd, 1H, J = 3.36 Hz), 8.96 (dd, 1H, J = 1.90 Hz), 9.11 (d, 1H, J = 8.76 Hz), 10.30 (s,
1H); 13C NMR (300 MHz, DMSO-d6, ppm): 21.1, 21.4, 50.3, 118.9, 123.4, 125.3, 125.8, 127.3,
127.6, 128.1, 129.2, 129.4, 131.9, 133.0, 136.5, 139.1, 139.2, 141.7, 149.6, 149.9, 166.2; IR (cm1

): 624, 644, 671, 721, 757, 790, 811, 835, 889, 910, 946, 966, 1022, 1049, 1114, 1155, 1187,

1230, 1371, 1400, 1461, 1498, 1533, 1629, 3307.

196
N-((5-chloro-8-hydroxyquinolin-7-yl)(4-chlorophenyl)methyl)-4-methylbenzamide (138)

Synthesized according to general procedure A using 4-chlorobenzaldehyde and 4methylbenzamide; Yield: 81%; mp: >250 oC; Purity (HPLC): 254 nm: >99% (TR = 21.13 min, H
= 395 mAU, W = 0.14 min), 280 nm: Low Abs.; 1H NMR (DMSO-d6, ppm): 2.36 (s, 3H), 6.97
(d, 1H, J = 8.67 Hz), 7.28-7.31 (m, 4H), 7.39-7.42 (m, 2H), 7.73 (dd, 1H, J = 4.25 Hz), 7.84-7.86
(m, 3H), 8.49 (dd, 1H, J = 3.36 Hz), 8.97 (dd, 1H, J = 1.91 Hz), 9.19 (d, 1H, J = 8.73 Hz); 13C
NMR (300 MHz, DMSO-d6, ppm): 21.0, 49.6, 118.6, 123.1, 124.6, 125.0, 126.6, 127.6, 128.3,
128.8, 129.1, 131.2, 131.6, 132.5, 138.6, 140.6, 141.4, 149.2, 149.6, 165.8; IR (cm-1): 638, 673,
721, 759, 790, 842, 885, 910, 946, 1016, 1051, 1093, 1159, 1186, 1226, 1278, 1330, 1371, 1400,
1461, 1498, 1531, 1629, 3295.

197
N-((5-chloro-8-hydroxyquinolin-7-yl)(3-chlorophenyl)methyl)-4-methylbenzamide (139)

Synthesized according to general procedure A using 3-chlorobenzaldehyde and 4methylbenzamide; Yield: 73%; mp: >250 oC; Purity (HPLC): 254 nm: >99% (TR = 21.21 min, H
= 464 mAU, W = 0.16 min), 280 nm: Low Abs.; 1H NMR (300 MHz, DMSO-d6, ppm): 2.36 (s,
3H), 6.98 (d, 1H, J = 8.74 Hz), 7.29-7.39 (m, 6H), 7.73 (dd, 1H, J = 4.25 Hz), 7.84-7.87 (m, 3H),
8.49 (dd, 1H, J = 3.36 Hz), 8.98 (dd, 1H, J = 1.92 Hz), 9.22 (d, 1H, J = 8.76 Hz); 13C NMR (300
MHz, DMSO-d6, ppm): 21.0, 49.8, 118.6, 123.1, 124.4, 125.1, 126.0, 126.4, 126.8, 127.0, 127.6,
128.8, 130.4, 131.2, 132.5, 133.0, 138.7, 141.4, 144.2, 149.3, 149.6, 165.8; IR (cm-1): 632, 678,
711, 759, 775, 786, 813, 835, 885, 919, 943, 968, 1051, 1157, 1193, 1228, 1276, 1330, 1373,
1400, 1463, 1500, 1531, 1633, 3311.

198
N-((5-chloro-8-hydroxyquinolin-7-yl)(m-tolyl)methyl)-4-methylbenzamide (140)

Synthesized according to general procedure A using 3-methylbenzaldehyde and 4methylbenzamide; Yield: 75%; mp: >250 oC; Purity (HPLC): 254 nm: 99% (TR = 21.17 min, H
= 1590 mAU, W = 0.15 min); 280 nm: 76% (TR = 21.17 min, H = 432 mAU, W = 0.14 min); 1H
NMR (300 MHz, DMSO-d6, ppm): 2.26 (s, 3H), 2.35 (s, 3H), 6.97 (d, 1H, J = 8.76 Hz), 7.057.15 (m, 3H), 7.22 (t, 1H, J = 7.52 Hz), 7.28 (d, 2H, J = 7.98 Hz), 7.72 (dd, 1H, J = 4.25 Hz),
7.84-7.86 (m, 3H), 8.48 (dd, 1H, J = 3.37 Hz), 8.97 (dd, 1H, J = 1.91 Hz), 9.13 (d, 1H, J = 8.79
Hz); 13C NMR (300 MHz, DMSO-d6, ppm): 20.9 ,21.1, 49.9, 118.4, 122.9, 124.3, 124.9, 125.2,
126.8, 127.6, 127.7, 128.3, 128.7, 131.4, 132.5, 137.4, 138.6, 141.2, 141.7, 149.1, 149.4, 165.7;
IR (cm-1): 632, 657, 676, 707, 757, 781, 811, 835, 889, 927, 943, 1051, 1155, 1189, 1226, 1276,
1330, 1371, 1400, 1463, 1498, 1531, 1612, 1631, 3291, 3320.

199
N-((5-chloro-8-hydroxyquinolin-7-yl)(p-tolyl)methyl)-4-methoxybenzamide (141)

Synthesized according to general procedure A using 4-methylbenzaldehyde and 4methoxyybenzamide; Yield: 71%; mp: 240 – 242 oC; Purity (HPLC): 254 nm: >99% (TR = 20.83
min, H = 1969 mAU, W = 0.18 min), 280 nm: >99% (TR = 20.82 min, H = 474 mAU, W = 0.12
min); 1H NMR (300 MHz, DMSO-d6, ppm): 2.26 (s, 3H), 3.81 (s, 3H), 6.96 (d, 1H, J = 8.73 Hz),
7.01 (d, 2H, J = 8.91 Hz), 7.12-7.21 (m, 4H), 7.72 (dd, 1H, J = 4.24 Hz), 7.86 (s, 1H), 7.93 (d,
2H, J = 8.88 Hz), 8.48 (dd, 1H, J = 3.36 Hz), 8.97 (dd, 1H, J = 1.91 Hz), 9.05 (d, 1H, J = 8.76
Hz); 13C NMR (300 MHz, DMSO-d6, ppm): 20.6, 49.7, 55.3, 113.4, 118.4, 122.9, 124.8, 125.4,
126.4, 126.8, 127.1, 128.9, 129.4, 132.5, 136.0, 138.6, 138.8, 149.1, 149.4, 161.7, 165.3; IR (cm1

): 603, 630, 673, 719, 794, 844, 889, 910, 946, 1025, 1051, 1108, 1157, 1180, 1255, 1282, 1305,

1332, 1371, 1400, 1461, 1498, 1535, 1608, 1625, 3305.

200
N-((5-chloro-8-hydroxyquinolin-7-yl)(4-chlorophenyl)methyl)-4-methoxybenzamide (142)

Synthesized according to general procedure A using 4-chlorobenzaldehyde and 4methoxyybenzamide; Yield: 74%; mp: > 250 oC; Purity (HPLC): 254 nm: 90% (TR = 20.57 min,
H = 1210 mAU, W = 0.15 min), 280 nm: >99% (TR = 20.59 min, H = 172 mAU, W = 0.15 min);
1

H NMR (300 MHz, DMSO-d6, ppm): 3.81 (s, 3H), 6.95-7.04 (m, 3H), 7.31-7.42 (m, 4H), 7.73

(dd, 1H, J = 4.25 Hz), 7.84 (s, 1H), 7.94 (d, 2H, J = 8.88 Hz), 8.49 (dd, 1H, J = 3.37 Hz), 8.97
(dd, 1H, J = 1.92 Hz), 9.12 (d, 1H, J = 8.64 Hz), 10.47 (s, 1H); 13C NMR (300 MHz, DMSO-d6,
ppm): 49.6, 55.4, 113.5, 118.6, 123.0, 124.7, 125.0, 126.2, 126.7, 128.3, 129.1, 129.5, 131.6,
132.5, 138.7, 140.7, 149.2, 149.6, 161.8, 165.4; IR (cm-1): 601, 630, 676, 717, 771, 792, 825,
842, 885, 912, 939, 1012, 1029, 1052, 1091, 1110, 1159, 1178, 1253, 1280, 1305, 1332, 1373,
1400, 1461, 1498, 1531, 1577, 1606, 1629, 3293.

201
N-((5-chloro-8-hydroxyquinolin-7-yl)(m-tolyl)methyl)-4-methoxybenzamide (143)

Synthesized according to general procedure A using 3-methylbenzaldehyde and 4methoxybenzamide; Yield: 10%; mp: 222 – 224 oC; Purity (HPLC): 254 nm: 94% (TR = 20.13
min, H = 1340 mAU, W = 0.13 min), 280 nm: >99% (TR = 20.13 min, H = 550 mAU, W = 0.13
min); 1H NMR (300 MHz, DMSO-d6, ppm): 2.26 (s, 3H), 3.81 (s, 3H), 6.95-7.14 (m, 6H), 7.22
(t, 1H, J = 7.52 Hz), 7.72 (dd, 1H, 4.25 Hz), 7.87 (s, 1H), 7.93 (d, 2H, J = 8.88 Hz), 8.47 (dd, 1H,
J = 3.36 Hz), 8.96 (dd, 1H, J = 1.90 Hz), 9.06 (d, 1H, J = 8.79 Hz); 13C NMR (300 MHz, DMSOd6, ppm): 21.1, 49.9, 55.3, 113.4, 118.4, 122.9, 124.3, 124.9, 125.3, 126.4, 126.8, 127.6, 127.7,
128.3, 129.4, 132.5, 137.4, 138.6, 141.7, 149.1, 149.4, 161.7, 165.3; IR (cm-1): 607, 628, 657,
680, 705, 721, 782, 813, 842, 892, 944, 1025, 1049, 1108, 1157, 1176, 1191, 1228, 1253, 1301,
1330, 1371, 1400, 1463, 1500, 1531, 1608, 1627, 3318.

202
N-((8-hydroxy-5-nitroquinolin-7-yl)(phenyl)methyl)benzamide (144)

Synthesized according to general procedure B using benzaldehyde and benzamide; Yield: 81%;
mp: >250 oC; Purity (HPLC): Insoluble; 1H NMR (300 MHz, DMSO-d6, ppm): 6.99 (d, 1H, J =
8.55 Hz), 7.29-7.32 (m, 1H), 7.46-7.56 (m, 3H), 7.88-7.96 (m, 3H), 8.79 (s, 1H), 9.01 (dd, 1H, J
= 1.91 Hz) 9.19 (dd, 1H, J = 3.46 hz), 9.49 (d, 1H, J = 8.58 Hz); 13C NMR (300 MHz, DMSO-d6,
ppm): 50.6, 122.1, 124.2, 125.7, 127.7, 127.8, 128.1, 128.7, 128.8, 129.0, 131.9, 133.5, 134.6,
134.7, 137.3, 141.4, 149.5, 158.3, 166.5; IR (cm-1): 630, 687, 704, 727, 752, 817, 921, 1112,
1143, 1195, 1214, 1278, 1305, 1348, 1409, 1461, 1488, 1513, 1641, 3286, 3403.

N-((8-hydroxy-5-nitroquinolin-7-yl)(phenyl)methyl)-3-methylbenzamide (145)

Synthesized according to general procedure B using benzaldehyde and 3-methylbenzamide;
Yield: 51%; mp: 229 – 230 oC; Purity (HPLC): 254nm: 84% (TR = 18.95 min, H = 403 mAU, W
= 0.14 min), 280 nm: >99% (TR = 18.95 min, H = 36 mAU, W = 0.14 min); 1H NMR (300 MHz,

203
DMSO-d6, ppm): 2.36 (s, 3H), 6.99 (d, 1H, J = 8.55 Hz), 7.23-7.37 (m, 8H), 7.71-7.76 (m, 2H),
7.89 (dd, 1H, J = 4.36 Hz), 8.78 (s, 1H), 9.02 (dd, 1H, J = 1.89 Hz), 9.17 (dd, 1H, J = 3.44 Hz),
9.38 (d, 1H, J = 8.55 Hz); 13C NMR (300 MHz, DMSO-d6, ppm): 21.4, 50.6, 122.1, 124.3, 125.3,
125.7, 127.7, 127.8, 128.5, 128.7, 129.0, 132.5, 133.5, 134.6, 134.8, 137.3, 138.0, 141.4, 149.5,
158.2, 166.6; IR (cm-1): 630, 669, 686, 701, 725, 748, 771, 804, 815, 850, 919, 1072, 1108, 1228,
1286, 1301, 1328, 1417, 1459, 1496, 1515, 1583, 1635, 3293.

N-((4-chlorophenyl)(8-hydroxy-5-nitroquinolin-7-yl)methyl)-3-methylbenzamide (146)

Synthesized according to general procedure B using 4-chlorobenzaldehyde and 3methylbenzamide; Yield: 34%; mp: 226 – 227 oC; Purity (HPLC): 254 nm: 98% (TR = 20.25
min, H = 1185 mAU, W = 0.15 min); 280 nm: 97% (TR = 20.25 min, H = 111 mAU, W = 0.14
min); 1H NMR (300 MHz, DMSO-d6, ppm): 2.36 (s, 3H), 6.95 (d, 1H, J = 8.46 Hz), 7.36-7.44
(m, 6H), 7.65-7.75 (m, 2H), 7.90 (dd ,1H, J = 4.36 Hz), 8.75 (s, 1H), 9.02 (dd, 1H, J = 1.89 Hz),
9.19 (dd, 1H, J = 3.44 Hz), 9.38 (d, 1H, J = 8.49 Hz); 13C NMR (300 MHz, DMSO-d6, ppm):
20.9, 49.8, 121.8, 123.3, 124.8, 125.3, 128.0, 128.4, 129.3, 131.8, 132.0, 133.1, 134.1, 136.8,
137.6, 139.9, 148.9, 158.0, 166.1; IR (cm-1): 636, 692, 721, 806, 842, 873, 933, 1014, 1093,
1168, 1207, 1263, 1284, 1307, 1409, 1463, 1496, 1517, 1633, 3284.

204
N-((8-hydroxy-5-nitroquinolin-7-yl)(p-tolyl)methyl)-3-methylbenzamide (147)

Synthesized according to general procedure B using 4-methylbenzaldehyde and 3methylbenzamide; Yield: 20%; mp: 222 – 224 oC; Purity (HPLC): 254 nm: 89% (TR = 20.00
min, H = 1077 mAU, W = 0.17 min), 280 nm: >99% (TR = 20.00 min, H = 77 mAU, W = 0.16
min); 1H NMR (300 MHz, DMSO-d6, ppm): 2.28 (s, 3H), 2.36 (s, 3H), 6.92 (d, 1H, J = 8.49 Hz),
7.14-7.25 (m, 4H), 7.35 (d, 2H, J = 2.57 Hz), 7.72-7.75 (m, 2H), 7.89 (dd, 1H, J = 4.35 Hz), 8.76
(s, 1H), 9.02 (dd, 1H, J = 1.90 Hz), 9.17 (dd, 1H, J = 3.46 Hz), 9.32 (d, 1H, J = 8.55 Hz); 13C
NMR (300 MHz, DMSO-d6, ppm): 20.6, 20.9, 49.9, 121.6, 124.0, 124.8, 125.2, 127.3, 128.0,
128.1, 129.0, 131.9, 132.9, 134.15, 134.21, 136.3, 136.8, 137.5, 137.9, 149.0, 157.7, 166.0; IR
(cm-1): 624, 644, 659, 692, 719, 773, 798, 817, 827, 842, 871, 935, 1062, 1108, 1168, 1216,
1284, 1309, 1378, 1409, 1461, 1500, 1517, 1633, 3291.

205
N-((8-hydroxy-5-nitroquinolin-7-yl)(m-tolyl)methyl)-3-methylbenzamide (148)

Synthesized according to general procedure B using 3-methylbenzaldehyde and 3methylbenzamide; Yield: 15%; mp: 237 – 238 oC; Purity (HPLC): 254 nm: 88% (TR = 20.06
min, H = 700 mAU, W = 0.21 min); 280 nm: 69% (TR = 20.06 min, H = 47 mAU, W = 0.21
min); 1H NMR (300 MHz, DMSO-d6, ppm): 2.28 (s, 3H), 2.36 (s, 3H), 6.94 (d, 1H, J = 8.52 Hz),
7.08-7.18 (m, 3H), 7.22-7.27 (m, 1H), 7.35-7.37 (m, 2H), 7.72-7.76 (m, 2H), 7.89 (dd, 1H, J =
4.37 Hz), 8.78 (s, 1H), 9.02 (dd, 1H, J = 1.91 Hz), 9.18 (dd, 1H, J = 3.47 Hz), 9.34 (d, 1H, J =
8.58 Hz);

13

C NMR (300 MHz, DMSO-d6, ppm): 20.9, 21.1, 50.1, 121.6, 123.8, 124.5, 124.8,

125.2, 127.86, 127.91, 128.0, 128.1, 128.2, 128.4, 131.9, 133.0, 134.1, 134.2, 136.8, 137.5,
137.6, 140.9, 149.0, 157.7, 166.0; IR (cm-1): 626, 671, 696, 709, 773, 800, 829, 943, 1110, 1168,
1220, 1292, 1322, 1411, 1465, 1502, 1513, 1633, 3280.

206
N-((4-chlorophenyl)(8-hydroxy-5-nitroquinolin-7-yl)methyl)-3-methoxybenzamide (149)

Synthesized according to general procedure B using 4-chlorobenzaldehyde and 3methoxybenzamide; Yield: 16%; mp: 222 – 223 oC; Purity (HPLC): 254 nm: 87% (TR = 19.74
min, H = 255 mAU, W = 0.14 min), 280 nm: 76% (TR = 19.74 min, H = 36 mAU, W = 0.13
min); 1H NMR (300 MHz, DMSO-d6, ppm): 3.81 (s, 3H), 6.94 (d, 1H, J = 8.49 Hz), 7.12 (dd,
1H, J = 3.29 Hz), 7.35-7.54 (m, 7H), 7.90 (dd, 1H, J = 4.37 Hz), 8.76 (s, 1H), 9.02 (dd, 1H, J =
1.91 Hz), 9.20 (dd, 1H, J = 3.46 Hz), 9.42 (d, 1H, J = 8.52 Hz);

13

C NMR (300 MHz, DMSO-d6,

ppm): 49.8, 55.3, 112.9, 117.2, 119.8, 121.8, 123.2, 125.3, 128.0, 128.4, 129.3, 129.5, 131.9,
134.1, 135.4, 136.8, 139.8, 148.9, 158.0, 159.1, 165.8; IR (cm-1): 619, 647, 690, 723, 796, 842,
875, 941, 1014, 1037, 1093, 1186, 1207, 1245, 1282, 1311, 1344, 1409, 1465, 1496, 1517, 1590,
1629, 3288.

207
N-((8-hydroxy-5-nitroquinolin-7-yl)(p-tolyl)methyl)benzamide (150)

Synthesized according to general procedure B using 4-methylbenzaldehyde and benzamide;
Yield: 66%; mp: >250 oC; Purity (HPLC): Insoluble; 1H NMR (300 MHz, DMSO-d6, ppm): 2.28
(s, 3H), 6.96 (d, 1H, J = 8.52 Hz), 7.15-7.26 (m, 4H), 7.46-7.55 (m, 3H), 7.87-7.95 (m, 3H), 8.79
(s, 1H), 9.01 (dd, 1H, J = 1.90 Hz), 9.18 (dd, 1H, J = 3.46 Hz), 9.38 (d, 1H, J = 8.58 Hz); 13C
NMR (300 MHz, DMSO-d6, ppm): 21.1, 50.4, 122.1, 124.4, 125.7, 127.8, 128.1, 128.6, 128.7,
129.5, 131.9, 133.4, 133.7, 134.7, 134.8, 136.9, 137.3, 138.4, 149.5, 158.2, 166.5; IR (cm-1): 669,
680, 700, 727, 744, 771, 788, 800, 817, 892, 925, 1025, 1070, 1112, 1230, 1284, 1307, 1324,
1378, 1415, 1461, 1513, 1635, 3299.

N-((8-hydroxy-5-nitroquinolin-7-yl)(m-tolyl)methyl)benzamide (151)

Synthesized according to general procedure B using 3-methylbenzaldehyde and benzamide;
Yield: 19%; mp: 227 – 228 oC; Purity (HPLC): 254 nm: 93% (TR = 19.14 min, H = 918 mAU, W
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= 0.13 min), 280 nm: >99% (TR = 19.14 min, H = 62 mAU, W = 0.12 min; 1H NMR (300 MHz,
DMSO-d6, ppm); 2.78 (s, 3H), 6.96 (d, 1H, J = 8.55 Hz), 7.09-7.25 (m, 4H), 7.46-7.56 (m, 3H),
7.87-7.96 (m, 3H) 8.79 (s, 1H), 9.01 (dd, 1H, J = 1.91 Hz), 9.17, (d, 1H, J = 3.46 Hz), 9.38 (d,
1H, J = 8.58 Hz); 13C NMR (300 MHz, DMSO-d6, ppm): 21.1, 50.1, 121.6, 123.8, 124.5, 125.2,
127.6, 127.9, 128.2, 128.3, 128.4, 131.4, 133.0, 134.1, 134.2, 136.8, 137.6, 140.9, 149.0, 157.7,
165.9; IR (cm-1): 617, 674, 703, 773, 804, 850, 933, 1000, 1041, 1110, 1159, 1220, 1236, 1295,
1309, 1332, 1413, 1465, 1502, 1515, 1529, 1637, 3270, 3315.

N-((8-hydroxy-5-nitroquinolin-7-yl)(phenyl)methyl)-4-methylbenzamide (152)

Synthesized according to general procedure B using benzaldehyde and 4-methylbenzamide;
Yield: 67%; mp: 243 – 245 oC; Purity (HPLC): Insoluble; 1H NMR (300 MHz, DMSO-d6, ppm):
2.35 (s, 3H), 6.99 (d, 1H, J = 8.55 Hz), 7.29 (d, 3H, J = 7.95 Hz), 7.35 (d, 4H, J = 4.35 Hz), 7.857.91 (m, 3H), 8.80 (s, 1H), 9.01 (dd, 1H, J = 1.90 Hz), 9.17 (dd, 1H, J = 3.46 Hz), 9.35 (d, 1H, J
= 8.58 Hz); 13C NMR (300 MHz, DMSO-d6, ppm): 21.4, 50.6, 122.1, 124.3, 125.7, 127.7, 127.8,
128.1, 128.7, 129.0, 129.3, 131.8, 133.5, 134.8, 137.3, 141.5, 141.8, 149.5, 158.2, 166.4; IR
(cm-1): 636, 686, 705, 727, 746, 806, 829, 850, 889, 923, 1012, 1064, 1085, 1112, 11143, 1193,
1211, 1261, 1276, 1303, 1348, 1375, 1409, 1461, 1494, 1517, 1562, 1612, 1637, 3288, 3401.

209
N-((4-chlorophenyl)(8-hydroxy-5-nitroquinolin-7-yl)methyl)-4-methylbenzamide (153)

Synthesized according to general procedure B using 4-chlorobenzaldehyde and 4methylbenzamide; Yield: 57%; mp: 238 – 239 oC; Purity (HPLC): 254 nm: 81% (TR = 20.17
min, H = 562 mAU, W = 0.12 min), 280 nm: 84% (TR = 20.17 min, H = 24 mAU, W = 0.12
min); 1H NMR (300 MHz, DMSO-d6, ppm) 2.36 (s, 3H), 6.95 (d, 1H, J = 8.43 Hz), 7.29 (d, 2H,
J = 7.95 Hz), 7.35-7.44 (m, 4H), 7.83-7.93 (m, 3H), 8.76 (s, 1H), 9.02 (dd, 1H, J = 1.91 Hz), 9.19
(dd, 1H, J = 3.47 Hz), 9.35 (d, 1H, J = 8.52 Hz); 13C NMR (300 MHz, DMSO-d6, ppm): 20.9,
49.7, 121.8, 123.3, 125.3, 127.6, 128.0, 128.4, 129.3, 131.1, 131.8, 133.1, 134.1, 136.8, 139.9,
131.4, 148.9, 158.0, 165.9; IR (cm-1): 634, 673, 688, 719, 759, 798, 836, 906, 1016, 1095, 1112,
1186, 1216, 1282, 1322, 1409, 1461, 1502, 1532, 1627, 3301.

210
N-((4-chlorophenyl)(8-hydroxy-5-nitroquinolin-7-yl)methyl)-4-methoxybenzamide (154)

Synthesized according to general procedure B using 4-chlorobenzaldehyde and 4methoxybenzamide; Yield: 24%; mp: 244 – 245 oC; Purity (HPLC): 254 nm: 87% (TR = 19.54
min, H = 690 mAU, W = 0.13 min), 280 nm: 70% (TR = 19.54 min, H = 154 mAU, W = 0.13
min); 1H NMR (300 MHz, DMSO-d6, ppm): 3.81 (s, 3H), 6.94 (d, 1H, J = 8.46 Hz), 7.03 (d, 2H,
J = 2.97 Hz), 7.34-7.43 (m, 4H), 7.88-7.95 (m, 3H), 8.77 (s, 1H), 9.02 (dd, 1H, J = 1.90 Hz), 9.19
(dd, 1H, J = 3.46 Hz), 9.28 (d, 1H, J = 8.55 Hz); 13C NMR (300 MHz, DMSO-d6, ppm): 49.7,
55.4, 113.5, 121.8, 123.4, 125.3, 126.1, 128.0, 128.4, 129.3, 129.5, 131.8, 133.1, 134.1, 136.8,
140.1, 148.9, 158.0, 161.8, 165.4; IR (cm-1): 603, 630, 657, 673, 700, 732, 744, 802, 813, 844,
902, 925, 962, 1024, 1079, 1108, 1166, 1180, 1216, 1253, 1297, 1326, 1415, 1457, 1498, 1535,
1575, 1606, 1635, 3255.

211
Anthranilic Acid Derivatives

General Procedure A: Synthesis of (155), (158 – 166) Methyl Esters
Methyl 5-bromoanthranilate (156) (1.30 mmol) was dissolved in methylene chloride (5 mL).
Pyridine (9.78 mmol) was then added and the resulting mixture was cooled to 0 oC. A sulfonyl
chloride (1.57 mmol) was then added to the reaction mixture and the solution was allowed to
warm to room temperature and remained stirring for 24 h. The reaction mixture was then poured
over water (20 mL) and extracted with methylene chloride (2 x 15 mL). The combined organic
extract was rinsed with saturated sodium bicarbonate (30 mL), 1M HCl (30 mL) and brine (30
mL). The solution was then dried over sodium sulfate and concentrated to dryness. Products
were isolated following column chromatography (0 to 100%; EtOAc:Hexanes).

General Procedure B: Ester Hydrolysis of (155), (158 – 166)
Anthranilate sulfonamide ester (100 mg) was dissolved in THF (2 mL). Sodium hydroxide (2.85
M, 1mL) was then added to the reaction solution. The resulting mixture was heated to 40 oC and
was allowed to stir at elevated temperature overnight. After cooling to room temperature, HCl (1
M, 5 mL) was then added to the reaction solution. The resulting aqueous mixture was extracted
with ethyl acetate (2 x 15 mL) and the combined organic extract was rinsed with brine (30 mL).
The solution was then dried over sodium sulfate and the solvent was removed in vacuo to afford
desired products.

212
General Procedure C: Synthesis of (167 – 169) Methyl Esters
This procedure was adapted from a previously reported synthesis130
To a suspension of methyl-5-bromoanthranilate (156) (1.30 mmol),
tetrakis(triphenylphosphine)palladium(0) (0.07 mmol), and 1M sodium carbonate (1.47 mmol) in
toluene (4 mL) was added an aryl boronic acid (1.76 mmol) as a solution in methanol (1 mL).
The reaction mixture as then heated to 40 oC and was allowed to stir for 5 hrs at elevated
temperature. The mixture was then poured over water (5 mL) and was extracted with ethyl
acetate (2 x 10 mL). The combined organic extract was rinsed with brine (20 mL), dried over
sodium sulfate, and concentrated to dryness. Desired products were isolated following column
chromatography (0 to 100%; EtOAc:Hexanes).

General Procedure D: Ester Hydrolysis of (167 – 169)
5-Aryl anthranilate ester (100 mg) was dissolved in THF (2 mL). Sodium hydroxide (50% w/v, 2
mL) was then added to the reaction solution. The resulting mixture was heated to 40 oC and was
allowed to stir at elevated temperature overnight. After cooling to room temperature, HCl (3 M,
5 mL) was then added to the reaction solution. The resulting precipitate was filtered and rinsed
with H2O to afford desired products.

213
5-bromo-2-(4-chlorophenylsulfonamido)benzoic acid (155)

Synthesized according to general procedures A and B using 4-chlorobenzenesulfonyl chloride;
Yield (A,B): 83%, 96%; mp: 221 – 222 oC (decomp); Purity (HPLC): 254 nm: >99% (TR =
19.28 min, H = 1676 mAU, W = 0.13 min), 280 nm: >99% (TR = 19.28 min, H = 392 mAU, W =
0.11 min); 1H NMR (500 MHz, Acetone-d6, ppm): 7.61 (dt, 2H, J = 2.28 Hz), 7.66 (d, 1H, J =
8.90 Hz), 7.74 (dd, 1H, J = 3.80 Hz), 7.88 (d, 2H, J = 4.35 Hz), 8.10 (d, 1H, J = 2.41 Hz); 13C
NMR (500 MHz, Acetone-d6, ppm): 115.3, 118.0, 120.8, 129.0, 129.6, 134.0, 137.4, 137.9,
139.3, 139.7, 168.2; IR (cm-1): 613, 630, 655, 684, 701, 754, 831, 875, 921, 968, 1010, 1083,
1166, 1180, 1241, 1290, 1307, 1349, 1390, 1436, 11477, 1567, 1658, 2850, 3093, 3216.

5-bromo-2-(methylsulfonamido)benzoic acid (158)

Synthesized according to general procedures A and B using mesyl chloride; Yield (A,B): 70%,
94%; mp: 211 – 213 oC (decomp); Purity (HPLC): 254 nm: >99% (TR = 13.41 min, H = 1417
mAU, W = 0.21 min), 280 nm: Neg. Abs.; 1H NMR (500 MHz, DMSO-d6, ppm): 3.22 (s, 3H),
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7.55 (d, 1H, J = 8.90 Hz), 7.82 (dd, 1H, J = 3.80 Hz), 8.08 (d, 1H, J = 2.50 Hz), 10.69 (s, 1H);
13

C NMR (500 MHz, DMSO-d6, ppm): 40.5, 114.7, 119.0, 120.6, 134.1, 137.5, 140.2, 168.8; IR

(cm-1): 655, 682, 696, 757, 806, 831, 844, 925, 966, 1087, 1101, 1147, 1166, 1241, 1290, 1315,
1332, 1384, 1419, 1442, 1479, 1567, 1658, 2937, 3027, 3224.

5-bromo-2-(phenylmethylsulfonamido)benzoic acid (159)

Synthesized according to general procedures A and B using phenylmethanesulfonyl chloride;
Yield (A,B): 40%, 86%; mp: 213 – 215 oC (decomp); Purity (HPLC): 254 nm: 98% (TR = 18.36
min, H = 1304, W = 0.12 min), 280 nm: Neg. Abs.; 1H NMR (500 MHz, Acetone-d6, ppm): 4.64
(s, 2H), 7.28-7.35 (m, 5H), 7.64 (d, 1H, J = 8.95 Hz), 7.72 (dd, 1H, J = 3.80 Hz), 8.18 (d, 1H, J =
2.45 Hz); 13C NMR (500 MHz, Acetone-d6, ppm): 57.9, 114.1, 116.7, 119.5, 128.5, 128.6, 129.0,
130.8, 133.9, 136.5, 137.4, 141.0, 168.0; IR (cm-1): 601, 622, 661, 694, 723, 777, 827, 840, 889,
937, 1093, 1141, 1243, 1288, 1313, 1340, 1390, 1415, 1444, 1481, 1569, 1654, 3195.

215
5-bromo-2-(thiophene-2-sulfonamido)benzoic acid (160)

Synthesized according to general procedures A and B using 2-thiophenesulfonyl chloride; Yield
(A,B): 56%, 94%; mp: 190 – 191 oC (decomp); Purity (HPLC): 254 nm: 97% (TR = 14.80 min,
H = 1853 mAU, W = 0.14 min), 280 nm: >99% (TR = 14.80 min, H = 740 mAU, W = 0.11 min);
1

H NMR (500 MHz, Acetone-d6, ppm): 7.13 (dd, 1H, J = 2.93 Hz), 7.70 (dd, 1H, J = 1.70 Hz),

7.74 (d, 1H, J = 8.90 Hz), 7.80 (dd, 1H, J = 3.78 Hz), 7.88 (dd, 1H, 2.12 Hz), 8.13 (d, 1H, J =
2.40 Hz); 13C NMR (500 MHz, Acetone-d6, ppm): 115.4, 118.1, 120.9, 127.7, 133.5, 133.8,
134.0, 137.4, 139.4, 139.7, 168.2; IR (cm-1): 653, 669, 734, 802, 827, 840, 914, 1018, 1093,
1149, 1164, 1205, 1240, 1328, 1344, 1384, 1402, 1432, 1479, 1573, 1592, 1668, 1704, 3106,
3185, 3237.

5-bromo-2-(phenylsulfonamido)benzoic acid (161)

Synthesized according to general procedures A and B using benzenesulfonyl chloride; Yield
(A,B): 54%, 97%; mp: 178 – 180 oC (decomp); Purity (HPLC): 254 nm: 99% (TR = 17.85 min,
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H = 1740 mAU, W = 0.13 min), 280 nm: 90% (TR = 17.85 min, H = 189 mAU, W = 0.12 min);
1

H NMR (500 MHz, Acetone-d6, ppm): 7.57 (dt, 2H, J = 3.07 Hz), 7.63-7.69 (m, 2H), 7.73 (dd,

1H, J = 3.78 Hz), 7.88 (dt, 2H, J = 1.91 Hz), 8.09 (d, 1H, J = 2.40 Hz); 13C NMR (500 MHz,
DMSO-d6, ppm): 115.0, 117.9, 120.6, 127.1, 129.4, 133.5, 133.9, 137.3, 139.2, 140.0, 168.2; IR
(cm-1): 657, 686, 719, 759, 792, 827, 842, 921, 1089, 1155, 1166, 1241, 1309, 1344, 1384, 1429,
1477, 1571, 1668, 3199.

5-bromo-2-(4-fluorophenylsulfonamido)benzoic acid (162)

Synthesized according to general procedures A and B using 4-fluorobenzenesulfonyl chloride;
Yield (A,B): 82%, 93%; mp: 198 – 200 oC (decomp); Purity (HPLC): 254 nm: 99% (TR = 18.38,
H = 1778 mAU, W = 0.14 min), 280 nm: >99% (TR = 18.38 min, H = 158 mAU, W = 0.11 min);
1

H NMR (500 MHz, Acetone-d6, ppm): 7.33 (dt, 2H, J = 2.94 Hz), 7.66 (d, 1H, J = 8.90 Hz),

7.75 (dd, 1H, J = 3.78 Hz), 7.96 (ddd, 2H, J = 2.33 Hz), 8.10 (d, 1H, J = 2.40 hz); 13C NMR (500
MHz, Acetone-d6, ppm): 115.2, 116.5 (d), 118.0, 120.8, 130.3 (d), 134.0, 135.4, 137.4, 139.8,
164.3, 165.3 (d), 168.2; IR (cm-1): 657, 692, 707, 827, 896, 923, 1087, 1151, 1170, 1234, 1288,
1309, 1342, 1388, 1430, 1479, 1569, 1590, 1664, 2852, 3241.

217
2-([1,1'-biphenyl]-4-ylsulfonamido)-5-bromobenzoic acid (163)

Synthesized according to general procedures A and B using [1,1’-biphenyl]-4-sulfonyl chloride;
Yield (A,B): 48%, 92%; mp: 232 – 235 oC (decomp); Purity (HPLC): 254 nm: >99% (TR =
20.88 min, H = 1703 mAU, W = 0.12 min), 280 nm: >99% (TR = 20.88 min, H = 1775, W = 0.12
min); 1H NMR (500 MHz, Acetone-d6, ppm): 7.41-7.50 (m, 3H), 7.67-7.78 (m, 4H), 7.83 (dt,
2H, J = 2.52 Hz), 7.96 (dt, 2H, J = 2.53 Hz), 8.10 (d, 1H, J = 2.32 Hz); 13C NMR (500 MHz,
Acetone-d6, ppm): 115.0, 117.7, 120.5, 127.2, 127.7, 127.8, 128.6, 129.1, 134.0, 137.4, 137.8,
138.8, 140.1, 245.9, 168.2; IR (cm-1): 624, 657, 669, 690, 715765, 829, 838, 923, 1004, 1089,
1155, 1166, 1241, 1309, 1344, 1384, 1429, 1477, 1573, 1594, 1668, 3195.

5-bromo-2-(3-chlorophenylsulfonamido)benzoic acid (164)

Synthesized according to general procedures A and B using 3-chlorobenzene sulfonyl chloride;
Yield (A,B): 85%, 88%; mp: 191 – 193 oC (decomp); Purity (HPLC): 254 nm: >99% (TR =
18.88 min, H = 1347 mAU, W = 0.12 min), 280 nm: >99% (TR = 18.88 min, H = 356 mAU, W =
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0.12 min); 1H NMR (500 MHz, Acetone-d6, ppm): 7.60 (t, 1H, J = 7.95 Hz), 7.67-7.70 (m, 2H),
7.77 (dd, 1H, J = 3.80 Hz), 7.83 (ddd, 1H, J = 1.51 Hz), 7.87 (t, 1H, J = 1.90 Hz), 8.11 (d, 1H, J
= 2.45 Hz); 13C NMR (500 MHz, Acetone-d6, ppm): 115.4, 118.3, 120.8, 125.7, 126.9, 131.3,
133.5, 134.0, 134.7, 137.4, 139.5, 141.0, 168.2; IR (cm-1): 603, 657, 674, 784, 821, 842, 873,
933, 1083, 1108, 1170, 1236, 1290, 1344, 1388, 1434, 1481, 1573, 1668, 3195.

5-bromo-2-(3-fluorophenylsulfonamido)benzoic acid (165)

Synthesized according to general procedures A and B using 3-fluorobenzene sulfonyl chloride;
Yield (A,B): 83%, 93%; mp: 184 – 186 oC (decomp); Purity (HPLC): 254 nm: >99% (TR =
18.66 min, H = 1085 mAU, W = 0.12 min), 280 nm: >99% (TR = 18.66 min, H = 299 mAU, W =
0.12 min); 1H NMR (Acetone-d6, ppm): 7.45 (tdd, 1H, J = 1.86 Hz), 7.62-7.78 (m, 5H), 8.11 (d,
1H, J = 2.45 Hz); 13C NMR (500 MHz, Acetone-d6, ppm): 114.2 (d), 115.4, 118.1, 120.6 (d),
120.8, 123.3 (d), 131.7 (d), 134.0, 137.4, 139.6, 141.1 (d), 162.3 (d), 168.2; IR (cm-1): 611, 653,
674, 696, 786, 823, 842, 881, 923, 1085, 1133, 1164, 1226, 1272, 1309, 1332, 1346, 1386, 1436,
1479, 1573, 1592, 1670, 1700, 3199.
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4-amino-4'-chloro-[1,1'-biphenyl]-3-carboxylic acid (166)

Synthesized according to general procedures C and D using (4-chlorophenyl)boronic acid; Yield
(C,D): 59%, 99%; mp: 224 – 226 oC (decomp); Purity (HPLC): 254 nm: 90% (TR = 19.05 min,
H = 674 mAU, W = 0.12 min), 280 nm: 97% (TR = 19.06 min, H = 1626 mAU, W = 0.17 min);
1

H NMR (300 MHz, DMSO-d6, ppm): 6.86 (d, 1H, J = 8.67 Hz), 7.42-7.62 (m, 5H), 7.98 (d, 1H,

J = 2.22 Hz); 13C NMR (300 MHz, DMSO-d6, ppm): 110.7, 117.8, 125.8, 127.6, 129.23, 129.25,
131.3, 132.5, 139.1, 151.2, 169.8; IR (cm-1): 669, 690, 750, 784, 815, 1010, 1103, 1166, 1189,
1236, 1303, 1322, 1427, 1481, 1506, 1556, 1583, 1623, 1677, 3384, 3498.

4-amino-4'-nitro-[1,1'-biphenyl]-3-carboxylic acid (167)

Synthesized according to general procedures C and D using (4-nitrophenyl)boronic acid; Yield
(C,D): 61%, 99%; mp: >250 oC; Purity (HPLC): 254 nm: Neg. Abs., 280 nm: Neg. Abs.; 1H
NMR (300 MHz, DMSO-d6, ppm):6.72 (d, 1H, J = 8.40 Hz), 7.54 (d, 1H, J = 6.51 Hz), 7.82 (d,
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2H, J = 8.52 Hz), 8.19-8.28 (m, 3H); 13C NMR (300 MHz, DMSO-d6, ppm): 116.5, 119.4, 122.9,
124.6, 125.7, 129.6, 131.2, 145.1, 148.0, 171.9; IR (cm-1): 617, 688, 713, 750, 821, 852, 1110,
1166, 1193, 1257, 1334, 1378, 1434, 1496, 1538, 1589, 1614, 1681, 3305, 3382.

4-amino-3'-nitro-[1,1'-biphenyl]-3-carboxylic acid (168)
1

Synthesized according to general procedures C and D using (3-nitrophenyl)boronic acid; Yield
(C,D): 61%, 99%; mp: >250 oC; Purity (HPLC): 254 nm: >99% (TR = 17.19 min, H = 836 mAU,
W = 0.19 min), 280 nm: >99% (TR = 17.23 min, H = 997 mAU, W = 0.19 min); 1H NMR (300
MHz, DMSO-d6, ppm): 6.90 (d, 1H, J = 8.70 Hz), 7.73 (dd, 1H, J = 3.46 Hz), 7.84 (d, 2H, J =
8.70), 8.14-8.24 (m, 3H); 13C NMR (300 MHz, DMSO-d6, ppm): 110.4, 117.8, 120.0, 121.2,
124.3, 129.9, 130.8, 132.3, 132.6, 141.9, 148.9, 152.2, 169.8; IR (cm-1): 676, 692, 738, 792, 821,
860, 912, 1172, 1245, 1303, 1334, 1353, 1421, 1473, 1504, 1525, 1666, 3394, 3500.

CHAPTER 5
CONCLUSIONS

The projects explored and discussed herein are broadly related in the practical application
of synthetic and analytical chemistry, as well as biochemistry. Each project began with the
identification of a biological target (either a macromolecule or pathogenic unicellular species).
We focused on the inhibition of enzyme species (urease and MetAP) and malarial pathogens,
using literature detailing the inhibition of these targets as a starting point for the development of
potent inhibitors. Attractive compounds were then synthesized or purchased and screened against
the respective target. The resulting SARs were then used to design more potent inhibitors.
Although our efforts regarding the inhibition of urease focused on the development of an assay,
potent compounds were discovered for both the antimalarial and MetAP projects.
The first project involved the screening of natural products (tannins) against urease
isolated from jack bean for enzymatic inhibitory activity. The results from the in vitro enzymatic
assay were correlated with results obtained by collaborators (Wayne Zeller, USDA) regarding
the ammonia abatement of bovine excrement by tree bark extracts rich in tannins where
ammonia production was monitored in a simulated dairy barn floor. A test set of compounds was
first screened to determine the relative inhibitory activities for comparison with the simulated
barn floor, followed by the screening of the raw bark extract in each assay. While a relative
correlation was observed regarding the activities of the test compound set in both assays, the in
vitro enzymatic assay was able to distinguish activities between the various tree bark species,
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where the ex vivo simulated barn floor assay found similar activites regardless of the bark
identity. Future efforts will involve the separation of the tree bark by extraction with solvents of
increasing polarity.
The second project involved the exploration of flavonoids as antimalarial
chemotherapies. Because quercetin, a natural product found distributed within plant sources, had
been previously published as exhibiting weak antimalarial activity48, we began our discovery
efforts utilizing this compound as a nucleophile for Mannich reactions. The most significant
drawbacks involving the use of quercetin for the development of novel antimalarials are
promiscuous enzyme activity and minimal aqueous solubility. Of these, it would be easiest to
first attempt to increase the solubility of the quercetin scaffold by the addition of amine groups
via the Mannich reaction. A total of 18 compounds were therefore synthesized and converted to
HCl or TFA salts and screened for antimalarial activity against three drug-resistant strains of the
malarial parasite (Richard Sciotti, WRAIR). To our delight, the most potent compounds were
discovered to exhibit sub-micromolar (~70 nM) activity against parasite proliferation.
Additionally, the aqueous solubility of each compound was determined and the most potent
compounds were not the most soluble compounds, suggesting the observed activity is
structurally based. Finally, the in vivo activity data against each malarial strain was utilized to
construct CoMFA models of the steric and electrostatic contribution to the observed activity of
each compound. Of the models generated, two were found to be suitable and could be used to
guide future discovery efforts.
Finally, the third project involved the synthesis and screening of suspected MetAP
inhibitory compounds as broad spectrum antibacterial species. A series of compounds based
upon reported MetAP hit motifs were therefore synthesized or purchased, and screened for
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enzymatic inhibitory activity. Synthesized compounds were based upon furoic acid, 1,2,4triazole, quinolinol, and anthranilic acid scaffolds. Of these, furoic acid based inhibitors were
found to exhibit the most potent activity. Computational modeling was then used to aid in the
design of more potent inhibitors. Although docking methods are known to have a low tolerance
for metalloenzymes and often provide misleading output,132 the predicted binding pose and
relative binding affinities were found to correlate to those observed through experimentation.
The most potent species from each chemical class were then sent to collaborators for
screening in a host-cell viability assay to determine anti-Rickettsial activity in the presence of
mammalian (rat) host cells. It was found that inhibitory compounds based upon the quinolinol
scaffold were the most potent antibacterial agents in vivo. Finally, a library of suspected
inhibitors was screened in the MetAP inhibitory assay to discern novel chemical space that had
not been previously reported. A total of 294 compounds were screened for enzymatic inhibitory
activity and 11 compounds were found to exhibit IC50 values of less than 10 µM. Of these, only
two were based upon unreported hit motifs, while the most potent compounds were determined
to be furoic acid derivatives. Future discovery efforts will focus on the optimization of this
chemical class of inhibitors by synthesizing suspected inhibitory compounds and screening for in
vitro activity.
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APPENDIX A
DOSE-RESPONSE CURVES FOR UREASE INHIBITION
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NBPT (Agrotain®)

Dose-response curve for inhibition of JBU by NBPT. The compound was screened at the
following final concentrations (nM): 0, 10, 30, 50, 100, 150, 200, 300, 400, 500, 750, 1000.
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(+)-Catechin

Dose-response curve for inhibition of JBU by (+)-catechin. The compound was screened at the
following final concentrations (µM): 0, 1, 5, 10, 25, 50, 75, 100, 250, 500, 750, 1000, 2500,
5000.

243
(-)-Epicatechin

Dose-response curve for inhibition of JBU by (-)-epicatechin. The compound was screened at the
following final concentrations (µM): 0, 0.1, 0.25, 0.5, 1, 5, 10, 50, 100, 200, 500, 1000, 2000.
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1,2,3,4,6-Pentagalloyl glucose (PGG)

PGG (6) Structure on page 25

Dose-response curve for inhibition of JBU by PGG. The compound was screened at the
following final concentrations (µM): 0, 1, 5, 10, 25, 50, 75, 100, 250, 500, 750, 1500, 3000,
6000.
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Tannic Acid

Tannic acid (10) structure on page 25

Dose-response curve for inhibition of JBU by tannic acid. Tannic acid is supplied as a mixture;
concentrations are therefore reported in ng/mL. The mixture was screened at the following final
concentrations (ng/mL): 0, 0.1, 1, 5, 10, 25, 50, 75, 100, 200, 350, 500, 750, 1000.
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(-)-Epigallocatechin gallate

Dose-response curve for inhibition of JBU by (-)-epicatechin gallate. The compound was
screened at the following final concentrations (µM): 0, 0.1, 0.3, 0.5, 1, 3, 10, 50, 100, 200.
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Quebracho Extract

Dose-response curve for inhibition of JBU by quebracho tannin extract. Bark extracts are
supplied as mixtures; concentrations are therefore reported in ng/mL. The mixture was screened
at the following final concentrations (ng/mL): 0, 10, 25, 50, 100, 250, 500, 1000, 2500, 5000,
10,000, 25,000, 50,000, 100,000, 250,000.
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Chestnut Extract

Dose-response curve for inhibition of JBU by chestnut tannin extract. Bark extracts are supplied
as mixtures; concentrations are therefore reported in ng/mL. The mixture was screened at the
following final concentrations (ng/mL): 0, 5, 10, 25, 50, 100, 200, 350, 500, 750, 1000, 2500,
5000, 10,000.
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Quebracho/Chestnut Extract

Dose-response curve for inhibition of JBU by quebracho/chestnut tannin mixture. Bark extracts
are supplied as mixtures; concentrations are therefore reported in ng/mL. The mixture was
screened at the following final concentrations (ng/mL): 0, 10, 25, 50, 100, 250, 500, 1000, 2500,
5000, 10,000, 25,000, 50,000, 100,000.

APPENDIX B
RESULTS OF LIBRARY SCREENING
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Table 29: Results of Library Screening

Otava Vial
Number

% Inhiba

RpMetAP
IC50b

484

1121266

12 ± 47

-

485

7020090343

13 ± 58

-

486

1088027

34 ± 49

-

487

1033790

31 ± 52

-

488

1055076

13 ± 49

-

489

1055338

14 ± 45

-

461

1901307

2 ± 51

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

490

1215761

-4 ± 50

-

491

1036175

32 ± 55

-

492

1035592

3 ± 51

-

493

1035603

41 ± 1

-

494

1805699

85 ± 6

1.099 ±
0.037

495

2655632

8 ± 34

-

496

1317786

32 ± 4

-

497

1035775

21 ± 13

-

498

1779335

13 ± 3

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

499

1035776

15 ± 24

-

500

1035778

9 ± 32

-

501

1783389

14 ± 34

-

502

1035777

16 ± 36

-

503

1055332

22 ± 43

-

504

1218750

8±5

-

505

1055050

47 ± 3

-

506

1593018

9±5

-

507

4000134

44 ± 3

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

508

4197423

82 ± 2

1.441 ±
0.034

509

5569469

43 ± 2

-

510

1136789

Insoluble

-

511

4250112

38 ± 6

-

512

5730446

1 ± 29

-

513

0107830098

13 ± 40

-

514

2293342

47 ± 5

-

515

6641942

2 ± 47

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)

255
Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

516

1876136

5 ± 56

-

517

3695544

9 ± 56

-

26

1188902

10 ± 66

-

518

1121225

31 ± 70

-

519

3705848

38 ± 5

-

520

2085856

13 ± 77

-

521

701400172

20 ± 76

-

522

7110950063

4 ± 76

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

523

7218190011

32 ± 49

-

524

7110940280

47 ± 14

-

525

7017520059

48 ± 14

-

526

7115740117

44 ± 12

-

527

7115740131

51 ± 21

>100

528

7112904514

54 ± 20

>100

529

7218010901

66 ± 6

>100

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

530

7115740095

19 ± 2

-

531

7115740099

18 ± 7

-

532

7115740105

15 ± 12

-

533

7115740144

15 ± 12

-

534

7119960238

14 ± 9

-

535

7110940282

12 ± 10

-

772

7110940281

11 ± 10

-

536

7110950104

15 ± 12

-

537

7015170012

15 ± 11

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

538

7215700055

17 ± 10

-

539

7110940279

22 ± 4

-

540

7110940259

21 ± 6

-

541

7110940255

23 ± 5

-

542

7110940246

20 ± 6

-

543

7110940240

18 ± 9

-

544

7110940237

16 ± 10

-

545

7110940223

16 ± 8

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

546

7110940215

16 ± 6

-

547

7110940302

17 ± 3

-

548

7110940406

19 ± 3

-

549

7110940235

36 ± 1

-

550

7110940228

33 ± 3

-

551

7110940224

34 ± 3

-

552

7110940214

28 ± 1

-

553

7110940303

29 ± 2

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

554

7110940278

31 ± 3

-

555

7110940275

29 ± 3

-

556

7110940260

23 ± 4

-

557

7110940254

22 ± 5

-

558

7110940252

53 ± 2

>100

559

7110940245

37 ± 47

-

560

7110940243

43 ± 57

-

561

7110940239

46 ± 46

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

562

7110940238

47 ± 42

-

563

7110940236

48 ± 41

-

564

7212080016

62 ± 25

45.4 ±
12.1

565

7110940363

49 ± 22

-

566

7110940353

68 ± 19

38.8 ±
14.6

567

7110940407

66 ± 15

22.9 ± 3.5

568

7110940404

41 ± 11

-

569

7110940541

20 ± 33

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

570

7110940539

21 ± 44

-

571

7212010196

17 ± 41

-

572

7012790058

18 ± 43

-

573

128760441

18 ± 42

-

574

157802

67 ± 34

0.273 ±
0.011

575

7216513158

26 ± 48

-

576

0128660156

18 ± 39

-

577

7119870010

15 ± 37

-

578

1088043

16 ± 28

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

579

7015170002

20 ± 32

-

580

0111070242

22 ± 28

-

581

7018880317

18 ± 27

-

582

7119920654

32 ± 30

-

583

1361748

29 ± 23

-

584

1035580

29 ± 19

-

585

114090184

30 ± 21

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

586

7014211646

31 ± 25

-

587

7210540035

36 ± 22

-

588

1033420

30 ± 25

-

589

7014000193

17 ± 27

-

590

7216050514

18 ± 28

-

591

0109160035

54 ± 37

3.72 +/0.22

592

0109160041

21 ± 36

-

593

7020601178

10 ± 35

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

594

7015170011

18 ± 50

-

595

7119510008

24 ± 54

-

596

7015170010

25 ± 48

-

597

7110940218

28 ± 53

-

598

7110940355

24 ± 52

-

599

7413920214

47 ± 20

-

600

7020601871

35 ± 23

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

601

7020570049

41 ± 25

-

602

7014000160

44 ± 29

-

603

7014000161

46 ± 29

-

604

7014000165

45 ± 27

-

605

7014000167

42 ± 29

-

606

7014000168

39 ± 30

-

607

7014000169

35 ± 32

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

608

7014000174

24 ± 20

-

609

7014000204

46 ± 44

-

610

7014000157

38 ± 40

-

611

7014000177

50 ± 40

8.35 ±
0.88

612

7014000194

37 ± 41

-

613

7014350010

35 ± 39

-

614

7014000170

35 ± 40

-

615

7014000171

37 ± 37

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

616

7014000176

34 ± 35

-

617

7014000195

32 ± 39

-

618

7014000196

28 ± 38

-

619

7014000203

18 ± 2

-

620

7014000192

37 ± 15

-

621

7014000205

28 ± 6

-

622

7017470659

38 ± 9

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

623

7017470656

39 ± 6

-

624

7017470662

36 ± 4

-

625

7017470663

51 ± 4

33.00 +/5.37

626

1017470664

38 ± 3

-

627

7016400121

27 ± 7

-

628

7017470654

1±3

-

629

7017470655

29 ± 20

-

388

7017470661

27 ± 14

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

257

7020594687

29 ± 8

-

630

7018771010

32 ± 6

-

27

7020090337

36 ± 1

-

631

7020090339

44 ± 3

-

632

7018661215

41 ± 7

-

633

7018661216

63 ± 5

12.57 +/1.51

634

7018661220

78 ± 7

5.02 +/0.64

635

7018661221

57 ± 11

11.18 +/3.55

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

636

7018771001

11 ± 16

-

637

7018771004

11 ± 9

-

638

7020090331

37 ± 14

-

639

7020090332

28 ± 13

-

640

7020090340

26 ± 11

-

641

7015170013

25 ± 15

-

642

7020430830

30 ± 11

-

643

7014000175

64 ± 5

9.42 ±
0.68

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

644

7017470653

27 ± 10

-

645

7017470657

11 ± 12

-

646

7020090333

45 ± 18

-

647

7014000189

34 ± 24

-

648

7020090314

36 ± 24

-

649

7020330044

28 ± 29

-

650

1087374

47 ± 24

-

651

1033297

28 ± 25

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

652

7119330078

23 ± 30

-

653

1121269

27 ± 28

-

654

1121271

28 ± 27

-

655

7119930282

50 ± 5

3.13 ±
0.29

656

7014000202

46 ± 16

-

657

7014000199

52 ± 27

>100

658

1035945

46 ± 14

-

659

7020710057

46 ± 12

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

660

7020710056

50 ± 6

>100

661

1344540

51 ± 16

>100

662

2125368

51 ± 6

>100

663

7020618387

53 ± 13

>100

664

7119870051

47 ± 4

-

665

1298458

46 ± 6

-

666

0112842205

55 ± 14

>100

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

667

1888464

47 ± 4

-

668

7110952702

48 ± 5

-

669

1056615

47 ± 6

-

670

1060301

56 ± 4

>100

671

1981275

53 ± 9

>100

672

3485522

60 ± 6

>100

673

1045880

69 ± 30

>100

674

1112063

50 ± 4

>100

675

7114890061

89 ± 1

9.99 ±
1.51

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

676

2190301

25 ± 5

-

677

2190308

26 ± 1

-

678

2275507

28 ± 1

-

679

5044306

26 ± 2

-

680

3644630

38 ± 1

-

681

7119831751

32 ± 1

-

682

4434694

29 ± 3

-

683

4434993

29 ± 1

-

684

7118560478

28 ± 4

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

685

4802692

27 ± 7

-

686

7020618355

0 ± 32

-

687

1218740

12 ± 34

-

688

1312616

10 ± 33

-

689

1312628

15 ± 26

-

690

4434818

14 ± 24

-

691

4435004

17 ± 24

-

692

4435098

19 ± 19

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

693

4435291

25 ± 16

-

694

3165404

26 ± 17

-

695

0125330235

20 ± 20

-

696

4802716

6±4

-

697

6056939

10 ± 1

-

698

1101952

19 ± 4

-

699

4788998

13 ± 4

-

700

3148357

11 ± 8

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

701

6466238

24 ± 6

-

702

1090522

28 ± 8

-

703

1051746

15 ± 5

-

704

1055218

17 ± 10

-

705

1055475

61 ± 10

0.403 ±
0.070

706

2819415

53 ± 21

11.505 ±
2.822

707

6666324

36 ± 28

-

708

3461329

21 ± 27

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

709

1055496

19 ± 27

-

710

1148900

20 ± 28

-

711

2201799

13 ± 2

-

712

0105860029

28 ± 27

-

713

6328802

21 ± 23

-

714

1007086

30 ± 22

-

715

1705230

27 ± 23

-

716

2153749

16 ± 10

-

717

6057970

8±7

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

718

7127352

2 ± 28

-

719

4788159

12 ± 21

-

720

4788448

15 ± 14

-

721

4788577

14 ± 11

-

722

4790094

19 ± 4

-

723

4790597

25 ± 2

-

724

4790632

14 ± 2

-

725

4792499

20 ± 10

-

726

4793712

3 ± 68

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

727

4802121

5 ± 63

-

728

6057143

6 ± 60

-

729

7020330001

32 ± 11

-

730

7020330009

0 ± 55

-

731

7119984200

21 ± 54

-

732

7119987169

15 ± 47

-

733

7020618384

7 ± 45

-

734

7020618385

33 ± 16

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)

283
Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

735

7020661688

2 ± 43

-

736

7020662802

19 ± 30

-

737

7020684966

27 ± 25

-

738

1087372

78 ± 4

1.185 +/0.124

739

1257901

30 ± 20

-

740

1257945

30 ± 19

-

741

1288000

32 ± 15

-

742

1312340

33 ± 17

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

(Continued on next page)

284
Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

743

1312344

25 ± 25

-

744

1312348

30 ± 13

-

746

1312354

15 ± 39

-

747

1312378

18 ± 41

-

748

1312380

15 ± 38

-

749

1691978

3 ± 35

-

750

2189828

33 ± 17

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

751

2189829

46 ± 13

-

752

2190757

48 ± 12

-

753

21991153

42 ± 11

-

754

2191395

Insoluble

-

755

2191420

Insoluble

-

756

2194057

48 ± 11

-

757

2195684

14 ± 31

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

758

3710257

5 ± 39

-

759

5006202

20 ± 44

-

760

6138894

18 ± 49

-

761

7017690273

13 ± 41

-

762

7020618386

19 ± 37

-

763

1087361

45 ± 35

-

764

3461631

51 ± 26

14.318 ±
3.506

765

3462737

41 ± 22

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM
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Table 29: Continued
Otava Vial
Number

% Inhiba

RpMetAP
IC50b

766

3463436

55

Insoluble

767

6237511

44 ± 2

-

768

6667344

49 ± 3

-

769

6667345

47 ± 3

-

770

6667348

46 ± 1

-

771

6667380

44 ± 1

-

HGN #

a.
b.

Structure

Percent inhibition of enzyme activity at 10 µM versus uninhibited control
IC50 values expressed in unites of µM

APPENDIX C
1

H AND 13C NMR OF SYNTHESIZED COMPOUNDS
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8-(phenethylaminomethyl)quercetin (14)

290
8-(2,4-dichlorophenethylaminomethyl)quercetin (15)

291
8-(3-chlorophenethylaminomethyl)quercetin (16)

292
8-(3-fluorophenethylaminomethyl)quercetin (17)

293
8-(2-fluorophenethylaminomethyl)quercetin (18)

294
8-(4-fluorophenethylaminomethyl)quercetin (19)

295
8-(2,6-dichlorophenethylaminomethyl)quercetin(20)

296
8-(2-chlorophenethylaminomethyl)quercetin(21)

297
8-(4-chlorophenethylaminomethyl)quercetin(22)

298
8-(benzylaminomethyl)quercetin (23)

299
8-(3-chlorobenzylaminomethyl)quercetin (24)

300
8-(4-chlorobenzylaminomethyl)quercetin (25)

301
8-(4-fluorobenzylaminomethyl)quercetin (26)

302
8-(3-fluorobenzylaminomethyl)quercetin(27)

303
8-(furfurylaminomethyl)quercetin(28)

304
8-(tetrahydrofurfurylaminomethyl)quercetin (29)

305
8-(1-methylpiperizinomethyl)quercetin(30)

306
6,8-(Dipiperidinomethyl)quercetin(31)

307
1-(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)ethanone (109)

308
[1,1'-biphenyl]-4-yl(5-amino-3-(4-methylbenzyl)thio-1H-1,2,4-triazol-1-yl)methanone (110)

309
1-(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)-2-methylpropan-1-one (111)

310
1-(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)-2-phenylethanone (112)

311
1-(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)-3-phenylpropan-1-one (113)

312
(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)(4-DMAP) methanone (114)

313
[1,1'-biphenyl]-3-yl(5-amino-3-(4-methylbenzyl)thio-1H-1,2,4-triazol-1-yl)methanone (115)

314
(5-amino-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-1-yl)(phenyl)methanone (116)

315
1-((4-chlorophenyl)sulfonyl)-3-((4-methylbenzyl)thio)-1H-1,2,4-triazol-5-amine (117)

316
N-((5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl)benzamide (126)

317
N-((5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl)-3-methylbenzamide (127)

318
N-((5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl)-3-methoxybenzamide (128)

319
N-((5-chloro-8-hydroxyquinolin-7-yl)(p-tolyl)methyl)-3-methoxybenzamide (129)

320
N-((5-chloro-8-hydroxyquinolin-7-yl)(4-chlorophenyl)methyl)-3-methoxybenzamide (130)

321
N-((5-chloro-8-hydroxyquinolin-7-yl)(p-tolyl)methyl)-3-methylbenzamide (131)

322
N-((5-chloro-8-hydroxyquinolin-7-yl)(4-chlorophenyl)methyl)-3-methylbenzamide (132)

323
N-((5-chloro-8-hydroxyquinolin-7-yl)(p-tolyl)methyl)benzamide (133)

324
N-((5-chloro-8-hydroxyquinolin-7-yl)(m-tolyl)methyl)benzamide (134)

325
N-((5-chloro-8-hydroxyquinolin-7-yl)(3-chlorophenyl)methyl)benzamide (135)

326
N-((5-chloro-8-hydroxyquinolin-7-yl)(phenyl)methyl)-4-methylbenzamide (136)

327
N-((5-chloro-8-hydroxyquinolin-7-yl)(p-tolyl)methyl)-4-methylbenzamide (137)

328
N-((5-chloro-8-hydroxyquinolin-7-yl)(4-chlorophenyl)methyl)-4-methylbenzamide (138)

329
N-((5-chloro-8-hydroxyquinolin-7-yl)(3-chlorophenyl)methyl)-4-methylbenzamide (139)

330
N-((5-chloro-8-hydroxyquinolin-7-yl)(m-tolyl)methyl)-4-methylbenzamide (140)

331
N-((5-chloro-8-hydroxyquinolin-7-yl)(p-tolyl)methyl)-4-methoxybenzamide (141)

332
N-((5-chloro-8-hydroxyquinolin-7-yl)(4-chlorophenyl)methyl)-4-methoxybenzamide (142)

333
N-((5-chloro-8-hydroxyquinolin-7-yl)(m-tolyl)methyl)-4-methoxybenzamide (143)

334
N-((8-hydroxy-5-nitroquinolin-7-yl)(phenyl)methyl)benzamide (144)

335
N-((8-hydroxy-5-nitroquinolin-7-yl)(phenyl)methyl)-3-methylbenzamide (145)

336
N-((4-chlorophenyl)(8-hydroxy-5-nitroquinolin-7-yl)methyl)-3-methylbenzamide (146)

337
N-((8-hydroxy-5-nitroquinolin-7-yl)(p-tolyl)methyl)-3-methylbenzamide (147)

338
N-((8-hydroxy-5-nitroquinolin-7-yl)(m-tolyl)methyl)-3-methylbenzamide (148)

339
N-((4-chlorophenyl)(8-hydroxy-5-nitroquinolin-7-yl)methyl)-3-methoxybenzamide (149)

340
N-((8-hydroxy-5-nitroquinolin-7-yl)(p-tolyl)methyl)benzamide (150)

341
N-((8-hydroxy-5-nitroquinolin-7-yl)(m-tolyl)methyl)benzamide (151)

342
N-((8-hydroxy-5-nitroquinolin-7-yl)(phenyl)methyl)-4-methylbenzamide (152)

343
N-((4-chlorophenyl)(8-hydroxy-5-nitroquinolin-7-yl)methyl)-4-methylbenzamide (153)

344
N-((4-chlorophenyl)(8-hydroxy-5-nitroquinolin-7-yl)methyl)-4-methoxybenzamide (154)

345
5-bromo-2-(4-chlorophenylsulfonamido)benzoic acid (155)

346
5-bromo-2-(phenylmethylsulfonamido)benzoic acid (159)

347
5-bromo-2-(thiophene-2-sulfonamido)benzoic acid (160)

348
5-bromo-2-(phenylsulfonamido)benzoic acid (161)

349
5-bromo-2-(4-fluorophenylsulfonamido)benzoic acid (162)

350
2-([1,1'-biphenyl]-4-ylsulfonamido)-5-bromobenzoic acid (163)

351
5-bromo-2-(3-chlorophenylsulfonamido)benzoic acid (164)

352
5-bromo-2-(3-fluorophenylsulfonamido)benzoic acid (165)

353
4-amino-4'-chloro-[1,1'-biphenyl]-3-carboxylic acid (166)

354
4-amino-4'-nitro-[1,1'-biphenyl]-3-carboxylic acid (167)

355
4-amino-3'-nitro-[1,1'-biphenyl]-3-carboxylic acid (168)

APPENDIX D
2D NMR OF AMINOALKYLATED QUERCETIN ANALOGS

357
8-(phenethylaminomethyl)quercetin (14) HSQC NMR

358
8-(phenethylaminomethyl)quercetin (14) HMBC NMR

APPENDIX E
ASSAY DESCRIPTIONS SUPPLIED BY COLLABORATORS

360
Ex vivo Simulated Barn Floor Assay

Note: the description of this assay procedure was supplied by collaborators (Wayne Zeller) at the
USDA (Madison, WI); the experiment and data collection were performed by the Zeller group

The ex vivo studies utilized ammonia emission chambers as previously described33b with
minor modifications in experimental detail. Briefly, feces from lactating cows fed a standard
ration (on a dry matter basis approximately 25% corn silage, 25% alfalfa silage, high moisture
corn-soybean meal, mineral and vitamins) were collected and pooled to insure all feces samples
arose from a common lot. This common lot was then subdivided into separate containers, each
containing about 50 g to conduct each separate run, and frozen. Emission chambers are
constructed of plastic drainage pipe (10 cm diameter x 19 cm high) with a glued end-cap base.
The chamber is partially filled with concrete, leaving a headspace in the chamber of
approximately 350 mL. Each chamber lid contains two inlet and two outlet ports. Acid traps
containing aqueous solutions of orthophosphoric acid (0.2 M, 75 mL each) are placed on both
the air inlet ports (to scrub incoming air of any ambient NH3) and the outlet ports (to trap the
emitted NH3). To minimize adsorption of NH3 by the apparatus, glass or Teflon tubing is used to
connect outlet ports to the acid traps and the internal surfaces of the chamber is sprayed with
Teflon (Dupont,Wilmington, DE). Air is drawn through the chamber using a vacuum pump
operating such that airflow through the chamber is ~4 L/min). The tannin compound is added to
freshly thawed feces (8.0 g) in a glass insert (petri dish), thoroughly mixed, covered with
Parafilm® and allowed to stand at room temperature for 1 h. The commercially available tannins
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and flavan-3-ols were added at 0 mg (negative control), 45.0 mg (duplicate), and 90.0 mg
(duplicate) and a positive control of 90.0 mg of quebracho/chestnut tannin extract whose
composition has been previously described33. Analysis of the quebracho/chestnut tannin mixture,
and separate quebracho and chestnut tannin extracts were performed in triplicate at 45, 90, 180
and 360 mg dosing levels and performed in conjunction with negative and positive controls listed
above. Agrotain® was diluted 100-fold with water to allow accurate dosing and dosed at the
concentration recommended by the vendor (78 uL NBPT solution/liter liquid manure). A 0.3 M
urea solution (8.0 mL) was then added to the feces/tannin mixture, briefly mixed to achieve
homogeneity, generating a liquid manure solution with a dissolved solid content of 8-10%, and
placed into the ammonia emissions chamber. A lid is fitted to the top of the chamber and sealed
with silicone grease to provide an airtight seal and the air flow through the emission chambers is
initiated. Emission chambers are housed in a large incubator so all trials are run at the same
temperature (15 °C). Outlet acid traps were changed at designated intervals (8, 24, 32 and 48 h).
Each sample (outlet acid trap) was then analyzed for ammonium (NH4+) by flow injection
analysis (QuickChem Methods 12–107–06–2-A; Lachat Instruments, 1996). Summation of the
NH3 emissions for all the samples of the run provides the cumulative NH3 emission.

Statistics: Statistical analysis of data generated from the ammonia emissions chambers was
conducted using PROC MIXED in SAS Version 9.2 (SAS Institute, Gary, N.C) with treatment
(tannin type and concentration) as class variables. Least squares means were compared using the
Tukey test with significance declared at P < 0.05.

362
Antimalarial Activity Assay

Note: the description of this assay procedure was supplied by collaborators (Richard Sciotti,
Patricia Lee) at the WRAIR (Silver Springs, MD); the experiment and data collection were
performed at the WRAIR.

The Malaria SYBR Green I - Based Fluorescence (MSF) Assay is a microtiter plate drug
sensitivity assay that uses the presence of malarial DNA as a measure of parasitic proliferation in
the presence of antimalarial drugs or experimental compounds. As the intercalation of SYBR
Green I dye and its resulting fluorescence is relative to parasite growth, a test compound that
inhibits the growth of the parasite will result in a lower fluorescence. D6 (CDC/Sierra Leone),
TM91C235 (WRAIR, Thailand), and W2 (CDC/Indochina III) laboratory strains of P.
falciparum were used for each drug sensitivity assessment. The parasite strains were maintained
continuously in long-term cultures as previously described in Johnson et. al137. Pre-dosed
microtiter drug plates for use in the MSF assay were produced using sterile 384-well black
optical bottom tissue culture plates containing duplicate or quadruplicate 12 two-fold serial
dilutions of each test compound suspended in dimethyl sulfoxide. The final concentration range
tested was 0.5 – 10000 ng/mL for all assays. Predosed plates were stored at 4°C until used, not
to exceed five days. No difference was seen in drug sensitivity determinations between stored or
fresh drug assay plates (data not shown). A batch control plate using Chloroquine (SigmaAldrich Co., Catalog #C6628) at a final concentration of 2000 ng/mL was used to validate each
assay run. The Tecan Freedom Evo liquid handling system (Tecan US, Inc., Durham, NC) was
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used to produce all drug assay plates. Based on modifications of previously described methods
by Plouffe et. al138 and Johnson et al.137, P. falciparum strains in late-ring or early-trophozoite
stages were cultured in the predosed 384-well microtiter drug assay plates in 38 µL culture
volume per well at a starting parasitemia of 0.3% and a hematocrit of 2%. The cultures were
then incubated at 37°C within a humidified atmosphere of 5% CO2, 5% O2 and 90% N2, for 72
hrs. Lysis buffer (38 µl per well), consisting of 20mM Tris HCl, 5mM EDTA, 1.6% Triton X,
0.016% saponin, and SYBR green I dye at a 20x concentration (Invitrogen, Catalog #S-7567)
was then added to the assay plates for a final SYBR Green concentration of 10x. The Tecan
Freedom Evo liquid handling system was used to dispense malaria cell culture and lysis buffer.
The plates were then incubated in the dark at room temperature for 24 hrs and examined for the
relative fluorescence units (RFU) per well using the Tecan Genios Plus (Tecan US, Inc.,
Durham, NC). Each drug concentration was transformed into Log[X] and plotted against the
RFU values. The 50% and 90% inhibitory concentrations (IC50s and IC90s, respectively) were
then generated with GraphPad Prism (GraphPad Software Inc., SanDiego, CA) using the
nonlinear regression (sigmoidal dose-response/variable slope) equation.

364
Antigametocyte Activity Assay.

Note: the description of this assay procedure was supplied by collaborators (Vicky Avery) at the
Griffith University (Queensland, AUS); the experiment and data collection were performed at
the Griffith University.

The assay is described in detail elsewhere66. Briefly, a Plasmodium falciparum NF54pfs16-GFP expressing parasite is induced to produce gametocytes, which after 8 days of
development are harvested and added to plates containing compounds. The plates are incubated
for 72 hrs before addition of the viability marker MitoTracker Red CM-H2XRos and further
incubated for 16 hrs. The plates are then imaged on the Opera QEHS micro-plate confocal
imaging system (PerkinElmer) where viable parasites are identified. The activity of the test
compounds is normalized to % inhibition of Puromycin at 5 μM within the assay.

365
Rickettsia Prowazekii Infected, Host-Cell Viability Assay

Note: the description of this assay procedure was supplied by collaborators (Jonathon Audia) at
the University of South Alabama (USA) (Mobile, AL); the experiment and data collection were
performed at USA.

All infection experiments used the virulent R. prowazekii strain Breinl propagated in and
isolated from hen egg yolk sacs as previously described139 with the modifications described in140.
Post-isolation, R. prowazekii were suspended in a solution consisting of 220 mM sucrose, 12
mM potassium phosphate, 4.9 mM potassium glutamate, and 10 mM magnesium chloride, pH
7.0 (SPGMg2+) and stored as frozen aliquots at – 80 oC until used. Post-thaw on ice, total
infectious organisms per mL of suspension were determined using the modified hemolysis assay
of Winkler and Walker141, which was subsequently used to calculate experimental multiplicities
of infection (MOI). All manipulations of infectious R. prowazekii were performed under BSL-3
conditions.
Primary pulmonary vascular endothelial cells (ECs) of CD rat origin were isolated and
characterized as previously described142. For the studies described here, cultured ECs of low
passage number (< 15) were kindly provided by the University of South Alabama Center for
Lung Biology Cell Culture Core. ECs were routinely cultured as adherent monolayers in plastic
culture dishes (at 37 °C, 5% CO2, atm O2) in DMEM high glucose medium (without phenol red)
supplemented with 10% fetal bovine serum and 4 mM L-glutamine (DMEM/FBS). For all
experiments, ECs suspended in DMEM/FBS were stained with erythrosin B (0.025% final
concentration) and enumerated in a Fuchs-Rosenthal counting chamber prior to seeding.
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To prepare ECs for infection, 2.5 x 104 total ECs (per 0.1 mL DMEM/FBS) were seeded
in 96-well culture plates and incubated overnight to allow for adherence and monolayer
formation (~18 hrs, at 37 °C, 5% CO2, atm O2). A frozen aliquot of R. prowazekii was thawed on
ice, diluted in DMEM/FBS to give a concentration of infectious rickettsiae per 0.1 mL equivalent
to a MOI of either 100 rickettsiae per host cell (100:1) or 50 rickettsia per cell (50:1). The
DMEM/FBS seeding medium was removed from each well and replaced with 0.1 mL of
rickettsiae-containing medium to initiate infection. Control, uninfected wells received only
DMEM/FBS. Culture plates were then returned to the incubator (at 37 °C, 5% CO2, atm O2).
At 24-hrs post-infection the culture medium was removed from each well and replaced
with 0.1 mL of 1) DMEM/FBS only (control), 2) DMEM/FBS containing 0.3% DMSO
(RpMetAP inhibitory compound solvent/vehicle control), or 3) DMEM/FBS containing
RpMetAP1a inhibitory compounds (see Table 27, page 175). Culture plates were returned to the
incubator (37 °C, 5% CO2, atm O2). All conditions were tested in triplicate and monolayers were
visually inspected by light microscopy every 18-20-hrs subsequently.
At 72-hrs post-infection (corresponding to 48-hrs post-compound addition), host EC
viability was determined using Roche’s WST-1 cell proliferation reagent. A ratio of 1 mL WST1 reagent was added per 10 mL DMEM/FBS medium (now DMEM/FBS+WST-1) and mixed
thoroughly by pipetting. Culture medium was removed from each well and replaced with 0.11
mL of DMEM/FBS+WST-1. Culture plates were returned to the incubator for 60-mins (at 37 °C,
5% CO2, atm O2). A volume of 0.015 mL of 37% formaldehyde solution was added to each well
to stop the WST-1 reaction and fix-kill the rickettsiae. We verified that the addition of
formaldehyde did not adversely affect the WST-1 signal compared to wells that were not
formaldehyde-treated (data not shown). Culture plates were returned to the incubator for an
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additional 20 mins (at 37 °C, 5% CO2, atm O2). The amount of WST-1 metabolism was
determined as per the manufacturer’s directions using a microplate reader and medium only
wells (with no cells) were also included on the culture plate for background subtraction. Data
were plotted as the mean normalized WST-1 signal ± standard deviation.

RpMetAP1a Cloning and Purification

Note: the description of this assay procedure was supplied by collaborators (Bart Staker, Thomas
Edwards) at the SSGCID (Seattle, WA); the experiment and data collection were performed at
the SSGCID.
Cloning, expression and purification were conducted as part of the Seattle Structural
Genomics Center for Infectious Disease (SSGCID) following standard protocols described
previously143. All constructs of RpMetAP (Uniprot: Q9ZCD3) were PCR-amplified from
Rickettsia prowazekii str. Madrid E kindly provided by Dr. David H. Walker. A full length (1259) and five variant open reading frames (ORF) were cloned into the ligation independent
cloning (LIC) expression vector pAVA0421 encoding a cleavable 6xHis fusion tag followed by
the human rhinovirus 3C protease-cleavage sequence (MAHHHHHHMGTLEAQTQGPGSM)
followed by the ORF144. The human rhinovirus 3C protease-cleavage site is between the
glutamine and glycine residues that are underlined. An additional full length construct was
cloned into the expression vector pBG1861 which encodes a non-cleavable 6xHis fusion tag
(MAHHHHHH).
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Plasmid DNA was transformed into chemically competent E. coli BL21 (DE3) R3
Rosetta cells. Cells were expression tested in 96 well blocks according to the procedures
described in Choi, et al., 2011143e. Briefly, cells are inoculated into 600 µl ZYP-5052 autoinduction medium [Sterile ZY Broth (10 g l−1 tryptone, 5 g l−1 yeast extract), 1 mM MgSO4, 1×
metals mix, 1× 5052 (0.5% glycerol, 0.05% glucose, 0.2% α-lactose monohydrate) and 1× NPS]
supplemented with the correct antibiotics. The block was sealed and incubated on a plate shaker
inside a refrigerated incubator set at 293 K for roughly 27 h to allow the cultures to reach
saturation or early stationary phase. The cultures were not harvested until OD600nm readings of
at least 0.6 were obtained. Once the induced cells were at the correct density, they were
centrifuged at 4300 rev min−1 for 30 min at 277 K. After centrifugation, the supernatant was
discarded and the block with the semi-dry cell pellets were stored at 193. Cell pellets were
analyzed for expression of insoluble and soluble RpMetAP by re-suspension in 600 µl lysis
buffer [20 mM HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 0.5% CHAPS (A.G. Scientific Inc.,
San Diego, California, USA), 30 mM imidazole, 10 mM MgCl2, 400 µg/mL lysozyme (Sigma,
St Louis, Missouri, USA) and 3 units/mL Benzonase nuclease (EMD Chemicals, San Diego,
California, USA). After resuspension, 600 µl lysis buffer was added to each well and the sample
was mixed a second time. The deep well block was then sealed and incubated at room
temperature for 1 h on a titer shaker set to moderate. The block was clarified by centrifugation at
4300 rev min−1 for 30 min. Soluble and insoluble fractions were analyzed by SDS-PAGE for
bands of appropriate MW. Only RpMetAP constructs which showed soluble expressed protein
progressed into further large scale fermentation and purification. Constructs B1, A4 and A6
expressed soluble protein and were further upscaled and purified by IMAC and Size exclusion
chromatography (SEC) as described previously (Ryan, et al., 2011).143e Proteins were
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concentrated and stored in the final SEC running buffer was composed of 20mM HEPES pH 7,
0.3M NaCl, 5% glycerol, 1mM TCEP. Aliquots of 100 µl were cryo-cooled in liquid nitrogen
and stored at −80 °C until use for crystallization.
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